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Abstract 
Background: Screening is offered to individuals who have an identified increased risk of pancreatic 
cancer.  Such risks may be increased because of a family history or a known genetic mutation which 
has been shown to confer increased risk.  Amongst those being screened intraductal papillary 
mucinous neoplasm (IPMN) of the pancreas are increasingly common entities being detected 
incidentally; their risk of malignancy can be as high as 85%.  Consensus guidelines exist for the 
management of these lesions – the morbidity associated with pancreas resection is as high as 50%.  
We set out to identify a marker which could be used to identify those IPMN which should be resected 
and those which may be safely observed. 
Methods: Individuals were identified from the European Registry of Hereditary Pancreatitis and 
Familial Pancreatic Cancer (EUROPAC) or patients identified in Liverpool or Hedielberg with cystic 
lesions and/or pancreatic cancer. Cancer screening was performed by imaging and with molecular 
analysis (including mutation analysis of TP53) of pancreatic juice obtained by endoscopic retrograde 
cholangiopancreatography (ERCP). Matched tissue sections and frozen sections of pancreatic tissue 
from 73 patients who underwent resection for IPMN were assessed histologically and for mutations 
in TP53 status using a novel limiting dilution Next Generation Sequencing technique.  Results were 
assessed relative to clinical outcomes. 
Results:  
Amongst those 29 individuals who were screened with ERCP, 11 had IPMN, 7 IPMN with cancer (IPMC) 
and 3 pancreatic ductal adenocarcinoma (PDAC).  The remaining cases were benign neoplastic or 
inflammatory conditions.  Kaplan-Meier survival analysis at 5 years found that the presence of p53 
mutation in the tissue was a better prognostic marker of survival than the histological diagnosis alone 
(p=0.0152 vs. p=0.0819).  Sensitivity and specificity of p53 mutation as a predictor of survival was 
calculated as 0.89 and 0.95 respectively.    There was 100% correlation between the p53 mutational 
status of the resected tissue and the pancreatic juice obtained at ERCP. 
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When ERCP was assessed as a method for screening, however, there was found to be an unacceptably 
high incidence of post-ERCP pancreatitis (PEP) 7 cases of PEP in 16 ERCPs (44%).  This rate was shown 
to be significantly reduced to 15% (6/40) with the use of pancreatic stent and diclofenac, but the 
overall prevalence of PEP was 23.2% over 14 years.  There were no cases of PEP amongst those 
individuals being screened because of hereditary pancreatitis. 
Of 27 IPMN cases with frozen tissue 23 individuals had TP53 mutations. Seven cases died of pancreatic 
cancer after resection.  Kaplan-Meier survival analysis revealed that one mutation p.L264R predicted 
survival regardless of histology (p=<0.0001). The mutation was present in 6 of the 7 cases who died 
and in none of those who survived to 5 years. Mutation specific PCR was used to validate results 
showing that p.L264R discriminated between survivors and IPMN cases who died of cancer (AUC = 
0.79). 
Conclusions:  IPMN continues to cause concern and uncertainty among those individuals being 
screened for cancer who are largely well and asymptomatic.  The p.L264R mutation could be used to 
differentiate those IPMN which result in poor survival to facilitate potentially curative surgery. The 
mutation may be present in pancreatic juice which can be collected endoscopically as a screening tool.  
The use of prophylactic measures to reduce PEP may be considered sufficient to bring the risk of 
complications to an acceptable level when compared to the relative certainty of prognosis afforded 
by a positive test for p.L264R. 
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CHAPTER 1 
BACKGROUND 
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1.1 - Overview 
That pancreatic cancer is a terrible disease need not be overstated; the symptoms often present too 
late and even with surgical resection and adjuvant chemotherapy survival rates are abysmal.  One 
method utilised to try to improve the odds for patients is that of selecting high risk individuals in whom 
screening can be undertaken with the aim of early detection and cure.  
Identifying such individuals is relatively easy - the risk factors and associated mutations for some forms 
of pancreatic cancer are well known - what is not well known, however, is the best method of early 
detection.  Such screening investigations invariably carry risk to the patient and also present the 
uncomfortable clinical quandary of the ‘incidentaloma’; a lesion which is likely to be benign but once 
found cannot lightly be ignored.  Commonly these lesions are cystic in nature, for example IPMN. 
The ability to separate those lesions which harbour sinister potential from those which do not is a 
‘holy grail’ of sorts for the world of pancreatologists.  In doing so we would be able to spare patients 
unnecessary (and potentially fatal) operative procedures and focus our attentions on those who would 
benefit from surgery and other treatments. 
This thesis outlines my work, undertaken at the Royal Liverpool University Hospital in conjunction with 
the University of Liverpool between 2010 and 2014 to improve the safety and effectiveness of 
screening for pancreatic cancer among high risk individuals. 
It also describes the discovery of a mutation of TP53 previously unreported in IPMN which was 
detected within resected cystic lesions of the pancreas, the presence of which shows a significant 
correlation with poor overall survival. 
Novel data include: 
1.) Data to support the notion that a mutation of the TP53 gene is more reliable at predicting 
malignant potential than histological diagnosis. 
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2.) Data relating to a 12 month collection of secretin stimulated pancreatic juice from the 
duodenum of 120 patients with benign and malignant conditions of the pancreas. 
3.) The results of screening investigations performed on 172 individuals identified as being high 
risk for pancreatic cancer. 
4.) A description of a novel next-generation sequencing method used to analyse TP53 with 
increased accuracy and depth. 
5.) Evidence that a single mutation of TP53 can be used to predict mortality in IPMN of the 
pancreas. 
This work also includes data previously published wholly, or in part, wherein I am the first author: 
 Nicholson JA, Greenhalf W, Jackson R, Cox TF, Butler JV, Hanna T, et al. Incidence of Post-
ERCP Pancreatitis From Direct Pancreatic Juice Collection in Hereditary Pancreatitis and 
Familial Pancreatic Cancer Before and After the Introduction of Prophylactic Pancreatic 
Stents and Rectal Diclofenac. Pancreas. 2015; 44(2): 260-5.  
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1.2 - Pancreatic Cancer 
Pancreatic cancer is the 10th most common cancer in the UK, it has a male to female ratio of 1:1 and 
there are 13.9 new cases per 100,000 population every year.1  The age-standardised rate is 9.2 per 
100,000.1  Five year relative survival rates for pancreatic cancer are the lowest of the 21 common 
cancers in England.2  The relative current survival at 5 years is 3.6% and 3.8%, for men and women 
respectively and 2.9% and 2.7% at 10 years.3 It should be noted however, that these rates include 
cases of pancreatic cancer which have been treated and those which have not. 
Whilst there can be varying forms of malignant neoplasms which affect the pancreas, the commonest 
by far is pancreatic ductal adenocarcinoma. There are many different forms of pancreatic cancer, 
which can be grouped into those which arise in the exocrine pancreas and those which arise in the 
endocrine pancreas.  A third rare subgroup of pancreatic cancer consists of pancreatic lymphoma.4 
Table1: Overview of 5-year survival and incidence of pancreatic neoplasms. 
Neoplasm % of Pancreatic Neoplasms 5-year Survival 
Pancreatic Ductal 
Adenocarcinoma (PDAC) 
90%5 3-5%6, 7 
Intraductal Papillary Mucinous 
Neoplasm (IPMN) 
3% varies depending on progression 
to malignancy.8 
Mucinous Cystadenoma (MCA) <1%9 33%10 
Serous Cystadenoma (SCA) 2% 50-70% 
Acinar Cell Carcinoma 1% <5% 
Primary Pancreatic Lymphoma 0.5%4 45% 
Non-functioning Islet Cell 
Tumour 
2% 50-60% 
Functioning Islet Cell Tumours: 0.2%  of which: 33% 
 Gastrinoma (46%) 11 - 
 Insulinoma (27%)12 - 
 Glucagonoma (17%)13 - 
 VIP-oma (10%)14 - 
 Somatostainoma (no data) - 
 
The obvious question becomes – why the abysmal survival rate when this is clearly a common cancer?  
The answer is multi-factorial. 
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Diagnosis 
The symptoms of pancreatic cancer are notoriously non-specific, a recent qualitative analysis of 
interviews with 32 pancreatic cancer patients and 8 relatives confirmed that not only is there no true 
pathognomonic sign or symptoms, but any symptoms which do occur may well be intermittent for up 
to 12 months prior to the diagnosis.15  The symptoms which were most often reported included: pain 
in the upper abdomen; pain in the back or shoulder and indigestion or heartburn.15  At presentation 
with exocrine pancreatic cancer, the most frequent symptoms were lethargy (86%), anorexia (85%), 
weight-loss (85%), abdominal pain (79%), and choluria (59%).16   One Italian study of 170 patients 
treated for pancreatic cancer concluded that time of diagnosis to surgery negatively correlated with 
survival and that the time from presentation to diagnosis was shorter when the presenting symptom 
was pain compared with weight loss.17  The inference here is that survival depends on prompt 
diagnosis. 
The risk factors for pancreatic cancer are generally well known; in 2001 Debra Silverman published an 
epidemiological review of the aetiological factors associated with pancreatic cancer.  These have been 
reproduced in Table 2.18  This work is currently being updated as part of the PanGen-EU study.  
Table 2: Risk factors for PDAC.18 
Risk factor Odds Ratio for Pancreatic Cancer (95% CI) 
Family history (≥ 1 case of pancreatic cancer) 3.2 (1.8 – 5.6) 
Heavy drinking (>85.5 units per week) 2.2 (0.9 – 5.6) 
Cigarettes (>20 per day) 2.0 (1.6 – 2.9) 
Obesity (BMI ≥ 35) 1.5 (0.9 – 2.5) 
Diabetes Mellitus for >10yrs 1.5 (1.01 – 2.2) 
 
Even if the patient presents promptly with sufficient symptoms to alert a doctor – the next hurdle to 
be cleared is actually making the diagnosis.  Broadly speaking a diagnosis is implied by history and 
examination, suggested by investigations such as imaging and serum analyses and confirmed by 
histology or cytology. 
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Current investigations in routine use which are aimed at diagnosing pancreatic cancer consist of serum 
biomarkers (CA19-9) and imaging techniques such as multi-slice computed tomography (CT), 
endoscopic ultrasound (EUS), and magnetic resonance imaging (MRI). 
Carbohydrate antigen 19-9 (CA19-9) was first identified as a tumour marker for colonic cancer in 1981, 
however at that point only 2 patients with pancreatic cancer had been included in the first study.19  In 
2007 a systematic review of published data on CA19-9 concluded that the median sensitivity was 79% 
(95% CI: 70-90%) and median specificity was 82% (95% CI: 68-91%).20  More recently a meta-analysis 
of 14 studies has suggested that the addition of CA242 could increase the specificity even further.21  A 
further problem for CA19-9 is that it is shown to be raised in non-malignant obstruction of the biliary 
tree,20 also patients who are Lewis Antibody negative (Lea-/b-) (5-7% of the population in Japan) do not 
express CA19-9.22, 23  
CT is the most widely used imaging modality in the developed world when it comes to making a 
diagnosis of pancreatic cancer, and is especially useful in the staging of PDAC.24-27  The sensitivity of 
lesion detection with CT is 93-100% in various series whilst the positive predictive value for tumour 
detection is greater than 90% although this obviously depends upon the screened population.24, 28  
Unfortunately, approximately 25% of patients considered to have resectable disease on CT are found 
to be unresectable intra-operatively.28  One of the greatest difficulties for a radiologist reporting a CT 
of the pancreas is to differentiate between chronic pancreatitis and adenocarcinoma.  
MRI is now generally reserved for assessment of fluid-filled cystic lesions of the pancreas but the 
addition of dynamic gadolinium enhanced MRI scanning has made MRI comparable to CT in some 
studies.26 
EUS was initially considered to be superior to both CT and MRI prior to refinements and enhancements 
in their use.27  It has been shown to be more accurate than CT in tumour size determination and in 
assessing nodal involvement but is inferior for assessment of loco-regional extent, vascular invasion, 
distant metastases and resectability.29 
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As well as chronic pancreatitis, numerous other ‘benign’ conditions may be mis-diagnosed as 
malignant or allocated into the ‘uncertain’ category where resection is often the only way to achieve 
a definitive diagnosis.  Such asymptomatic lesions (or “incidentalomas”) are now known to comprise 
between 6 to 23% of all pancreatic resections for any cause.30-32 
Treatment 
Initially the treatment of pancreatic cancers must be separated into those which are deemed 
inoperable and those which are felt to be amenable to attempted curative resection.  The treatment 
of patients who have localised advanced disease, metastases or a poor performance status is directed 
at symptom control.33 
At present tumours which are felt to be resectable usually progress to the operating theatre as soon 
as is practical – neoadjuvant chemotherapy or radiotherapy is only indicated in the context of a clinical 
trial because PDAC is highly resistant to conventional methods of cytotoxic treatment and 
radiotherapy.34-37  Recent prospective cohort studies of neoadjuvant treatment have shown a modest 
survival benefit but the duration of treatment is still contentious.38, 39 
Surgical resection of the pancreas, or part thereof, is incredibly delicate surgery and international 
consensus now agrees that such procedures should only be undertaken in supra-regional centres with 
a high volume of procedures being performed annually.40-44  Despite advances in surgical technique 
the published figures for morbidity and mortality are generally around 46% and 3.8% worldwide.  
Table 3 shows pooled mortality and morbidity figures for pancreatic resection identified in a meta-
analysis by Chen, et. al in 2013.45 
Once a patient has undergone their (hopefully successful and uncomplicated) surgical intervention 
there is usually a requirement for adjuvant chemotherapy – radical resection alone will result in a 5-
year survival of only 10%.40  As a consequence systemic chemotherapy is offered – trials have shown 
that there is no survival benefit between adjuvant chemo-radiation and systemic chemotherapy 
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alone.35  The results from two large randomised trials show that adjuvant systemic chemotherapy will 
increase the 5-year survival from 10% to 21-29%.46-48 
Table 3: Morbidity & mortality rates for selected studies of pancreatic resections. aMorbidity includes: pancreatic fistulae; 
anastomotic leak; post-operative bleeding; return to theatre within 30 days; surgical site infection; pulmonary or deep vein 
thrombosis. 
Study Country n Morbidity Rate (%)a Mortality Rate (%) 
deCastro et.al. (2009)49 The Netherlands 652 50.9 3 
Debinska et.al. (2011)50 Poland 65 32.4 - 
Gallacher et.al. (2011)51 UK 81 54.1 - 
Khan et.al. (2003)52 UK 50 46 4 
Knight et.al. (2010)53 UK 99 40.9 - 
Pratt et.al. (2008)54 USA 326 53.1 1.2 
Tamijmarane et.al. (2008)55 UK 241 - 7.8 
Zhang et.al. (2009)56 China 265 39.6 3.8 
TOTALS / MEDIAN 1997 46 3.8 
 
Summary 
Although the overall picture for surviving pancreatic cancer is poor, survival rates are increasing and 
with a combination of surgical resection and adjuvant chemotherapy a 5-year survival of 29% is 
obtainable.  The real problem is identifying those patients with cancer early and separating those 
patients with potentially malignant disease from those with benign conditions – as I have shown, 
undergoing a resection of the pancreas still carries a risk to life and ideally should never be undertaken 
unless it is absolutely necessary. 
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1.3 - Cystic Lesions 
Cystic lesions of the pancreas present a difficult clinical quandary to pancreatologists – to operate or 
not to operate.  Some of these cystic neoplasms have the potential for malignancy and thus timely 
resection can prevent pancreatic cancer.   As shown, resection of the pancreas (or part thereof) carries 
significant risk of morbidity and mortality (28%-50% morbidity). 30, 31, 57, 58 As mentioned previously, 
asymptomatic pancreatic lesions or “incidentalomas” are now known to comprise between 6-23% of 
pancreatic resections for any cause and the prevalence of cystic asymptomatic pancreatic lesions is 
now reported to be between 1.2 and 2.6%.31, 32, 44, 57, 59, 60 
The detection of these incidental lesions is becoming increasingly burdensome to regional pancreatic 
multidisciplinary teams (MDT) both in terms of the number of patients which need to be reviewed but 
also in terms of the regular surveillance imaging required once such a lesion has been found. 
IPMN 
In reality cystic neoplasms represent only a minority of pancreatic cystic lesions as most ‘cysts’ in the 
pancreas are pseudocysts (histological examination of a pseudocyst reveals a cyst surrounded by 
inflammatory tissue with no epithelial lining).61 Since malignancies most commonly arise from cysts 
with mucinous contents, focus has shifted to a particular sub-type of cyst which harbours malignant 
potential: intraductal papillary mucinous neoplasm (IPMN).62, 63  Although the true potential for 
malignancy depends upon the subtype of IPMN the overall incidence of IPMN associated malignancy 
is estimated to be 50%.64  First reported in 1982, IPMN was recognised as a distinct pancreatic 
neoplasm by the World Health Organisation in 1996.65   
IPMN is defined as a grossly visible, non-invasive, mucin producing, predominantly papillary or rarely 
flat epithelial neoplasm arising from the main pancreatic duct or branch ducts, with varying degrees 
of duct dilatation.61  Put more simply an IPMN is  an intraductal proliferation of mucin-producing cells 
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arranged in papillary formations.66  IPMN can be classified according to various parameters based 
upon:  
1) Their degree of cyto-architectural atypia. 
2) The morphology of the neoplastic epithelium. 
3) The location within the pancreas (main duct/side branch). 
4) The expression of various mucins (e.g. MUC1, MUC6). 
5) Their size.67-70 
At the simplest level IPMN can be categorised into: Main Duct (MD) IPMN meaning that the cavity of 
the mucinous lesion has arisen from the epithelial lining of the main pancreatic duct; or side-branch 
(SB) IPMN where the neoplasm is found in one of the smaller side-branch sub-divisions of the 
pancreatic ductal tree.66  In reality it is not unusual for IPMNs to extend microscopically several 
centimetres beyond the grossly visible lesions.70  Essentially current opinion among surgeons asserts 
that MD-IPMN should proceed to surgical resection on the basis that the risk of malignancy among 
MD and mixed-duct IPMN is 60-70%.71  Often the differentiation between MD, SB and mixed-duct 
IPMN can be made on imaging. 
Histologically there are two classification of IPMN in use – the first is related to the observed degree 
of nuclear atypia and the second is based upon the morphology of the epithelium. 
There are three main groups of cyto-architectural atypia:72 
1.) Adenoma or low-grade dysplasia. 
2.) Borderline or moderate dysplasia. 
3.) In-situ carcinoma or high-grade dysplasia. 
It is perhaps obvious that the higher the degree of dysplasia the more likelihood of the neoplasm 
invading the surrounding tissue to become malignant or an invasive cancer. 
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The other sub-classification of IPMN is made based upon the histological appearance, Table 4.68 
Table 4: Histological sub-types of IPMN. 
IPMN sub-type Histological description66 Incidence73 
Gastric Neoplastic epithelium resembling gastric foveolae with short 
finger-like papillae, small pyloric-type glands are often present at 
the base. 
39.3% 
Intestinal Long villous projections lined with mucin-rich columnar cells 
(similar to colonic adenoma). 
36.1% 
Pancreatobiliary Complex branching papillae which are lined with cuboidal cells 
containing little mucin. 
19.7% 
Oncocytic Neoplastic epithelial with abundant eosinophillic cytoplasm but 
usually little mucin and line the papillae in several layers which 
can combine to form complex aggregates. 
4.9% 
 
Recently a further, 5th sub-type has been proposed: ‘intraductal tubulopapillary neoplasm’, however 
at the time of writing the number of references to this in peer-reviewed journals is very low.74 
The relative incidence of these sub-types is demonstrated in the table above and this correlates 
somewhat with the progression to invasive malignancy.  A review of IPMN cases in one large specialist 
centre in Japan concluded “Intraductal papillary-mucinous neoplasm of the gastric and intestinal types 
may have less malignant potential than that of the pancreatobiliary type. Invasive carcinomas derived 
from intestinal-type IPMNs may be less invasive and slower growing than those derived from the 
pancreatobiliary type”.73   
The relationship between histological sub-type and overall survival is not as clear cut however.  Gastric 
type has been shown to occur multi-focally but malignant transformation is considered to be rare.75 
However, when invasive adenocarcinoma originates from gastric type IPMN, it seems to be associated 
with a markedly worse survival compared with those originating from other types of IPMN.76 Intestinal 
type IPMN have a higher propensity than other sub-types to progress to invasive carcinoma.68, 75  
Pancreatobiliary type IPMN tends to display aggressive biological behaviour and invasive carcinoma 
from this sub-type occurs in approximately 50% of cases.75, 77, 78  usually the oncocytic sub-types of 
IPMN do not display invasive carcinoma, and if such invasion is present it is usually limited in extent.79 
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Mucin staining has been used in numerous studies to try to differentiate between various ‘sub-types’ 
of IPMN.80-85  Mucins are a family of high molecular weight (>120 KDa), heavily glycosylated proteins 
produced by epithelial tissues.  The commonest mucin proteins (and their loci) which are detected via 
immunohistochemistry are: MUC 1 (1q22); MUC 2 (11p15); MUC 5AC (11p15); and MUC6 (11p15). 
In 2003 an international consensus meeting was held at the Johns Hopkins Hospital in an effort to 
combine the histological sub-types with the MUC staining, the efforts are summarised in Table 5.68  
Table 2: Presence or absence of various MUC proteins on IHC by histological sub-type of IPMN. 
Histological sub-type Nuclear Atypia MUC 1 MUC 2 MUC 5AC MUC 6 
Gastric Mild/Low-grade - - + - 
Intestinal Moderate/High-grade - + + - 
Pacreatobiliary Severe/High-grade + - + - 
Oncocytic Severe/High-grade + - + + 
 
The molecular genetics of IPMN have been a focus of research for a number of years.  There is general 
consensus that an activation mutation in KRAS2 is an early step on the path to malignant change in 
most IPMN.86  There is less agreement over the role of p53, p16 and SMAD4 mutations.66  p53 loss of 
heterozygocity (LOH) has been observed to occur in 38-100% of IPMN with carcinoma (IPMC), p16 
LOH is more common (92-100%).63, 87-89 Loss of SMAD4 expression is significantly less common in 
IPMN/IPMC than in pancreatic ductal adenocarcinoma.90, 91  The assessment of expression of p53 has 
usually been conducted on tissue specimens using immunohistological methods. 
The importance of defining subtype can be seen when one considers the likelihood of progression to 
malignancy.  If the clinician can define the probability of invasive change within an IPMN he/she may 
be better placed to make a management decision based upon the risks versus benefits of resection in 
a more tailored way for each individual patient. 
Once an IPMN is found to have progressed to invasion of the surrounding tissue, this becomes an 
invasive IPMN.  Once again this invasive element has distinct histological sub-types recognised by 
pathologists: tubular, colloidal, oncocytic.92  Evidence is growing that these sub-types of invasive IPMN 
P a g e  | 19 
 
are associated with differing survival rates – so far several studies have shown that the oncocytic and 
colloid sub-types compare favourably to ‘standard’ pancreatic ductal adenocarcinoma, whereas the 
tubular sub-type is associated with a poorer prognosis.76, 93-95 
From this summary of the histological descriptions of IPMN it can perhaps be appreciated that the 
histological reporting of such lesions is cumbersome and far from standardised internationally.  It is 
possible for a single IPMN specimen to be reported as: “side-branch IPMN with intestinal type 
epithelia (MUC 2 +ve), showing local invasion with oncocytic features”.  If this were a biopsy of a lesion 
in the pancreatic head the treatment of choice here would surely be resection.  However in the 
absence of invasion can such an IPMN be safely observed? 
Analysis of cyst content to determine malignant potential is a growing area of research. The pancreatic 
cyst fluid DNA analysis (PANDA) study has so far published results relating to KRAS mutations.62  This 
study has comprehensively examined the mutations in KRAS using direct sequencing.  So far in the 
published literature there have been few reports of attempts at direct sequencing undertaken of p53 
in aspirates.89 
Correlation has already been shown between various DNA/protein markers and malignant potential 
in cysts.  Abe et.al. found that there was no over-expression of p53 in 22 ‘benign’ IPMN (when 
reviewed histologically).96 As previously mentioned most such studies to date have used 
immunohistochemistry to identify p53 in tissue.89  
As mentioned earlier, today over 20% of all pancreatic resections are attributed to IPMNs in high 
volume surgical centres.59, 93, 94, 97-99  This raises the question as to why there has been such an increase 
in the detection of IPMN since its first description in 1982.  The answer almost certainly lies in the rise 
of more advanced and accurate diagnostic modalities such as dual-phase computed tomography (CT) 
scans and advanced linear endoscopic ultrasound (EUS).71  
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There are currently no formal recommendations for population-based screening of IPMN and the 
exact incidence of pancreatic malignancies occurring within IPMN is unknown.100  An epidemiological 
study conducted in California by Le et.al. reported 15,000 cases of pancreatic cancer of which 880 
(5.9%) arose within cystic lesions.101  A separate study of IPMN incidence in Korea over 12 years 
revealed that 1 in 2.4 cystic neoplasms were biopsy proven IPMN.102 
The difficulties in deciding when to resect IPMN were directly addressed at the conference in Sendai 
in 2004 which published guidelines for the resection of IPMN.68  Essentially the consensus opinion was 
that surgical intervention should be considered for all MD-IPMN and any SB- IPMN which were greater 
than 3cm in diameter or had worrying features on imaging.68   
As early as 4 years later the Sendai Guidelines were being questioned.  In a retrospective study of 190 
IPMN which would normally not have been resected under the Sendai criteria, Woo et.al. found 53 
cases with histological evidence of malignant invasion.103 
Clearly we have yet to identify a robust method of differentiating potentially malignant IPMN from 
those which are likely to remain benign.  It is also apparent that as imaging techniques become ever 
more sensitive for small side branch IPMN there will be an increasing burden on the clinical services. 
In 2010 the 14th International Association of Pancreatology (IAP) began work on the consensus 
guidelines for the management of IPMN and MCN which was designed to highlight the shortcoming 
of the Sendai Criteria as well as offering insights into the accumulated knowledge and understanding 
of IPMN.  These were published in 2012.104 
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1.4 - The European Registry of Hereditary Pancreatic Diseases 
(EUROPAC) 
Founded in 1997 in Liverpool, EUROPAC was conceived by Professor J P Neoptolemos of Liverpool and 
Professor M Büchler of Heidelberg.  Initially the registry existed to collect demographic, symptomatic 
and genetic data from individuals with hereditary pancreatitis (HP).  The Department of Molecular 
Genetics was located at The Liverpool Women’s Hospital and it was here that the early analyses for 
PRSS1 mutations were undertaken.  After Whitcomb et.al. had identified the PRSS1 mutation as a 
causative factor in HP, followed by the description of SPINK-1 and CFTR as potential mechanisms for 
idiopathic familial pancreatitis, the registry began to amass a large number of kindreds which enabled 
publication of descriptive papers relating to the incidence of various point mutations.105-108 
With the description of familial pancreatic cancer (FPC) in 1990 by Lynch et.al. (based upon a case 
series of familial cases published between 1973-1987) several registries sprung up across Europe and 
the United States.109-112  Other registries include: the Seattle Cancer Care Alliance,113 the American 
Cancer of the Pancreas Screening Consortium,114, 115 the German National Case Collection for Familial 
Pancreatic Cancer (FaPaCa),116 and the Dutch Registry for Hereditary Tumours.117 
On the basis that HP and FPC confer an increased risk of pancreatic cancer to individuals within 
affected kindreds a screening arm of EUROPAC was established in 2007.  Prior to this patients on the 
HP registry already received screening by virtue of the published 40% lifetime risk of pancreatic cancer 
conferred by HP.118 
Hereditary Pancreatitis 
Inclusion on the HP Registry required pancreatitis occurring in at least two first degree relatives in a 
single kindred.  Those individuals within the kindred who are symptomatic are said to be ‘affected’ 
individuals.  HP can then be further subdivided as: 
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“True” HP: the pattern of disease within the kindred is autosomal dominant and/or there is a 
confirmed mutation of the cationic trypsinogen gene PRSS1.  The functional affect of this mutation 
may be to alter the export of trypsinogen, self-activation of trypsin or increased caldecrin activation 
of trypsinogen.119 How these mutations cause pancreatic cancer is unclear, but pancreatic cancer is 
associated with hereditary pancreatitis regardless of the underlying gene mutation.120 
“Neg All” HP: the pattern of disease within the kindred is autosomal dominant with wild type genotype 
for PRSS1 among affected individuals. The presumption being there are further, as yet unidentified 
mutations, which act in a similar way to PRSS1 mutations.  Copy number variation (CNV) is a type of 
structural variation, specifically, it is a type of duplication or deletion event that affects a considerable 
number of base pairs.  CNV can be generally categorized into two main groups: short repeats and long 
repeats. Short repeats include mainly bi-nucleotide repeats and tri-nucleotide repeats. Long repeats 
include repeats of entire genes.  
“Familial Idiopathic Pancreatitis”: A non-autosomal dominant cluster of symptomatic individuals 
within a kindred. 
There are geographical differences in the reported penetrance of PRSS1 mutations, from 40% in Spain, 
80% in the USA, 93% in France to 96% in the UK.121-124 
The risk of pancreatic cancer within these kindreds varies with their genotype.  For example an 
individual with true HP and the p.R122H mutation of PRSS1 has been shown to have a >50 times 
increased risk of pancreatic neoplasia.118  Conversely, an individual with CFTR associated familial 
pancreatitis has a more modestly elevated risk.125 
The mechanism through which an individual with HP incurs an elevated risk of pancreatic cancer is still 
contentious – assessment of the functional qualities of the various mutations have yet to provide a 
clear causative route for the malignant predisposition leading many to think that the changes within 
the gland as a consequence of chronic pancreatitis increase the risk rather than the mutation per se. 
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Familial Pancreatic Cancer 
The term “FPC” applies to families with two or more first-degree relatives with pancreatic cancer that 
do not fulfil the criteria of any other inherited tumour syndrome.126 
In the EUROPAC registry an FPC kindred is sub-defined as: 
“True” FPC: Pancreatic cancer which has occurred within 2 or more first degree individuals across 2 or 
more generations (e.g. father and son).  Within the EUROPAC cohort there are also kindreds in which 
there have been more than 2 cases of cancer.   
“?” FPC: Kindreds in which there have been 2 or more cases of pancreatic cancer amongst first degree 
relatives within one generation (e.g. brother and sister).  
“Other” FPC:  This includes kindreds in which there have been at least one case of pancreatic cancer 
in conjunction with either; an associated mutation known to predispose to pancreatic cancer, or more 
than two cases of another cancer known to predispose to pancreatic cancer in the absence of any 
proven mutation.  
When discussing FPC it is important to exclude families that fit within other cancer syndromes or 
defined syndromes predisposing to conditions such pancreatitis, that are associated with high risk of 
pancreatic cancer. Segregation analysis of FPC families suggests that there is a rare major gene 
conferring predisposition.127 Other studies claim an autosomal dominant transmission.128 The 
question of autosomal dominance has been the subject of some debate, but as cancer is widely 
accepted to develop by multiple mutations (“hits”) any disease allele that can predispose to cancer 
when homozygous must also predispose to cancer in a heterozygous individual as a result of the 
potential somatic loss of the wild-type allele. Therefore, the issue is not whether inheritance is 
autosomal dominant, but rather the age of penetrance. EUROPAC, along with its German sister 
registry FaPaCa, was instrumental in demonstrating the phenomenon of ‘anticipation’ (the lowering 
of age of onset from earlier to later generations) among individuals of FPC kindreds.129, 130 
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One large American FPC kindred (known as Family X) did demonstrate autosomal dominant 
inheritance of pancreatic cancer with high penetrance, and anticipation among younger 
generations.131  Subsequent linkage analysis pointed to the PALLD gene (4q32-34) which encodes 
palladin and the germline mutation p.239S was identified as the oncogenic trigger in these 
individuals.132  Unfortunately subsequent analyses of families by the various National cancer registries 
failed to demonstrate this mutation elsewhere. 
In the United States the National Familial Pancreas Tumour Registry (NFPTR) estimated the relative 
risk and cumulative lifetime risk of the development of pancreatic cancer in FPC kindreds to be 6.4% 
and 12%, respectively for individuals with two affected first degree relatives, and 32% and 16-30% for 
individuals with three affected first degree relatives, respectively.133, 134  It should be noted, however, 
that within the NFPTR some groups include kindreds with three or more cases of pancreatic cancer in 
non-first degree relatives as ‘FPC kindreds’.135, 136   
Screening 
A quantitative analysis of the timing of the genetic evolution of sporadic pancreatic cancer indicated 
a time span of at least 10 years between the occurrence of the cancer-initiating mutation and the birth 
of the ‘founder’ malignant cell.134, 137  This creates an ideal window for screening to detect malignant 
transformation and affect potentially curative therapy before the disease progresses to become 
incurable.  The optimal method of screening for early cancer in individuals from FPC and HP families 
is still being developed.113-117, 126, 138-140 
Although there is a potential window of opportunity for the detection of pancreatic intraepithelial 
neoplasia (PanINs), once malignant transformation occurs then metastases develop very early, 
necessitating the need for pre-symptomatic screening.33, 139-141  A number of screening programmes 
are reliant on imaging of early tumours using endoscopic ultrasound (EUS) including the Seattle Cancer 
Care Alliance,113 the American Cancer of the Pancreas Screening Consortium,114, 115 the German 
National Case Collection for Familial Pancreatic Cancer (FaPaCa),116 and the Dutch Registry for 
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Hereditary Tumours.117  The screening approach undertaken by EUROPAC has been to identify 
molecular alterations in pancreatic juice predictive of cancer in parallel with imaging evidence of 
neoplasia.139, 140  This has the potential advantage of a longer lead time in diagnosis thereby not only 
increasing the interval between screening periods but also minimising the risk of early metastases. 
There has been a direct comparison of different imaging techniques carried out within a screening 
study; EUS showed a greater sensitivity for detecting pancreatic lesions in asymptomatic individuals 
than CT or MRI.114 Compared to CT, EUS has a superior rate of detection of pancreatic tumours, 94-
100% vs. 69-85%.142 Perhaps more importantly in the context of screening asymptomatic individuals, 
CT comes with the considerable disadvantage that it involves a dose of radiation equivalent to 10-
20mSv/1-2 rem (500 – 1,000 chest x-rays).143  This is of particular concern as it is likely some of the 
screening participants will have DNA repair defects.144-146 Therefore EUS is currently the imaging 
modality most extensively used in screening.113, 140, 147-149  
The results and interpretations of the different screening studies have been variable; cancers have 
been missed and the cost/benefit ratio has been questioned, 117 yet some groups have reported 
exceptionally high diagnostic yield.116, 117, 150 Certainly there is a need for improved screening 
modalities that are safer, cheaper and more effective.  A serum marker would be ideal as it is would 
be minimally invasive.  However, the best of these currently, CA19-9, lacks specificity and as there is 
no expression of this marker in 5-10% of individuals who are Lewisa-b-, it also lacks sensitivity. This has 
led the American Society of Clinical Oncology to reject it for screening.151, 152  
Samples of pancreatic juice obtained from the pancreatic duct at endoscopic retrograde 
cholangiopancreatography (ERCP) have been used for molecular analysis as part of the EUROPAC 
screening programme since 1998.  The molecular analysis is an adjunct to imaging in an effort to 
determine the optimal frequency of EUS.  Pancreatic juice is the secretion most intimately in contact 
with tumours and so may contain either tumour cells sloughed from the duct or cellular components 
including DNA liberated from cancer cells by necrosis.153   
P a g e  | 26 
 
In Chapter 5 I will present the screening outcomes from patients who were recruited to the registry 
and screened prior to and during my period of research (2010-2014). 
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1.5 - p53 
Wild Type 
Initially thought to be an oncogene, the p53 protein of the TP53 gene was first described in 1979 and 
published in Nature in 1984.154  p53 is now recognised as a transcription factor which is found to be 
present in about half of all malignant tumours regardless of their cell of origin, a single mutant allele 
of which leads to Li Fraumeni Syndrome.155, 156   
The mechanisms by which p53 accomplishes all of its biological functions are not completely 
understood, it has been shown that p53 specifically binds to sequences of DNA within the intron or 
promoter sequences of genes which are known as p53 responsive elements (p53RE).157-160  Through 
various mediators and transcriptional activity p53 is able to inhibit cell proliferation or induce 
apoptosis and is therefore an active molecule in neoplasia especially where dysplasia is present.161   
The most described activity of p53 is probably apoptosis in response to various stimuli; it was only in 
2009 that a comprehensive mechanism of increased mitochondrial outer-membrane permeability was 
shown to be the means by which this was achieved.162, 163 
p53 can thus be described either with reference to the triggers for activation, e.g. DNA damage, 
oxidative stress, oncogene activation, hypoxia; or by its effects as described above.  It is also known, 
however, that p53 does more than simply affect the cell cycle – numerous down-stream effects have 
been and are being documented.164  Using various animal models p53 has also been implicated in the 
development of the neural tube in embryos with p53 null mice developing significant neural tube 
defects.165, 166  Even earlier than the embryonic stage, p53 is known to increase fertility by enhancing 
the chances of implantation of a fertilised egg;167, 168 even the skin tone and propensity to a sun-tan 
may also be determined, in part, by the same gene.168, 169 
It is important to note that the effects of p53 are not limited to cancer – work has shown that as we 
age we garner more p53 mutations which in turn lead to increasing cellular signs of aging and 
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conversely accumulated wild-type p53 is associated with increasing signs of aging in murine 
subjects.170, 171 
As well as regulatory physiological roles, p53 is also active in certain diseases and conditions which are 
non-malignant – it promotes a senescence response to insulin in adipose tissues leading to diabetes 
as well as being shown to promote apoptosis in response to ischaemia in both neurons (stroke) and 
cardiac muscle (myocardial infarct).172-174  As well as stimulating apoptosis there has been evidence to 
suggest that by enforcing it’s role of ‘cellular guardian’ p53 mediated destruction accelerates 
neurodegenerative conditions such as Alzheimer’s, Parkinson’s and Huntington’s.175-178 
p53 is, to a certain extent, auto regulated via Mouse double minute 2 homolog (MDM2) which is an 
E3 ubiquitin-protein ligase.179  MDM2 recognises the N-terminal of activated p53 and is an important 
step in the ubiquination pathway (in combination with a E2 ubiquitin-protein ligase) which eventually 
leads to degradation of p53 via the proteasome activation.180  MDM2, produced in tandem with p53 
has also been shown to be an inhibitor of p53 post translational activity – acting as a negative feedback 
loop.181-183 
At its most basic level p53 encodes a 393-amino acid protein which will bind with DNA.184, 185  When 
activated p53 will bind with DNA and stimulate the production of many transcripts including miR-34a 
and WAF1/CIP1 also known as p21.186, 187  When p21 combines with CDK2/cyclin the cell cycle is halted 
at the G1/S checkpoint, thus rendering the cell amenable to various DNA repair mechanisms before 
progressing to S phase.157, 188, 189  When p53 binds to CDK1/cyclin B it halts the cell cycle at G2/M.  As 
p53 responds to DNA damage, wild-type p53 can therefore be described as the “guardian of the 
genome”.190 
Cells lacking normal p53 suppressor gene activity, such as most neoplastic cells, suffer from genomic 
instability resulting from loss of checkpoint activity during the G1 phase, eventually culminating in 
gene amplification, aneuploidy and other chromosomal aberrations. These abnormalities then 
contribute to the clonal evolution of cancer cells and tumour progression.191, 192 
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p53 activation is also triggered by the presence of free oxygen radicals which can be produced as a 
consequence of chronic inflammation such as that seen in chronic pancreatitis or as a consequence of 
ductal obstruction in pancreatic cancer.182, 193   
Hypoxia, too, is a potent stimulator of p53 – this mechanism is most strikingly demonstrated as a 
consequence of expansive cellular proliferation with insufficient angiogenesis as is seen in 
malignancy.182, 194, 195  Interestingly various mutant genotypes of p53 have been identified which are 
resistant to hypoxia-induced apoptosis, such variants are common in larger tumours.196, 197  
 
Figure 1: Select p53 pathways (after Brady & Attardi).198 
Prevention of autophagy may also be among the possible consequences of p53 activation in response 
to established tumoreogensis, this allows a cell to catabolise macromolecules for reuse, either as a 
survival strategy under stress conditions or as a means to remove harmful, damaged structures.199  It 
has been shown that even minute levels of wild-type p53 present within the cytoplasm can impede 
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the formation of autophagosomes thus effectively blocking this mechanism as a route for evading 
detection and continued survival of malignant cells.199, 200 
Mutant 
A p53 mutation is one of the most frequently found mutations in human cancers.181, 201  As already 
discussed a mutation in p53 may lead to p53-dependent apoptosis suppression among pre-malignant 
lesions and subsequently provides selective pressure for further p53 suppression.202, 203  Of course 
suppression of p53 activity can occur either through overexpression of MDM2, a mutation within p53 
itself or mutations downstream among p53 pathways.194  In murine models p53 null mice get 
completely penetrant cancer phenotypes.204 
It is estimated that 50% of all human cancers harbour a mutation in p53 – the incidence of this 
mutation, and indeed the timing of the mutation within the neoplasia-malignancy progression varies 
depending upon the tissue type.181, 182, 205, 206  Because of its inherent tumour suppressor activity, 
inactivation of p53 without mutation can also lead to spontaneous tumorigenesis.207  It is interesting 
to note that one theory of the evolution of p53 suggests that as organisms have evolved to live longer 
p53 has become more relied upon for neoplasia detection – given the significance of its role in 
physiological processes and pathological conditions it is thought probable that this was not the original 
role of p53 in simple organisms.208 
Because p53 functions by forming a tetramer of 4 individual p53 protein molecules, a single mono-
allelic mutation can exert a dominant negative effect in the presence of a majority of wild type 
expressed protein by disrupting the formation of an effective tetrameric transcription factor.209  The 
presence of mutant p53, rather than the lack of wild type, may confer a survival advantage for the 
evolution of tumour cells.210  This has been postulated as the “gain of function” hypothesis for mutant 
p53.211, 212  Some mutations can be shown to prevent only the cell cycle arrest function of p53 and 
others only the apoptotic function, of course a combination of such mutations would harbour 
significant malignant potential.213-215  Accordingly, human tumours with mutant p53 are associated 
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with poor patient prognosis and drug resistance.205, 216  More pertinent, perhaps, is the knowledge 
that the side effects of chemotherapy and radiotherapy are to a large extent mediated by p53.217 
p53 is also known to repress the action of other genes by directly binding or occluding the binding 
sites for other transcription factors.218, 219 
The relative effect of such mutations can be measured by monitoring the expression of auto-
regulatory proteins (e.g. MDM2) and downstream markers (e.g. p21, BCL2).  A description of the 
function of each known mutation of p53 (there are over 8000) can be found at the online International 
Agency for Research on Cancer (IARC) p53 database (http://p53.iarc.fr/TP53GeneVariations.aspx); 
along with the incidence and effects of the mutation using these surrogate markers.  As early as 1994 
it was shown that p53 mediated apoptosis can occur even in the presence of inhibitors of p53 DNA 
binding, thus it has been shown that there is cytoplasmic activity of p53.220 
The vast majority of p53 mutations which occur in cancer cause an inability of p53 to bind to sequence 
specific regions of genes and thus disables the regulatory mechanism, it has been shown that p53 
mutations typically occur within the DNA-binding region and involve either DNA contact residues or 
residues important for conformational structure, both resulting in loss of DNA binding.221, 222  More 
than 80% of p53 mutations occur as a single amino-acid substitution resulting in the synthesis of a full 
length-stable protein which lacks DNA binding specificity, rather than the usual frame-shift or 
nonsense mutations found in other tumour suppressor genes.181, 223 
As a consequence of the action of p53 the majority of described deleterious mutations occur within 
the DNA binding region of p53.  Exons 5, 6, 7 and 8 have been shown to contain over 90% of the 
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described mutations so far, 28% of these have been reported to occur at one of 6 codons (p.R175, 
p.G245, p.R248, p.R249, p.R273, p.R282).224   
 
 
 
 
 
 
 
Figure 2: p53 protein structure. 
P53 and the pancreas 
PDAC is one type of cancer in which p53 has been shown to significantly impact disease progression. 
The most popular model for PDAC development is that it usually arises from a background of PanIN 
which can persist indolently for years, mutation of p53 within such tissue, however, is associated with 
invasive metastatic PDAC in 75% of cases.225  p53 is a recognised late stage mutation in PanIN and has 
also been shown to be a contributing factor in local recurrence following presumptively curative 
resection.226-229  Further evidence of the metastatic role of p53 in PDAC can be found in the conclusion 
of Morton, et.al. who demonstrated that, in a murine model, PDAC driven by oncogenic Kras was 
unlikely to metastasise in mice with wild type p53 compared to those with concomitant mutant p53.230  
Recent work has identified platelet-derived growth factor receptor b (PDGFRb) as a mediator of the 
effects of mutant p53 on invasion and metastasis in both a murine model and human PDAC cells.231 
In cystic lesions of the pancreas, such as IPMN, the role of mutant p53 is less well described.  Mutations 
in p53 are thought to be less common in cystic lesions compared with solid PanIN derived precursor 
lesions, and in IPMN specifically the correlation appears to be with the grade of dysplasia rather than 
the epithelial subtype.87, 232, 233  One study estimated that the incidence of p53 mutations in IPMN were 
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50% lower than in PanIN.234 A recent next generation sequencing project of various cancer associated 
genes within IPMN found that only 10% carried mutant p53 (n=5), all of these mutations were found 
within high grade IPMN and 3 of them within codons 5 or 6.89  Until recently, the assessment of p53 
expression was usually made using IHC rather than direct sequencing.  As a result it is difficult to 
perform a systematic review of p53 mutation expression among cystic lesions of the pancreas.  Even 
with IHC, however, aberrant p53 expression was still only identified amongst IPMN with carcinoma as 
opposed to those with dysplasia (5/13 vs. 0/16).89, 90 
In terms of prognostic markers, the Johns Hopkins Group have reliably and recurrently identified 
aberrant CpG island hypermethylation, GNAS mutations and NRAS mutations as drivers of malignant 
change in IPMN.89, 235, 236  p53 has been less commonly seen in these genetic profiling experiments, 
this may be because the late development of p53 renders the malignant IPMN unresectable by virtue 
of local spread and thus tissue is not available or perhaps, in contrast to PanIN, p53 is not a common 
mutation in malignant transformation of IPMN.  
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Chapter 2 
AIM & OBJECTIVES 
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2 – Aim & Objectives 
Identify a novel genetic marker which can predict malignant transformation or overall survival in 
individuals with lesions which are high risk for developing pancreatic malignancy.  This marker 
should, ideally, be suitable for use in an appropriate population. 
1.) Identify suitable candidates for screening  
2.) Identify the number of lesions seen in a pilot study 
3.) Identify the chance of IPMN developing into pancreatic ductal adenocarcinoma (PDAC) 
4.) Identify means of improving yield of genuine positives in screening 
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Chapter 3 
HYPOTHESIS 
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3 – Hypothesis 
That there will be biomarkers that can adequately stratify screened individuals to allow secondary 
screening for pancreatic cancer to be effective. 
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Chapter 4 
METHODS 
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4.1 - Samples Obtained 
In line with the stated aims of my thesis I needed to obtain samples of resected pancreata which 
contained cystic neoplasms.  It was also important that these samples had matched accurate survival 
and follow-up data. 
Tissue samples from this project were donated by Professor Markus Büchler on behalf of Heidelberg 
University Hospital, Heidelberg, Germany. 
I chose to approach the Pancreas Research Group in Heidelberg (on the advice of my supervisors) for 
the following reasons: 
1.) The group resect far more cystic lesions of the pancreas than any centre in the UK.  This is 
mainly due to the differences in management (and the confines of the National Health Service 
in the UK) of such lesions.  In Germany, suspicious lesions are routinely resected whereas 
surveillance imaging is normally undertaken in the UK if there are no overt features of 
malignancy. 58, 95, 101, 237  
2.) Obtaining tissue samples from outside of my research group would make it much easier to 
stay blinded to the histological and survival data of the patients. 
3.) Our group already had strong collaborative ties to the Heidelberg Pancreatic Unit through 
work published as part of the various ESPAC trials. 46, 238-243 
73 separate unique snap frozen tissue specimens were transported to the NIHR Pancreas Biomedical 
Research Unit (PBRU) in dry ice at -80°C and were received in June 2012.  Each was randomly allocated 
an alphanumerical identifier in the format CYSTXXX (where XXX represented sequentially increasing 
numbers).  These new ‘Liverpool’ identifiers and their corresponding locations within the -150°C 
freezer NIHR PBRU tissue bank were recorded on the Laboratory Information and Management 
System (LIMS) in accordance with Good Clinical Practice (GCP). 
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As already outlined, my fellow researchers working on this project and I were blinded to any 
demographic, histological or survival data for the patients from whom these samples had been 
obtained. 
The samples now labelled CYST001 to CYST072 were then individually sliced into three separate pieces 
of roughly equal size without any reference to the presence or absence of macroscopically apparent 
tumour, duct, or cyst within them.  This dissection was not performed by a pathologist and was 
undertaken using separate scalpel blades on a non-porous surface cleaned with 70% ethanol between 
samples.  These ‘sub-divisions’ of the original samples were labelled as CYST001a, b or c.  One third of 
each sample (a) was destined to be used for immunohistochemistry (IHC) as part of this project; one 
third (b) for DNA analysis; the final third (c) was returned to storage at -150°C in anticipation of further 
work or validation related to any findings of this project. 
 
Figure 3: Tissue blocks created from Heidelberg samples ready for slicing with the microtome and then IHC. 
The samples which were to be used for IHC (a) were transferred to the Royal Liverpool University 
Hospital Department of Pathology for processing in 10% formalin and were each embedded into a 
separate paraffin block, labelled and stored in a designated tissue storage cabinet at room 
temperature and recorded on the laboratory information and management system (LIMS). 
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4.2 - Overview of Immunohistochemistry  
As previously detailed, the tissue samples which were destined to be used for IHC analysis had been 
prepared using formalin fixation and paraffin embedding.  This ensured ease of tissue slicing when 
preparing slides for pathological review and IHC. 
Prior to consideration of IHC I decided that it would be sensible to ensure that each specimen had 
exposed epithelial cells to bind with my chosen antibodies.  In this vein I enlisted the assistance of 
Professor Fiona Campbell, Consultant Histopathologist at the Royal Liverpool University Hospital. 
Once I had prepared the samples by slicing on a microtome (4µm) and mounting onto microscope 
slides I performed standard haematoxylin & eosin (H&E) staining and presented them to Professor 
Campbell for review.   
The first such review took place on 9th January 2013 and of the 72 slides presented 21 (29%) were 
identified as cystic lesions with sufficient epithelial cells to warrant IHC.  Over the following 2 months 
repeated 4µm slices were taken of the remaining 52 samples, stained with H&E and reviewed by 
Professor Campbell.  I was aware that as I had sliced the original frozen tissue samples with no 
reference to the gross pathology it was possible that the cystic neoplasm originally resected in 
Heidelberg may not actually be present in these slices.  To combat this I ensured 10 4µm slices were 
removed and stored prior to each new H&E stain, this way if I did start to cut into the cystic neoplasm 
I could ask for the previous slices to be examined.  Eventually after three ‘rounds’ of histological review 
I was left with 22 (30%) samples which were confirmed as displaying epithelial cells consistent with a 
cystic neoplasm and which were thus suitable for IHC analysis.     
As discussed in 1.3 - Cystic Lesions I had chosen to assess these 22 tissue samples for expression of 
the proteins MUC1, MUC2, MUC5AC and MUC6.  In preparation, I mounted 10 4µm slices of each 
tissue sample onto separate microscope slides and allowed them to dry in an incubator at 37°C for 48 
hours.  I determined that it would be fruitless and costly in terms of both time and money to try and 
P a g e  | 42 
 
IHC stain those remaining 50 samples which had been assessed as not displaying epithelium as there 
would be no specific antibody binding and so results would be meaningless.  As a positive control and 
quality assurance measure I was also provided with 4 tissue blocks of cystic neoplasms which had been 
resected at the Royal Liverpool University Hospital and which had already undergone IHC staining with 
MUC1, 2, 5AC and 6 as part of their clinical pathological assessment.  This staining had taken place 
within the Department of Pathology in the Clinical Pathology Association (CPA) accredited laboratory 
and so their findings could be considered as a gold standard against which I could measure my staining 
outcomes. 
MUC Antibodies 
All of the MUC antibodies were ordered from Leica (Leica Biosystems, Newcastle, UK) and arrived 
anhydrous.  All were mouse monoclonal antibodies, their catalogue numbers are given over the 
following pages.  They were each reconstituted with the required volume of molecular grade DNA free 
sterile water as indicated on their respective datasheets.  After this each antibody was stored at 4°C 
in a laboratory refrigerator. 
Control Tissue Samples 
The suggested positive and negative control tissues for each antibody was as detailed in their 
datasheet (Leica Biosystems, Newcastle, UK).  These tissues were obtained with thanks from the 
Liverpool Tissue Bank.   
Tris-EDTA Buffer pH9.0 
I created a 10x stock solution of Tris-EDTA buffer, using the following formula:  
 12.1g of tris(hydroxymethyl)aminomethane (Tris) 
 3.7g of Ethylenediaminetetraacetic acid (EDTA) 
 800mL of distilled water 
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This was brought to pH of 9.0 using pellets of NaOH and diluted to 1000mL using distilled water.  This 
stock was then stored at 4°C in a laboratory refrigerator. 
TBS 
I created a 20x stock solution of Tris Buffered Saline (TBS), under the guidance of Mrs Elizabeth Garner, 
using the following formula:  
 121.4g of Tris 
 175.32g of NaCl 
 800mL of distilled water 
This was brought to pH of 7.6 using aqueous HCl and diluted to 1000mL using distilled water.  This 
stock was then stored at room temperature.   
Scott’s Tap Water 
 30g of Magnesium Sulphate (MgSO4)  
 2g of Sodium Bicarbonate (NaCO3) 2.0 gm 
 3L of distilled water 
Acid Water 
 10mL of 10M HCl 
 900mL of distilled water 
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4.2.1 - Immunohistochemistry Methods 
Each of the antibodies arrived with a specific datasheet which outlined the manufacturers’ suggested 
protocol for optimal results.  Optimisation of these antibodies took a considerable length of time and 
I am indebted to Mrs Elizabeth Garner who made the breakthrough suggestion that I should incubate 
MUC 2 overnight rather than the ‘suggested’ 1 hour. 
In essence there are three variables which should be considered when performing IHC: 
1) Antigen retrieval  
2) Primary antibody concentration 
3) Incubation Time 
I set about testing each of these in turn to try to optimise the conditions.  After each IHC run I 
presented the samples to Professor Campbell for assessment of which slides had optimal antibody 
uptake. 
Antigen retrieval 
The datasheets for each of the antibodies recommended “high temperature antigen retrieval using 
0.01M citrate retrieval solution at pH6.0”.  I therefore began my IHC experiments with a single run of 
8 slides (one positive and one negative control tissue slice for each antibody) and a constant primary 
antibody concentration of 1:50 dilution.  The incubation time was similarly standardised at 60 minutes 
for the primary and 60 minutes for the secondary antibody. 
Some 4 hours later none of the positive (nor indeed negative) slides showed any antibody uptake.  I 
reasoned that the concentration must be sufficient (it being the minimum suggested for each 
antibody) and that 60 minutes incubation was standard according to the data sheets.   After reviewing 
the literature specifically related to MUC antibodies in pancreatic lesions it became apparent that an 
EDTA based buffer may be more appropriate.  I repeated the experiment with EDTA Buffer (pH6.0) 
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which yielded some weak staining for MUC 1, 5AC and 6 but no staining for MUC 2.  Finally another 
run was conducted with EDTA at pH9.0 and I also increased the concentration of MUC 2 antibody to 
1:10 whilst maintaining the others at 1:50.  There was now very strong staining (with background cells 
positive) in MUC 1, 5AC and 6 but still nothing in MUC 2.  I concluded that EDTA buffer at pH9.0 was 
the optimum method of antigen retrieval for the remaining antibodies (excluding MUC 2). 
Primary Antibody Concentration 
After optimising retrieval, IHC analysis was repeated on the positive control tissues using 
concentrations of primary antibody at: 1:100; 1:200; 1:500 and 1:1000 to find the optimum stain of 
epithelium without excessive background artefact.   
After review by Professor Campbell I found that the optimum concentrations were: 
 MUC 1 = 1:200 
 MUC 5AC = 1:100 
 MUC 6 = 1:200 
Incubation Time 
Incubation time was established at 60 minutes for all other antibodies but was increased to 12 hours 
at 4°C for MUC 2.  I maintained the retrieval methods already established (high temperature EDTA 
pH9.0) and performed a run at concentrations of 1:50; 1:100; 1:200 and 1:1000 leaving the primary 
antibody on for 12 hours in the cold store (4°C) and the secondary antibody on for 60 minutes at room 
temperature.  Finally, the positive tissues stained appropriately and the optimum concentration was 
identified as 1:100. 
For each run of IHC I focussed on a single antibody and used a maximum of 10 sample slides in 
conjunction with one positive and one control sample.  Thus each antibody was run three times (26 
samples). 
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Assessment of IHC 
Each slide was reviewed by Professor Campbell who reported whether the tissue staining was positive 
or negative.   
4.2.2 – Materials for MUC Staining 
MUC 1 Specification 
Novocastra™ Lyophilized Mouse Monoclonal Antibody Muc-1 Glycoprotein. 
NCL-MUC-1 (Leica Microsystems, Newcastle, UK) 
Control Tissues 
Positive:  Normal Pancreas 
Negative: Skeletal Muscle 
MUC 2 Specification 
Novocastra™ Lyophilized Mouse Monoclonal Antibody Muc-2 Glycoprotein. 
NCL-MUC-2 (Leica Microsystems, Newcastle, UK) 
Control Tissues 
Positive:  Duodenum 
Negative: Skeletal Muscle 
MUC 5AC Specification 
Novocastra™ Lyophilized Mouse Monoclonal Antibody Muc-5AC Glycoprotein. 
NCL-MUC-5AC (Leica Microsystems, Newcastle, UK) 
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Control Tissues 
Positive:  Stomach 
Negative: Tonsil 
MUC 6 Specification 
Novocastra™ Lyophilized Mouse Monoclonal Antibody Muc-2 Glycoprotein. 
NL-MUC-6 (Leica Microsystems, Newcastle, UK) 
Control Tissues 
Positive:  Duodenum 
Negative: Tonsil 
Preparation of Paraffin Embedded Tissue 
Firstly the tissue was placed in xylene for 5 minutes followed by another agitation in fresh xylene for 
a further 5 minutes.  This was repeated for a third time. The tissue was then washed in 3 separate 
containers of fresh 100% ethanol for 3 minutes each with gentle agitation. The tissue was next placed 
in reducing concentrations of alcohol (95%, 75%, 30%) for 2 minutes each with gentle agitation.  Finally 
the tissue was left to ‘rest’ in a container of distilled water for 5 minutes. 
Antigen Retrieval 
To retrieve the antigen I created 2L of EDTA Buffer pH9.0 by combining 200mL of stock with 1,800mL 
of distilled water and poured this into a pressure cooker which was brought to the boil.  The slides 
were placed in the solution in a metal rack and the pressure cooker was sealed and set to 1 bar (14.50 
psi, 99.9 kPa).  Once the pressure was reached the slides were left to boil for 2 minutes and 30 seconds. 
Once the time had elapsed the pressure was released and the pan was immersed in a sink full of cold 
water.  Once the rack had cooled it was removed and placed into a container of distilled water. 
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One Litre of TBST was created by combining 50mL of stock TBS (p.42) with 949.5mL of distilled water 
and 0.5mL of Tween (Polysorbate 20), this was placed into wash bottle. 
Excess water was gently removed from each slide with a clean piece of tissue and a continuous circle 
was drawn around the tissue with a PAP-pen (Sigma-Aldrich, St Louis, MO, USA) which creates a 
hydrophobic barrier when dry.  Each specimen was covered with sufficient drops of Endogenous 
Peroxidase Block (Dako, Denmark) to form a raised ‘bubble’ within the hydrophobic barrier. These 
were then incubated at room temperature for 10 minutes. Each slide was next irrigated with TBST 
sufficient to remove the Endogenous Peroxidase Block and leave each sample covered with TBST for 
5 minutes. The washing of the slides was repeated 4 further times. 
Primary Antibody 
120µL of a 1:200 dilution of MUC 1, 1:100 MUC 2, 1:100 MUC 5AC and 1:200 MUC 6 was placed onto 
each slide, covering each tissue specimen, this was then incubated under a cover for 60 minutes at 
room temperature.  After 60 minutes each slide was irrigated with TBST sufficient to remove the 
primary antibody and each sample was covered with TBST for 5 minutes.  This process was repeated 
a further 4 times. 
Secondary Antibody 
Each specimen was covered with 120µL of Labelled Anti-Mouse Antibody (Dako), and incubated under 
a cover for 60 minutes at room temperature.  In the case of MUC 2 the slides were left for 12 hours at 
4°C.  The slides were then irrigated with TBST sufficient to remove the Anti-Mouse Antibody and left 
covered with TBST for 5 minutes, this was repeated a further 4 times. 
Antibody Staining 
Firstly 5 drops of Chromagen Substrate Buffer (Dako, Denmark) were combined with 5mL of distilled 
water and 120µL was placed onto each slide, covering each tissue specimen.  Secondly the slides were 
incubated under a cover for 10 minutes at room temperature.  The slides were then individually 
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irrigated with TBST sufficient to remove the Chromagen Substrate Buffer and left covered with TBST 
for 5 minutes.  This process was repeated a further 4 times before the slides were immersed in distilled 
water for 5 minutes. 
Preparation of Tissue for Assessment 
Each slide was placed into haematoxylin for 1 minute then rinsed under running tap water for 1 minute 
until water ran clear.  The slides were then placed into Acid Water (p.43) for 1 minute and rinsed again 
for a further 1 minute.  Next, the slides were immersed in Scott’s Tap Water (p.43) for 1 minute and 
rinsed thereafter.   
Following this the slides were once again immersed in ethanol of increasing concentration for 1 minute 
each – 30%, 75%, 95%, 100%, with gentle agitation  before being placed  in  three separate containers 
of xylene for 1 minute each. 
Finally, 1 drop of DPX mounting glue (Sigma-Aldrich, St Louis, MO, USA) was placed over the tissue 
which was then covered with a microscope cover slip.  The tissue was allowed to dry at room 
temperature for 48 hours before viewing under microscope. 
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4.3 – Overview of Mutational Analyses 
The Personal Genome Machine originally manufactured by Ion Torrent and now by Thermo Fisher will 
be described here, in line with common usage, as the Ion Torrent next generation sequencer. It is 
capable of generating a sequence of DNA by flooding a well, which contains the reference sequence, 
with alternating nucleotides (A, C, G or T).  If the exposed base of the reference sequence is Adenine 
then when the well is flooded with the complimentary base Tyrosine there will be a polymerase 
reaction between the nucleotide and the terminal ribose of the nascent strand and as a consequence 
a H+ ion will be released.  At the base of the well a pH meter will recognise the H+ ion and will record 
that a reaction has taken place.  The processor will be aware that the base released was T and so will 
report the length of DNA being sequenced as containing an A.  If there are two nucleotides then twice 
as many protons would be released and the pH meter would record accordingly. Should the base 
which is used to flood the well be non-complimentary there will be no polymerisation, no H+ release 
and so no change in pH detected.  Each well is flooded with a given base every 15 seconds until the 
end of the template fragment is reached. 
The well is contained within a small microchip, the number of wells available on a chip is denoted by 
the reference number: 314 has 4million wells, 316 has 6million etc…  Clearly if 100% of wells are filled 
with the same sequence of reference DNA then 4 million sequences, known as reads, would be 
produced.  Alternatively 4 million separate reference sequences of DNA could be placed upon a chip 
which (again assuming 100% coverage) would result in a unique read per well.  Of course one can 
never guarantee that every well will receive a strand of reference DNA.  A refinement to this approach 
is to use more than one sample (patient) and for this it is necessary to add a unique sequence of bases 
which enable identification of each sequence.  In relation to this point the ideal reaction would entail 
an equal distribution of individual samples across the wells. 
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Prior to the reference sample(s) of DNA being added to the chip they must be enriched and impurities 
(e.g. primer-dimers) removed as far as is practicable to ensure the quality of the reads produced. 
It can be seen that there is an optimum equilibrium between the number of samples placed upon a 
chip and the resulting quality of the sequences produced.  In part this depends upon the ‘depth’ of 
the sequences produced.  This is defined as the number of bases called at a given locus, the greater 
the number of reads the ‘deeper’ the read and the more confidence can be inferred that the base 
called is an accurate facsimile of the reference sequence.   
I have already alluded to the fact that the optimum confidence in the accuracy of sequence output 
would come from the maximum number of wells being filled solely with that reference sequence.  
However, the cost of analysis of a single chip on the ion torrent (including necessary reagents) would 
be approximately £400.  To analyse all of my samples (n=42) on individual chips and perform the 
required 10 repetitions would therefore cost 10 x 42 x £400 = £168,000. 
Another option would be to run a single chip and design 420 individual primers for each of the 16 
fragments of TP53 to be analysed.  The mean primer length including ion torrent adaptors is 42 mer.  
The number of additional bases required to create 420 unique sequences would be 5 per primer (4^5).  
The resulting mean length would be 47 mer per primer at a cost of £0.20 per base this would equate 
to 420 x 16 x 47 x £0.20 = £63,168 (+£400 for the chip).  Of course this would only give a single read 
per sample at best – assuming 100% of the wells were filled.  Confidence would be correspondingly 
poor. 
Using a combination of: average depth required (5,000 reads); number of samples to be processed 
(42); and the cost of chips and primers I calculated that the optimum financial ratio was to have three 
patients (each with 10 repetitions) per chip.  This would necessitate 480 primers with three base 
barcodes, thus 45 mer.  Total cost 480 x 45 x £0.20 = £4,320.  I would also need 14 chips (42/3) and 
sufficient reagents at a cost of £5,600, giving a total of £9,920.  
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If there was 100% coverage of the chip I could expect 5,000 reads at each locus of every fragment 
analysed.  With 10 barcodes per sample I could hope to achieve sufficient confidence that the 
sequences produced were accurate. 
4.3.1 - DNA Extraction 
The first step in the analysis of DNA from the frozen samples was to extract the nucleic acid from the 
tissue.  This was performed using the following protocol, modified from Qiagen DNeasy Blood & Tissue 
Kit (Qiagen, Germany).  Forty-eight hours prior to the commencement of DNA extraction the tissue 
samples labelled CYST001b to CYST072b were removed from -150°C storage to -20°C and recorded on 
LIMS.  
The principle behind DNA extraction is that cells need to be lysed and the released DNA purified, 
bound to a matrix, washed to remove RNA and impurities and then eluted from the matrix into a 
suitable elution buffer (usually molecular grade DNA free sterile water). 
Lysis 
A pestle, mortar and metal forceps were ‘sterilised’ with 90% ethanol and then left under UV light for 
30 minutes, the mortar was then transferred to a suitable container full of ice and placed on a balance.  
Ten milligrams of frozen tissue from one sample (e.g. CYST001) was placed into the mortar using the 
sterile forceps whilst wearing sterile gloves. The mortar was then removed from the balance but left 
inside the ice box to allow the tissue to be macerated using a single use, sterile, size 15 scalpel blade 
(Swann-Morton, England).  The tissue was then crushed using the pestle.   
This crushed tissue was next transferred into a sterile 1.5mL Eppendorf tube using the blade and 
forceps and 180µL of Buffer ATL (Qiagen, Germany) was added, as was 20µL of Proteinase-K (Qiagen, 
Germany).  The Eppendorf was then placed into a heat block at 56°C for 4 hours and vortexed 3 times 
each hour.  Finally the Eppendorf was centrifuged at maximum speed for 15 seconds (RCF 60,000). 
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Purification 
A further 4µL of RNAse A (Qiagen, Germany) was added and the sample vortexed for 2 minutes.  
Following this the Eppendorf was centrifuged at maximum speed (RCF 60,000) for 15 seconds before 
another 200µL of Buffer AL (Qiagen, Germany) was added.  The sample was once again subjected to a 
15sec vortex. 
Binding 
The samples were placed into a heat block at 70°C for 10 minutes before being spun at 60,000 RCF for 
15 seconds. 
Washing 
To wash the samples, 200µL of 98% Ethanol was added prior to a 15 second vortex and 15 second 
centrifuge.  Each sample was then transferred to a Qiagen Mini-Column (Qiagen, Germany) and 
centrifuged at 6,000G for 1 minute.  The Mini-Column was then placed  into a Qiagen Collection tube 
(Qiagen, Germany) and 500µL of Buffer AW1 (Qiagen, Germany) was added. This was centrifuged at 
6,000G for 1 minute.  Next the Mini-Column was placed into a new Qiagen Collection tube and 500µL 
of Buffer AW2 (Qiagen, Germany) was added.  The samples were centrifuged at 17,000G for 3 minutes 
before being placed into another new Qiagen Collection tube and being centrifuged at 17,000G for 1 
minute. 
Elution 
For the elution of the sample DNA, each Mini-Column was placed into a 1.5mL Eppendorf tube and 
200µL of molecular grade DNA free sterile water was added.  This was left at room temperature for 5 
minutes before being centrifuged at 6,000G for 1 minute.  The resultant eluate was collected and 
stored as DNA CYST001.1. 
The Mini-Column was then placed into another fresh 1.5mL Eppendorf tube and a further 100µL of 
molecular grade DNA free sterile water was added.  Again this was left at room temperature for 5 
P a g e  | 54 
 
minutes before being centrifuged as before.  The resultant eluate from this second collection was 
labelled as DNA CYST001.2.  Both eluates were stored at -20°C and their location recorded on LIMS. 
As can be seen from the protocol above this resulted in two elutes for each sample.  These eluates 
were then analysed using the Nanodrop Reader (Thermo Scientific, Boston, USA) and the resultant 
concentrations of DNA recorded as ng of DNA / µL of eluate.   
The resultant concentrations for each elute of CYST001 – CYST 072 are recorded in Appendix A.  The 
median concentration of extracted DNA was 43.25ng/µL (IQR: 19.8 – 77.3). There was no significant 
difference between the concentrations obtained from first or second elute (p=0.944).   
For the remainder of the thesis it can be assumed that where DNA analyses took place on a sample, 
the eluate with the highest concentration of DNA was used. 
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4.3.2- Assessing Concentration 
Throughout my lab work I have needed to assess the concentration of DNA within my samples – two 
methods were used; NanoDrop (ThermoScientific, Boston, USA) and Qubit (Life Technologies, New 
York, USA).  Initially, until the purchase of the Qubit I used only the NanoDrop to assess the 
concentration of DNA extracted from the frozen samples. 
NanoDrop uses UV absorbance measurements of samples, at 260nm to quantify DNA and the 260/280 
ratio to estimate purity (quality) of nucleic acid – but is unable to differentiate between DNA and 
RNA.244, 245  Furthermore at low concentrations the NanoDrop has been shown to be inaccurate by 
significantly overestimating the measurement; reliability can only be assured at sample 
concentrations of between 2 ng/μL to 15 μg/μL.246, 247 
Conversely the Qubit uses Fluorometry based upon dyes which bind specifically with either DNA or 
RNA.247  Most importantly to my work the Qubit has shown to be accurate down to concentrations of 
10pg/µL.247 
Qubit Flourometer 
It is important that during the analyses of concentration only thin-walled, clear 0.5mL PCR tubes are 
used so as not to impede the flourometer.  The reagents provided should be kept refrigerated at 4°C 
(with the exception of the dye) and then allowed to reach room temperature prior to use.  The 
following protocol was followed: 
1) The number of thin-walled clear PCR tubes needed was calculated as follows: n+2 (where n= 
the number of samples to be assayed). 
2) The ‘working solution’ was made by diluting the Quant-iT (Life Technologies, Boston, USA) 
reagent 1:200 into the Quant-iT buffer.  200µL is required for each tube. 
3) Into the first two tubes 190µL of working solution was placed, 195µL was placed into the 
remaining sample tubes. 
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4) In the first tube 10µL of Standard 1 (Life Technologies, Boston, USA) was added and this was 
labelled as ‘standard 1’. 
5) In the second tube 10µL of Standard 2 (Life Technologies, Boston, USA) was added and this 
was labelled as ‘standard 2’. 
6) Each of the remaining tubes had 5µL of individual sample added and were then labelled. 
7) All tubes were then vortexed for 3 seconds. 
8) The Qubit was calibrated by selecting ‘calibrate’ from the menu and inserting Standards 1 and 
2 when prompted. 
9) Each sample was then inserted in turn into the flourometer using the ‘calculate’ function to 
record the concentration of DNA in ng/µL.  
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4.3.3 - Limiting Dilution 
Theory 
Limiting Dilution describes the process of reducing the concentration of genomes in a sample to try to 
increase the concentration of mutant genomes within an aliquot to increase the sensitivity of 
detection at PCR. 
Only approx. 1% of genomes from my samples may be mutant – PCR will introduce an error of ~1% so 
how do we distinguish the PCR error from genuine mutants? 
Conventional PCR would not be sensitive enough to distinguish ‘true’ mutants from PCR inferred error.  
If we start with a definite number of genomes we can expect that ‘true’ mutants would be amplified 
at the same ratio as they appear in the sample. 
If we accept a minimum of 1 in 10 (10%) and ensure each sample is 10 genomes we should see mutants 
of ≥10% of total reads where the mutant sequence is present and 0% otherwise.   
If we take PCR error in the region of 1% any mutations <10% can be ignored as erroneous. 
For illustration assume that of 100 genomes of p53, 1 is mutant.  If I take 10 non-sequential dilutions 
of this down to 10 genomes per sample there will likely be at least 1 dilution which contains a mutant 
genome.  This dilution then has 1 mutant out of 10 genomes (10%), compared to the original sample 
of 1 per 100. 
PCR of each separate dilution will introduce a 1% error in calling ‘false’ mutations.  It can be seen that 
if the original ‘stock’ solution was used the 1% error rate would mask the 1% ‘true’ mutation rate.  
Using the limiting dilution method 10 samples are created, one of which will probably have a mutant 
sequence and in this sample there will be a  mutation ratio of 10% thus, whilst the remaining 9 samples 
may appear as wild type, there will be a 10% mutation read alongside the background 1% error rate. 
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It is analogous to try to blindly select a single black snooker ball from a bag which contains 99 red balls.  
If you are allowed to select a ball 10 times (replacing the ball each time) there is a probability of 0.01 
that you will select the black ball (1:99).  If the sample of 100 balls is randomly placed into 10 separate 
bags and you can select one ball from each bag the probability is now 0.1 (1:9) that you will select the 
black ball in one of the bags. 
What is 10G? 
A genome is defined as one complete copy of an organism’s DNA.  As humans have diploid cells, each 
cell will contain two copies of TP53.  I aimed to ensure that only 10 copies of sample genome were 
present in each well of the PCR reaction. 
Before I could begin the process of diluting my samples down to 10G I needed to try to ensure that 
they were all at the same starting concentration – real-time PCR was used to analyse my samples for 
their concentration against a purchased sample of standardised 10G human DNA (Sigma, 2ug).  I was 
aware that whilst each sample likely contained millions of genomes I needed to ensure that I did not 
inadvertently dilute below 10G during this first step.  The mass of 10G of human DNA was calculated 
using the following assumptions: 
A. Number of base pairs in haploid human genome = 3^109  
B. Average molecular mass of 1 base pair = 660 Daltons 
C. 1Da = 1.67^10-27g 
This means that a single genome of human diploid DNA weighs 6.6^10-27g or 6.6pg (((AxB)x2)xC).  Thus 
10G = 6.6pg x10 = 66.6pg.  As long as the concentrations did not fall below 66.6pg/µL at least 10G 
would be likely. 
Standardisation 
Each sample of extracted DNA had been analysed using the NanoDrop (Thermo Scientific, Boston, 
USA) to ascertain the concentration of DNA in each eluate.  As previously described, each sample 
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underwent two elutions (p.523) and the more concentrated of these elutes was taken for the following 
steps. 
The PCR protocol (p.68) would require a maximum of 5µL of sample DNA and that there were 8 Exons, 
each with a forward and reverse reaction for the ion torrent.  Furthermore, each reaction would need 
to be repeated 10 times, thus I needed a minimum of 800µL (8x2x10x5µL).  A 1mL stock of each sample 
was prepared at a concentration of 0.25ng/µL.  Where necessary serial dilution techniques were 
employed to ensure that 0.25ng of each sample was placed into a sterile Eppendorf and reconstituted 
with sufficient volume of molecular grade DNA free sterile water to result in 1mL.  I randomly selected 
ten samples and confirmed the concentration was 0.25ng/µL using the Qubit (Life Technologies, New 
York, USA) analysis (p.55). The median concentration was 0.25ng/µL (error +/- 0.02ng/µL). 
From now on all samples referred to as CYST0-- can be considered as being the 0.25ng/µL dilution of 
the original. 
Dilution Factor 
As 10G is a constant for each sample a constant factor can be calculated which could be applied to 
each sample to create a sample of an appropriate volume at a concentration of 66.6pg/µL.   
I performed KRAS light cycler analysis on two randomly selected samples (CYST003 and CYST012) and 
compared them to a known sample at 10G using the following protocol: 
1) 10µL of LC480 SYBR Green (Roche Diagnostics, Mannheim, Germany) 
2) 0.5µL of Forward and Reverse Primers for KRAS (Appendix B) 
3) 2µL of sample (either 10G standard, CYST003, CYST012, or Molecular Grade DNA free sterile 
water) 
4) 7µL Molecular Grade DNA free sterile water 
I performed the analysis twice. 
The cycle threshold for the 10G standard was 46 compared to 41 for CYST003 and 40 for CYST012. 
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Therefore, as each cycle represented a doubling of the DNA present I diluted CYST003 to 1:25 (52) 
which represented 5 cycles (46 – 41) and CYST012 to 1:36 (62) which represented 6 cycles (46 – 40). 
I then repeated the experiment using exactly the same protocol but with the new dilutions of CYST003 
and CYST012 included as well as the original 0.25ng/µL samples.  The results can be seen in Table 6. 
Table 6: Comparison of two samples against known 10G standard. 
Sample Cycle Threshold at Original 
Concentration 
Cycle Threshold of Diluted 
Sample 
10G 44 cycles - 
CYST003 42 cycles (1:25) 53 cycles 
CYST012 39 cycles (1:36) 48 cycles 
This is an example of samples being over-diluted and so the process was repeated using 1:4 dilution 
of CYST003 and 1:25 of CYST012 (Table ). 
Table 7: Second comparison of two samples against known 10G standard. 
Sample Cycle Threshold at Original 
Concentration 
Cycle Threshold of Diluted 
Sample 
10G 44 cycles - 
CYST003 42 cycles (1:4) 44 cycles 
CYST012 39 cycles (1:20) 44 cycles 
 
The concentration of DNA using the Qubit (p.55) was ascertained for each of these diluted samples, I 
then divided this by the required concentration needed to take them from 0.25ng/µL to 10G (44 
cycles) giving a constant ‘dilution factor’.  This can be expressed as: 
[DNA] 
Dilution 
Thus, the exact volume required to obtain 10G was calculated for the remaining samples using [DNA] 
x DF. 
The Qubit concentration of CYST003 was 0.267ng/µL and CYST012 was 0.663ng/µL. 
0.267ng/µL ÷ 4 cycles = 0.06675 
= Dilution Factor (DF)              
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0.663ng/µL ÷ 20 cycles = 0.03313  
The average of these values is 0.04994, rounded to give a Dilution Factor of 0.05. 
Preparation of Samples 
Each of the samples (at 0.25ng/µL) was diluted by 0.05 x their Qubit confirmed concentration, e.g. 
CYST073 had a concentration of 0.2610 – when multiplied by 0.05 this meant that 0.013µL contained 
10G.   
Once I had optimised the PCR reaction (p.68) I knew that I would be using 4µL of sample per reaction, 
so there needed to be a final concentration of 10G per 4µL.  I opted to create 1mL of each sample to 
allow for spillage/error/repeats/etc. 
Worked example using CYST073. 
 Initial concentration 0.2610ng/µL x DF 0.05 = 0.013µL would contain 10G. 
 To make 4µL at 10G would require 0.013µL of CYST073 + 3.987µL of molecular grade DNA free 
sterile water. 
 To make 1mL would require 250 x 0.013 (1000µL ÷ 4µL) = 3.25µL.  
 Thus 996.75µL of molecular grade DNA free sterile water (1000µL – 3.25µL) needs to be 
added. 
The above dilutions were made to every sample and accordingly labelled as CYST001/10G; 
CYST002/10G and so on.  
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4.3.4 - PCR Optimisation 
Dr Li Yan had already optimised a PCR programme for TP53 using her own primers (to which I had 
added barcodes and ion torrent adaptors, p.50) so the initial protocol was adapted from her protocol 
for a 25µL reaction: 
 2.5µL of 10x Buffer (Envitrogen LifeScience Technologies, New York,USA) 
 1.5µL of MgCl (25nM) (Envitrogen LifeScience Technologies, New York,USA) 
 0.52µL of dNTP (KAPA Biosystems, KAPA dNTP Mix,Mixture of dATP, dCTP, dGTP and dTTP, 10 
mM each) 
 0.129µL of Apmli-Taq Gold (Envitrogen LifeScience Technologies, New York,USA) 
 0.4µL of Forward and Reverse Primers (1 pMol) 
 17.49µL of molecular grade DNA free sterile water 
 2µL of DNA 
The PCR was optimised using the DNA diluted to a concentration of 0.25ng/µL to avoid wastage.  I 
started with one barcode primer from each exon.  The PCR programme was automated using the 
following steps: 
 Heated Lid 
 Hot start 
 5:00 at 90°C 
 Annealing - 70°C for 0:05 
 Binding - 55°C for 0:05 
 Melting - 95°C for 0:10 
 45 cycles 
 72°C Final 10:00 
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The resultant PCR product was then run on a 2% agarose gel (TAE Buffer + Agarose + Nucleic Acid Dye 
(Biotium, GelRedTM Nucleic Acid Gel Stain)) for 25 minutes at 130V / 400mA.  Each well was loaded 
with 5µL product and 2µL of loading dye (Promega, Blue/Orange Loading Dye, 6X).  For comparison 
1.2µL of ladder (Roch, DNA Molecular Weight Marker XIII) was used.  
There was a significant amount of primer-dimer, in fact it was impossible to identify the product which 
would have been expected at 180-205 bp.   
The specificity of primers can be improved using the following methods: 
1.) Decrease the concentration of pimers. 
2.) Increase the annealing temperature. 
3.) Decrease the concentration of MgCl. 
Thus using the same DNA extraction and primers (5F1A2.5; 6FA3.5; 7F1P3.4; 8F2A2.4) I set four 
separate PCR reactions with water controls, altering only the following parameters and maintained 
everything else constant: 
1.) a.) Primer dilution 1:10. 
b.) Primer dilution 1:100. 
       2.)  Annealing temperature increased to 60°C. 
       3.)  MgCl volume decreased to 1.0µL (the difference made up with water). 
The resulting 1.8% Agarose gel can be seen in Figure 4.  Appropriate bands can be observed for Exons 
7 and 8 at a dilution of 1:100 primers, annealing temperature of 55°C and MgCl (25nM) volume of 
1.5µL.  Unfortunately the control wells were also contaminated with DNA, but at least this proved that 
the primers were indeed amplifying product. There were no bands produced for Exons 5 or 6 using 
any of the variations above.  When I repeated exactly the same experiment using more primers from 
Exons 7 and 8 I did not produce any PCR product – the only discernible difference in the protocol was 
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that I had created the ‘master mix’ of sample DNA free PCR ingredients in the designated ‘DNA Free’ 
room in The University Clinical Department.   
 
 
 
 
 
 
 
Figure 4: 1.8% Agarose Gel showing appropriate bands for Primers of Exon 7 (F1 and F2) and Exon 8 (F1 and 2) but not 
Exons 5 or 6. 
Exons 5 and 6  
I designed a PCR protocol for a touch-down PCR with an annealing temperature from 60°C-50°C in the 
hope that I may see bands of product suggesting the range in which I should search for the optimum 
annealing temperature for Exon 5 and/or 6.  I also realised that the annealing temperature for exon 5 
may be different from that required for exon 6, which would make future analysis all the more 
complicated in a 96-well plate format. 
When I reviewed the gels from my first primer variable experiments, I noted that despite the lack of 
product there were strong bands representing primer-dimers in the wells of Exon 5 and 6 primers 
which were run with an annealing temperature of 60°C.  PCR reactions were set up using an annealing 
temperature of 61°C, 63°C, 65°C.  Primer-dimer was apparent at 61°C but there was no product at 
63°C or 65°C.  I ran a PCR protocol using primers from exon 5 and 6 at 62°C which revealed bands at 
the expected length for my product (Figure 5).  
              Exon:            5F1            6  7               8             5F2       5F3   
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Figure 5: 1.8% Agarose Gel showing appropriate bands for primers of Exon 5 (F1, 2 &3) 
I had now found the optimum annealing temperature for all 4 exons: 
 Exons 5 and 6 = 62°C 
 Exons 7 and 8 = 55°C 
So two separate PCR runs for each sample would be needed. 
Mass Production 
I took one sterile 96-well plate (Star Labs, Manchester, UK) and in a DNA-free room I pipetted the 
volumes of each ingredient as listed on p.62 into the first 10 wells rows A-H.  This plate became the 
PCR base for Exons 5 and 6 of sample CYST001.  The process was repeated for a second 96-well plate 
which became the base for Exons 7 and 8.  The plates were covered with adhesive aluminium foil and 
transferred to the main laboratory and 2µL of DNA from CYST001 (at 0.25ng/µL) was added to each 
well giving a total volume of 25µL.  The plates were sealed and centrifuged at 6,000G for 15 seconds 
then placed into the thermocycler.  The plate containing the primers for Exons 5 and 6 was set off 
using the protocol which included an annealing temperature of 62°C; the plate containing the primers 
for Exons 7 and 8 was set off using the protocol which included an annealing temperature of 55°C.  
The resulting agarose gels can be seen in Figure 6. 
 
Temp:                  61°C                63°C                65°C 
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Figure 6: 1.8% Agarose gel showing scanty product for Exon 5 and 6 primers. 
There was product in some wells but not in others which I found difficult to explain as the primers in 
adjacent wells were, by definition, only a single nucleotide different from those which had worked in 
my initial experiments.   
There was room for pipetting error given the sheer quantity (160) wells which were being injected 
with PCR ingredients.  Further none of the pipettes I had been using were ‘negative-pressure’ pipettes 
and so would not be accurate enough for ultra-low volumes such as those which I had been using for 
dNTP, primers and Taq. 
I concluded that another approach to this problem would be to create a “mastermix” of all PCR 
ingredients (excluding sample DNA and primers) which could them be pipetted into each well with 
DNA added separately.  This would also save me significant time.  I calculated that I would need 
sufficient material for each barcode to be used 25 times (73 samples ÷ 3 barcode sequences).  Each 
mix would therefore need the materials as detailed in Table 8.  
This gave a total ‘mastermix’ volume of 556.756µL which could be pipetted into 25 wells and then 
have DNA added to it.  I initially restricted this new mastermix method to Fragment 1 of Exon 5, Figure 
7 shows that this method did successfully create product. 
 
 
 
 
 
 
Primers:    5F1    5F2    5F3     6        7F1   7F2     8F1   8F2      Controls 
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Table 8: Mastermix volumes. 
Ingredient Initial Volume X 25 
10x Buffer  2.5µL 62.5µL 
MgCl (25nM) 1.5µL 37.5µL 
dNTP (10nM) 0.52 µL 13µL 
Apmli-Taq Gold  0.129µL 3.255µL 
Forward and Reverse 
Primers (1pMol) 
0.4µL 10µL 
Molecular grade DNA free 
sterile water 
17.49µL 437.25µL 
 
  
 
 
 
 
 
 
 
Figure 7: 1.8% Agarose Gel showing product for all primers.  First two wells on each row are controls, the test wells are: 
5F1forward; 5F1reverse; 5F2forward; etc… 
In order for this method to work I would need to create 480 separate mastermixes – this posed issues 
in terms of the storage space within the DNA-free room and the concern that if I contaminated one of 
these mastermix vials then the whole volume (sufficient for 25 reactions) would have to be wasted. 
This concern was compounded as dNTPs will degrade with multiple episodes of defrosting and re-
freezing. Also I had presumed that the AmpliTaq gold would remain stable and inactivated until it was 
heated to 96°C, however, as the enzyme is stabilised in glycerol dilution with the other ingredients 
(especially the molecular grade water) could alter the properties and affect the quality of the Taq.  On 
the basis of these factors I decided not to create these large volume mastermixes. 
The compromise I attained was to dilute the primers with molecular grade DNA free sterile water so 
that I could pipette a larger volume into each reaction – this would be far easier than trying to 
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accurately pipette 0.4µL into each well.  The forward primers only were diluted such that a volume of 
1µL could be added to each well. 
The Final Protocol 
Within the DNA free room three 96-well plates were prepared by being placed under a UV light for 30 
mins.  Each of these plates was labelled with indelible ink – e.g. CYST001 Exons 5 & 6; CYST002 Exons 
5 & 6; CYST003 Exons 5 & 6. 
8 Sterile DNA free Eppendorf tubes were placed into a rack and labelled 1 – 8. 
The following ingredients should be added to each of the eight tubes in turn: 
1.) 80µL of 10x Buffer.  
2.) 48µL of MgCl (25nM). 
3.) 16.64 µL of dNTP (10nM). 
4.) 540.48µL of molecular grade DNA free sterile water. 
The tubes had 12.8µL of reverse primers added in the following order: 
Tube 1 = Exon 5 F1 P – Reverse 
Tube 2 = Exon 5 F1 A – Reverse 
Tube 3 = Exon 5 F2 P – Reverse 
Tube 4 = Exon 5 F2 A – Reverse 
Tube 5 = Exon 5 F3 P – Reverse 
Tube 6 = Exon 5 F3 A – Reverse 
Tube 7 = Exon 6 P – Reverse 
Tube 8 = Exon 6 A – Reverse 
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Finally to each of these tubes 4.128µL of AmpliTaq Gold was added – it is important to add this last to 
try and reduce the incidence of primer-dimer.  The resulting tubes will have sufficient volume for 32 
reactions; only 31 reactions are required so there should be a sufficient margin for error. 
Using Tube 1, 22µL of the mixture was pipetted into the first 10 wells of row A in each of the three 
plates.  Discard the tube.  On the first plate column 11 was used as well, this was to be used as a 
control for the mastermix. I repeated this process for the remaining seven tubes in rows B – H 
respectively. 
Using the pre-diluted forward primers 1µL of Exon 5 F1 A 1.1 was added to the plate labelled CYST001 
in well A/1.  
1µL of Exon 5 F1 A 1.2 was added to well A/2.  This was continued along the row to Exon 5 F1 A 1.10, 
then continued along the next row with Exon 5 F1 P 1.1 in B/1.  The process was further completed 
until I reached Exon 6 P 1.10 in H/10. 
The process was repeated for the plate labelled CYST002 this time using the forward primers prefixed 
with 2, e.g Exon 5 F1 A 2.1 – 2.10, and for the plate labelled CYST003 this time using the forward 
primers prefixed with 3, e.g. Exon 5 F1 A 3.1 – 3.10. 
Into column 11 of the first plate I added 2µL of molecular grade DNA free sterile water to act as a 
control.  The eight wells in column 11 had corresponding forward primers added – these were 
randomly chosen from any of the barcoded primers which corresponded. 
Each of the plates were covered with a sterile aluminium (heat-proof) cover and transfered to the DNA 
lab. 
2µL of DNA at 10G was added to each of the wells in columns 1-10.  The DNA corresponded to the 
label on the plate, CYST001, CYST002, etc. Once the DNA was added the plates were re-covered and 
placed into the thermo-cycler and set off on the pre-loaded programme called JIMBOB EXONS 5 & 6 
(i.e. with an annealing temperature of 62°C). 
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This will provide PCR product and control reactions for Exons 5 & 6 for three samples. 
Once the PCR reaction had completed the plates were stored at 4°C. 
The entire process was repeated again this time for Exons 7 & 8.  This time the reverse primers were 
applied as below: 
Tube 1 = Exon 7 F1 P – Reverse 
Tube 2 = Exon 7 F1 A – Reverse 
Tube 3 = Exon 7 F2 P – Reverse 
Tube 4 = Exon 7 F2 A – Reverse 
Tube 5 = Exon 8 F1 P – Reverse 
Tube 6 = Exon 8 F1 A – Reverse 
Tube 7 = Exon 8 F2 P – Reverse 
Tube 8 = Exon 8 F2 A – Reverse 
The forward primers were applied as Exon 7 F1 A 1.1 – 1.10 and so on until Exon 8 F2 P 3.10. 
A complete list of barcoded forward primers and their corresponding reverse primers is given in 
Appendix C. 
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4.3.5 - Extraction and Purification 
Over the previous pages I have described the protocol for the preparation of the PCR mixture.  As a 
result of the PCR there were six 96-well plates labelled as follows: 
CYST001 Exons 5 & 6, CYST001 Exons 7 & 8 – Barcoded primers prefixed with ‘1’. 
CYST002 Exons 5 & 6, CYST002 Exons 7 & 8 – Barcoded primers prefixed with ‘2’. 
CYST003 Exons 5 & 6, CYST003 Exons 7 & 8 – Barcoded primers prefixed with ‘3’. 
Each sample therefore had 160 wells of product, each containing 25µL.  The first step was to confirm 
that the PCR has worked by running an agarose gel to confirm product was present.  Thereafter this 
product needed to be extracted from the mixture and prepared for IonTorrent analysis. 
Agarose Gel 
Using a gel made of 1.8% agarose (Star Labs, Manchester, UK) and TAE buffer, I ran multiple samples 
in one electrophoresis reaction.  Using the largest tank available, and the narrowest comb, I created a 
gel that was capable of holding 80 samples with marking ladders.  
The settings for the gel electrophoresis were: 
400mA and 130V for 25 minutes. 
For each of the gels I used 5µL of PCR product to confirm that the PCR reaction had been successful; 
this left me with 20µL for further purification.  In order to optimise my samples for the ion torrent I 
followed the published protocol provided with the torrent device – a technique known as AMPure 
(Life Technologies, New York, USA).  Once I had confirmed the presence of appropriate bands on the 
‘check’ gel I used the AMPure kit to prepare the DNA libraries ready for the ion torrent. 
AMPure Clean-up 
10µL of DNA product from each well was placed into a sterile 0.5mL Eppendorf. 
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I submitted the bottle of AMPure XP magnetic particle solution to a vortex to ensure the magnetic 
particles were fully suspended in the solution.  (Each bead is made of polystyrene surrounded by a 
layer of magnetite, which is coated with carboxyl molecules. It is these that reversibly bind DNA in the 
presence of polyethylene glycol and salt.  PEG causes the negatively-charged DNA to bind with the 
carboxyl groups on the bead surface).248  
I then added 18µL (i.e. 1.8x volume) of AMPure XP magnetic particle solution to each Eppendorf and 
mixed well by re-pipetting 10 times.  This was then incubated at room temperature for 10 minutes 
before being placed into the AMPure magnet (Figure 8) holder for 5 minutes (maximum of 16). 
Fragments of DNA with a particle size of >100bp were attached to the beads so the supernatant was 
aspirated and discarded and each cluster of adherent magnetic beads was washed with 60µL of 70% 
ethanol which was left in place for 30 seconds before being aspirated and discarded.  This was 
repeated once more to give a total of 2 washes.  I then pipetted 15µL of ‘Elution Buffer’ (Beckman-
Coulter) into each Eppendorf and mixed by pipetteing 10 times. The Eppendorfs were removed from 
the magnet and left to incubate at room temperature for 2 minutes. 
The DNA fragments were now eluted from the beads and into the solution. The final step involved 
placing the Eppendorfs back onto the magnet for 1 minute and the supernatant (10µL to ensure no 
inadvertent aspiration of beads) was aspirated and transferred to a separate Eppendorf.  This was 
then stored at 4°C in preparation for processing.  
As can be seen this is a laborious procedure which requires a lot of consumables (Eppendorfs and 
sterile pipette tips) but also carries a significant risk of accidental cross-contamination.  As only 16 
Eppendorfs could be processed at a time it became apparent that this step may well become a rate 
limiting stage in the completion of my lab work. 
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Figure 8: A pictorial schematic of Ion Torrent Methods. 
Gel Purification 
As I progressed through the purification of each of the PCR products from the first six 96-well plates I 
realised that I needed to find a way to speed up the process.  When the first round of ion torrent data 
became available from those three samples it was apparent that, despite my efforts at AMPure 
purification, there was still significant contamination with primer-dimer – the first run of the ion 
torrent revealed that the chip had preferentially sequenced runs of primer-dimer rather than the 
product.  I realised that this was most likely due to the fact that because of the addition of ion torrent 
adapters and barcodes the size of my primer-dimers would be in the region of 100bp, and thus they 
could not be adequately separated from the product during the magnetic bead purification. 
There were two options: 
1.) Decrease the ratio of AMPure beads to DNA from 1.8 to 0.8 which should increase the 
specificity of the procedure such that only fragments >200bp would be isolated, or: 
2.) Find an alternative method, such as gel purification. 
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The mechanism is simple – the product for the PCR reaction is run on an agarose gel as long as is 
necessary for the product and the primer-dimers to separate.  Then the agarose gel containing the 
DNA fragments of interest (the product) was cut out with a scalpel and the DNA was extracted using 
the following method: 
Each cut band of agarose gel was weighed in a sterile Eppendorf and then 300µL of Agarose 
Solubilisation Buffer (Roche, Hamburg, Germany) was added for every 100mg of agarose.  I then added 
10µL of Silica Suspension (Roche) and then each Eppendorf was mixed using a vortex until a 
homogenous suspension had been created. The Eppendorfs were then incubated at 60°C for 10 
minutes with each sample being vortexed every 3 minutes. Each Eppendorf was then centrifuged at 
maximum speed for 30 seconds – the supernatant was discarded.  I added 500µL of Nucelic Acid 
Binding Buffer (Roche) to each Eppendorf and mixed on a vortex for 10 seconds before centrifuging at 
maximal speed for 30 seconds and discarding the supernatant. 
Each pellet was re-suspended with 500µL of Washing Buffer (Roche) and mixed on a vortex for 10 
seconds before another round of centrifugation at maximal speed for 30 seconds again discarding the 
supernatant.  The washing step was repeated with 500µL of Washing Buffer. 
The samples underwent centrifugation again at maximal speed for 30 seconds and the supernatant 
was dicarded.  A final centrifugation was performed at maximal speed for 1 minute and any liquid 
carefully disposed of. 
Each Eppendorf was carefully inverted onto an absorbent piece of tissue and left to dry at room 
temperature for 20 minutes.  30µL of AMPure Elution Buffer (Life Technologies) was used to suspend 
each pellet using the pipette to mix.  The samples were then incubated at 60°C for 10 minutes, with a 
vortex being performed on each sample every 3 minutes. 
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Finally the samples were each centrifuged at maximal speed for 30 seconds and 25µL of supernatant 
(containing the extracted DNA) was transferred to a sterile Nunc tube and labelled accordingly.  The 
samples were then stored at 4°C. 
Refinements to Gel Extraction 
Initially the protocol from Roche had called for distilled water to be used as the extraction solvent, 
however, I was aware that the Elution Buffer supplied by Life Technologies was specifically adapted 
for the ion torrent and so I sought to use it where possible.  To ensure that the reagent did not interact 
negatively with any of the chemicals used in the process I performed a side by side comparison of the 
Elution Buffer versus distilled water over 4 random samples (Table 9). 
Table 9: Examples of DNA concentration when elution is performed with water vs. elution buffer. 
Sample Elution with 30µL Buffer 
(ng/µL) 
Elution with 30 µL Water (ng/µL) 
5 F2 A 1.1 (CYST001) 0.240 0.0972 
5 F2 P 2.6 (CYST002) 0.222 0.744 
5 F3 A 3.4 (CYST003) 0.370 - 
6 A 2.5 (CYST002) 0.240 - 
 
On this basis I elected to use the ion torrent Elution Buffer as it gave more consistent results than 
distilled water. 
Whilst this method was certainly quicker than the AMPure technique there was still the significantly 
labour intensive step of creating the large agarose gel on which I had to run each PCR well separately 
and then cut each band by eye. 
It occurred to me that as long as I ensured that barcoded primers from different samples didn’t mix I 
would be able to run a smaller number of wells by combining the PCR product for each barcode 1-10 
of each exon. 
Therefore once I retrieved the 96 well plate from the thermocycler at the end of the PCR run I could 
combine 10µL from each of the 10 barcodes for Exon 5 F1 A to create a single 100µL solution which 
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represented Exon 5 F1 A for that particular sample.  If I did the same for each of the other rows on the 
plate I would end up with sixteen 100µL combinations for each sample. 
These were then added to loading dye (5µL) and pipetted into two adjacent troughs on the agar gel.  
From now on I could run three entire samples on one single gel using this ‘combination’ method with 
far fewer extractions needed to prepare the libraries.  
Even with these modifications it became apparent that I would need a significant volume of Gel 
Solubilisation Buffer, Nucleic Acid Binding Buffer and Washing Buffer from Roche.  Purely in an effort 
to reduce costs I researched the contents of the kits using the manufacturers data sheets and used 
the following formulae to create two of the reagents from stock chemicals.  The silica matrix still 
needed to be purchased however. 
Gel Solubilisation Buffer = 6M NaCl + 0.05M Tris-Cl + 10mM EDTA. 
Washing Buffer = 20mM Tris-Cl + 2mM EDTA + 0.4M NaCl + 50% v/v 99% ethanol. 
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4.3.6 - Preparing the Libraries 
Once the DNA intended for sequence had been extracted from the agarose gel it needed to be 
prepared for use in the Ion Torrent Sequencer.  This was achieved in three stages which can be 
summarised as: Concentration; Combination; and Calculation. 
The overriding principle is to ensure that the distribution of each fragment of replicated DNA is 
equimolar across the chip – thereby ensuring that no single fragment dominates and will be 
preferentially sequenced at the expense of others.   
Each fragment is thus presented to the Ion torrent as if were an individual patient – thus I am provided 
with 10 independent sequences (barcodes) of each fragment for each of the three patients on the 
chip. 
Concentration 
Each sample which had been extracted from the gel, a volume of 25µL, was inserted into the Qubit to 
ascertain the concentration of DNA for each of the fragments 1-8, this was then noted in a table (e.g 
Table ). 
Table 10: Example of DNA concentrations after gel extraction. 
Patient e.g. CYST001 Concentration (ng/µL) 
Exon 5 Fragment 1 1.22 
Exon 5 Fragment 2 0.97 
Exon 5 Fragment 3 1.78 
Exon 6  1.37 
Exon 7 Fragment 1 1.04 
Exon 7 Fragment 2 0.76 
Exon 8 Fragment 1 1.67 
Exon 8 Fragment 2 1.08 
 
Three patient samples (CYST001 – CYST003) were analysed on each occasion, providing a total of 24 
concentrations.  I then combined the samples to result in one single sample for the Ion Torrent to 
sequence. 
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Combination 
In order to combine the samples in an equimolar distribution I first needed to calculate the 
concentration of each sample in pM using the following formula: 
pM = (
Sample Concentration (ng/µL)  × 109(µL/L)
660g x Size of Fragment (bp)
) 
Then, using the value of the lowest concentration in each sample, the following calculation is 
performed: 
Lowest concentration of Patient (ng/µL) ÷ Concentration of each sample (nM) 
The resulting value is the volume in microlitres of each sample required to result in the same 
concentration in nM as is present in the most dilute.  A worked example is shown in Table 11 . 
Table 11: An example of calculations required to establish volume of each sample needed based on concentration. 
Exon bp PCR Conc (ng/µL) pM nM Volume (µL) 
E5.1 215 1.22 8597.60 8.60 0.09 
E5.2 223 0.97 6590.57 6.59 0.12 
E5.3 188 1.78 12094.03 12.09 0.06 
E6 215 1.37 9308.33 9.31 0.08 
E7.1 193 1.04 7066.18 7.07 0.11 
E7.2 211 0.76 (lowest) 5163.75 5.16 0.15 
E8.1 197 1.67 11346.65 11.35 0.07 
E8.2 219 1.08 7337.95 7.34 0.10 
As can be seen from the example above, I would be required to pipette volumes as low as 0.07µL 
which is not possible to do with accuracy, as a result I applied the same multiplication factor to each 
volume until all of the volumes were greater than 1µL, see Table 12. 
Table 12: Serial volume increases required to establish adequate volume of final sample. 
Exon Volume (µL) x2 x4 x6 x10 x20 
E5.1 0.09 0.18 0.35 0.53 0.88 1.77 
E5.2 0.12 0.23 0.46 0.69 1.15 2.31 
E5.3 0.06 0.13 0.25 0.38 0.63 1.26 
E6 0.08 0.16 0.33 0.49 0.82 1.63 
E7.1 0.11 0.22 0.43 0.65 1.08 2.15 
E7.2 0.15 0.29 0.59 0.88 1.47 2.94 
E8.1 0.07 0.13 0.27 0.40 0.67 1.34 
E8.2 0.10 0.21 0.41 0.62 1.04 2.07 
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This would therefore result in a ‘combination sample’ for this patient with a volume of 15.47µL.  This 
combination sample would contain 10 barcoded PCR amplifications of each fragment of TP53 in an 
equal distribution. 
Once this was performed for all three patients I am left with 3 combination samples of varying volumes 
and concentrations depending, of course, on the lowest concentration within each one. 
The process of combination was then repeated again after first ascertaining the concentration of each 
combination sample using the Qubit.  The same formula is used, however as each combination sample 
contains 8 different fragments the value for fragment size within the calculation is changed to the 
average of all 8 i.e. 207.25bp. 
Using this calculation I obtained the volume required from each of the combination samples to create 
an equimolar final library to place onto the chip.  This final library contains the PCR amplified DNA 
from three different patients at a constant concentration. 
Calculation 
This ‘final sample’ was labelled as J1 which correlated with the chip it was to be run on.  Thus J1 
contained the first three patients: CYST001 -003; and J2 held CYST004 -006; etc… 
In order to begin the Ion Torrent process the concentration of J1 was defined using the Qubit and this 
was used to determine the final dilution which would be used based upon the premise that the ion 
torrent chip will hold a maximum volume of 5µL which, in turn, should contain 40 million molecules 
for optimal sequencing.a
Clearly then, whatever the resultant concentration of J1 significant dilution was required – the factor 
of dilution was obtained using: 
Dilution Factor = Library Concentration (nM) ×  (
5x109 molecules/µL
8.3 nM
) × (
5 uL
40x106 molecules
)  
                                                          
a This is taken from the Instructions for Use of the Ion Torrent, provided with the software. 
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Thus to calculate what starting concentration would not require a dilution: 
Library Concentration (nM) =  (
5x109 molecules/µL
8.3 nM
) × (
5 uL
40x106 molecules
) × 1 (i. e. no dilution)  
Library Concentration (nM) =
1
(5x10
9 molecules/µL
8.3 nM
) × (
5 uL
40x106 molecules
)
  
Library Concentration (nM) =
1
(6.02 × 108) × (12.5 × 10−8)
 
Library Concentration (nM) =
1
75.25
 
Library Concentration (nM) = 0.01328 
 
Using serial dilution of 5µL of J1 to 10µL of molecular grade DNA free sterile water the library can be 
sufficiently diluted to a concentration of 0.01325nM (i.e. 40 million molecules). 
For Example: 
If the concentration of J1 was 0.292ng/µL then 5µL combined with 10µL of water would result in a 
concentration of 0.973nM: 
nM =
(5µL × 0.292ng/µL)
(5µL + 10µL)
 
If 5µL of this resultant mixture was again added to 10µL of water the resultant concentration would 
be 0.032ng/µL. Finally, by re-arranging the formula above, the volume of water required to reach a 
concentration of 0.01325nM can be calculated: 
µL = (
(5µL × 0.032ng/µL) 
0.01325nM
) − 5µL 
= 7.216µL  
5µL of this resultant dilution can therefore be used in the Ion Torrent reaction. 
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Chapter 5 
RESULTS 
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5.1 – Results from the EUROPAC Registry  
During my tenure as the EUROPAC fellow at Liverpool I was responsible, with Miss Sara Harrison, for 
maintaining the EUROPAC database in compliance with GCP guidelines.  In this chapter I will relay the 
contents of the database for both FPC and HP, the definitions and descriptions of which can be found 
in my introduction. 
Hereditary Pancreatitis 
As discussed in the introduction, HP kindreds are recorded on the EUROPAC database under the 
mutation which they are proven to carry – or as Neg All, sporadic, CNV or familial HP if no PRSS1/CFTR 
mutation can be demonstrated.  Table 6 displays the relative frequencies of these kindreds as well as 
the number of cases of confirmed PDAC which have been recorded. 
Table 13: Relative frequencies of HP kindreds by type in the EUROPAC database. 
Mutation Families Affected Individuals PDAC cases 
p.R122H 101 477 25 
p.N29I/T 46 195 11 
p.A16V 11 26 3 
Other PRSS1 15 27 1 
Neg All HP/CNV 49 181 18 
Possible HP 62 106 3 
Familial IP 67 126 27 
CFTR 21 30 1 
Sporadic 187 192 3 
TOTAL 559 1,360 92 
 
Familial Pancreatic Cancer 
In the EUROPAC registry an FPC kindred is sub-defined as: 
“True” FPC: Pancreatic cancer which has occurred within 2 or more first degree individuals across 2 
or more generations (e.g. father and son).  Within the EUROPAC cohort there are also kindreds in 
which there have been more than 2 cases of cancer.  267 kindreds with 662 cases of PDAC. 
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“?” FPC: Kindreds in which there have been 2 or more cases of pancreatic cancer amongst first degree 
relatives within one generation (e.g. brother and sister). 100 kindreds with 225 cases of PDAC. 
“Other” FPC:  This includes kindreds in which there have been at least one case of pancreatic cancer 
in conjunction with either; an associated mutation known to predispose to pancreatic cancer, or more 
than two cases of another cancer known to be associated with a predisposition to pancreatic cancer 
in the absence of any proven mutation (Table 14).  
Table 14: Relative frequencies of FPC sub-type (with mutation or syndrome) where known, among EUROPAC kindreds. 
Family Diagnosis Number of Families 
Breast-Ovarian 25 
BRCA2  14 
FAMMM 4 
HNPCC 8 
Possible HNPCC 6 
Neurofibromatosis 2 
Peutz-Jehgers 4 
With gastric 17 
FAP 1 
Other 51 
 
The geographical distribution of FPC and HP patients can be seen in Figures 9 and 10. 
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Figure 9: Geographical (Europe) distribution of HP families according to EUROPAC database.
 
Figure 10: Geographical (Europe) distribution of FPC families according to EUROPAC database. 
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5.2 – Pilot Study Undertaken by EUROPAC  
Between 1996 and 2005 the EUROPAC study was collecting data and tissue samples from individuals 
who underwent pre-operative ERCP prior to resection of pancreatic cysts which were felt on clinical 
and radiological grounds, to harbour malignant potential.  The collection of this data began with Mr 
Nathan Howes and continued with each subsequent EUROPAC Fellow that followed him. 
These data and specimens remained in storage at the Pancreas Biomedical Research Unit until 5 years 
had passed from the date of the last recruit.  In 2010 work began to analyse the juice collected at ERCP 
and the tissue collected at the time of operation.  I suggested we should start our search for a novel 
genetic predictor of survival with p53 and so Dr Li Yan analysed the samples using the previously 
described modified functional yeast assay.139  I am presenting this as part of my thesis because I 
performed the analyses of the results and this serves to explain why my doctoral research took the 
direction that it did.   
The following data was presented by me at the American Hepato-Pancreato-Biliary Association 
(AHPBA) in Miami, USA on 25/02/2012. 
29 patients underwent partial resection of their pancreas for cystic neoplasm(s) in 9 years at a single 
institution (The Royal Liverpool University Hospital).  12 were male and 17 female.  The median age at 
the time of resection was 66yrs (IQR: 23-79).  All individuals underwent an ERCP pre-operatively with 
collection of pancreatic juice from the pancreatic duct stimulated by intravenous secretin 
administration at 1mg/kg. 
The pancreatic juice obtained by direct aspiration was centrifuged and both pellet and supernatant 
were stored separately at -80°C. 
The patients then went on to have their operative resection and samples of tumour were obtained 
from their resected pancreata by a consultant pathologist immediately prior to routine histological 
processing.  These representative tissue samples were snap-frozen in isopentane and stored at -150°C. 
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After 5 years these tissue samples were defrosted and analysed for the presence or absence of a p53 
mutation using the modified yeast assay in a blinded fashion.139  The matched samples of supernatant 
and pancreatic juice were similarly processed. 
Independent histological analysis was performed by a single consultant histopathologist without 
reference to the original histology reports provided at the time of resection.  This was performed using 
original H&E stains from resected pancreata. 
After this analysis 11 patients were diagnosed as having IPMN; 7 were IMPN with carcinoma in-situ 
(IPMC); 3 were PDAC; 6 were cystadeoma; and 2 were pseudocysts.  For the purposes of future 
assessment these were grouped into ‘Malignant’ (IPMC and PDAC), n=10; and ‘Benign’, n=19. 
p53 mutations were found in 9 tissue samples: 2 IPMN; 4 IPMC; 2 PDAC; and 1 cystadenoma.  The 
survival data at 5 years is demonstrated in Table 15. 
Table 15: Survival and mutational data from 29 patients who underwent operative resection 1996 – 2005. 
Diagnosis (n) Death from PDAC at 5 yrs (n) P53 mutation in deceased / 
p53 mutation total 
IPMN (11) - Benign 2 2/2 
IPMC (7) - Malignant 5 4/4 
PDAC (3) - Malignant 3 2/2 
Cystadenoma (6) - Benign 0 0/1 
Pseudocyst (2) - Benign 0 0/0 
 
When grouped into ‘malignant’ and ‘benign’ it can be seen that 6 patients within the malignant cohort 
had a p53 mutation (60%) compared to 3 patients within the ‘Benign’ cohort (16%).  Most striking of 
all the 2 patients with benign IPMN who had a p53 mutation went on to develop PDAC within 5 years; 
the remaining 9 patients who had benign IPMN with wild type p53 survived.  Similarly, 5 of the 7 
patients with IPMC died four of which had a p53 mutation. 
Overall survival was 780 days (IQR: 15-340) and there was no significant difference between median 
survival for the ‘malignant’ cohort (420 days; IQR: 15-1,800) and those patients with a p53 mutation 
(450 days; IQR: 15-1,800).  However, when analysed using the Kaplan-Meier method (with the Mantel-
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Cox log-rank test) it can be seen that mutant p53 was a more significant predictor of poor survival 
than histology alone (p=0.0017 vs. p=0.0091)(Figures 11 and 12). 
 
 
 
 
 
 
 
Benign 11 7 7 6 4 1 
Malignant 7 3 3 1 1 0 
Figure 11: Kaplan-Meier analysis of survival for malignant versus benign cohorts 
 
  
 
 
 
 
 
Wild Type 13 9 5 4 2 0 
Mutant 5 2 1 1 1 0 
Figure 12: Kaplan-Meier analysis of survival for p53 mutant versus wild type cohorts. 
A Cox-regression analysis was performed including age, diabetes and gender as co-variants (smoking 
status was not available) which revealed that histology vs. survival had a coefficient of 0.221 
(p=0.0819) compared with p53 status vs. survival; 15.073 (p=0.0152).  Thus a mutation of p53 
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correlated with survival independently of and more significantly than the correlation between 
histology and survival. 
The sensitivity and specificity of p53 status as a predictor of survival at 5 years was therefore calculated 
as 0.89 and 0.95 respectively. 
It was also noted that in all cases where a p53 mutation was detected in the tissue a mutation was 
also detected in the juice sample analysed.  In two cases, however, the mutation detected within the 
juice differed in genomic location from that which was detected in the corresponding tissue sample. 
The conclusions of this (albeit small) study were threefold: 
1.) p53 mutational analysis is not a surrogate marker for histology. 
2.) p53 mutation is at least as good at predicting survival as eventual histological diagnosis in 
IPMN. 
3.) p53 can be accurately detected in pancreatic juice. 
The remainder of this thesis sets out to examine wether there is a single nucleotide polymorphism 
which can predict which IPMN harbour malignant potential, and possibly present an opportunity for 
gene therapy in the future. 
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5.3 - EUROPAC Screening Outcomes 
When offering screening to individuals registered with the EUROPAC Study various options are 
available, the exact type of screening offered to an individual depends upon their physical status and 
risk as determined from their family history.  Initially screening takes the form of a fasting blood 
sample to look for glucose impairment, followed by the offer of CA19-9 and a CT scan of the pancreas.  
In certain high risk individuals an ERCP is offered in order to obtain (via direct cannulation of the 
pancreatic duct) some pancreatic juice which is analysed for the presence or absence of TP53 and 
KRAS mutations as well as the value of CDK2Na promoter methylation. 
Pancreatic juice collection at ERCP carries a risk of post-ERCP pancreatitis (PEP) which can be 
potentially fatal.  As those individuals undergoing screening are a healthy cohort with no clinical 
indication for ERCP it is imperative that all possible steps are taken to mitigate this risk.  Studies have 
shown that the use of rectal diclofenac (a non-steroidal anti-inflammatory) reduces the incidence of 
PEP in individuals undergoing ERCP for clinical indications (gallstones, malignant biliary obstruction, 
etc…).  Similarly the routine use of a short plastic stent inserted into the pancreatic duct after the 
procedure has been shown to improve outcomes.   
This chapter of the thesis contains a paper in which we demonstrated that in our heathy cohort of 
screened individuals we can significantly reduce the incidence of PEP using a combination of these 
methods.  The individuals referred to in this screening paper are EUROPAC registrants and not 
individuals from whom samples have been analysed as described in the methods section.  I hope the 
inclusion of these data will demonstrate that screening using pancreatic juice is safe and feasible and 
may be applied to all those high rick individuals who are identified to have IPMN during observation 
and follow-up. 
The following work was undertaken during my PhD research and was subsequently published in 
Pancreas as: 
P a g e  | 90 
 
 
Nicholson JA, Greenhalf W, Jackson R, et.al. “Incidence of Post-ERCP Pancreatitis From Direct 
Pancreatic Juice Collection in Hereditary Pancreatitis and Familial Pancreatic Cancer Before and After 
the Introduction of Prophylactic Pancreatic Stents and Rectal Diclofenac”.249 
Materials and Methods 
Study Design 
Participants were recruited from among UK residents on the EUROPAC registry. Written informed 
consent was obtained for screening by imaging, measurement of serum CA19-9 levels and collection 
of pancreatic juice by ERCP. Imaging comprised computed tomography (CT) or magnetic resonance 
imaging (MRI) for both FPC and HP and in addition EUS for FPC. Patients could opt just for imaging 
without undergoing ERCP.  Screening in patients with HP was not commenced before they were aged 
at least 40 years.108, 116, 140, 250  Individuals from FPC kindreds were either a first degree relative (sibling, 
offspring, or parent) or a second degree relative (grandchild, nephew, or niece) of an affected 
individual.  Screening in FPC kindreds was commenced 10 years sooner than the youngest death from 
pancreatic cancer in that family or from 40 years of age if the youngest death was over 50 years of 
age.116, 138  The study is approved by the relevant Research Ethics Committees [LREC, AAGPM97199 
(1998); MREC, 07/H1211/96 (2007) & 07/H1008/153 (2007), Protocol Version 3 (2014)].  The study is 
co-sponsored by the University of Liverpool and The Royal Liverpool and Broadgreen University NHS 
Hospitals Trust.  The characteristics of patients, procedures and complications were regularly 
reviewed by the EUROPAC Screening Trial Steering Committee. 
Pancreas juice collection and analysis 
ERCP was undertaken by consultant gastroenterologists in the Endoscopy Unit at the Royal Liverpool 
University Hospital as a day case. Each patient was given 750mg ciprofloxacin, before and after ERCP.  
Intravenous sedation consisted of midazolam (1-5mg) with hyoscine butyl-bromide (20-40mg) as an 
anti-peristaltic agent and either fentanyl (50-100μg) or pethidine (25-50mg).  Selective cannulation of 
the pancreatic duct was confirmed by radiological screening without contrast followed by 
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administration of 1IU/Kg secretin (Sanochemia, Germany) intravenously.  After two minutes, 
pancreatic juice was collected by gentle aspiration from the pancreatic catheter.  Pancreatic juice was 
analysed for TP53 and KRAS mutation and quantification of CDK2Na promoter methylation.126 
Post-ERCP acute pancreatitis 
This was defined as an increase in serum amylase of at least three times (>450 iu/L) the upper limit of 
normal (150 iu/L) and abdominal pain within 48 hours of ERCP.  In HP patients there was no 
requirement for a raise in the serum amylase.  Duration of inpatient stay was defined as the number 
of days spent in hospital from the day of the ERCP procedure and severity was determined by the 
Atlanta criteria.251  All complications were reported to the relevant authorities (Sponsor and Research 
Ethics Committees) as serious adverse events in line with Good Clinical Practice. 
Prophylaxis measures 
A 3cm 5Fr self-expelling stent (single pig-tail, no flap; Cook Medical, Zimmon) was deployed using a 
5Fr introducer following aspiration of pancreatic juice.  Confirmation of stent placement was by 
observation of the pigtail end of the stent protruding into the duodenum via the ampulla of Vater. 
Additionally, diclofenac (50mg) was given per rectum within 30 minutes of the procedure.  Patients 
were routinely discharged the same day if there were no complications.  For all patients who had had 
a stent inserted a plain abdominal X-ray was undertaken 6 weeks after the ERCP to determine whether 
the pancreatic stent had been expelled. All patients were contacted at 6 weeks following the ERCP 
with the results of their molecular analysis and any other post-ERCP complications were identified and 
recorded. 
Statistical analysis 
Continuous data are presented as median and inter-quartile intervals (IQR), categorical data are 
displayed as tables of counts and associated percentages.  Associations of factors across patient 
groups were carried out using a two tailed Mann-Whitney U test for continuous data and Fisher’s 
exact test for categorical variables.  Risks are presented as odds ratio with associated 95% confidence 
intervals and are obtained from the parameters of univariate logistic regression models.  Multivariate 
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modelling was not attempted due to the small number of events.  All analyses were carried out using 
R version 2.15 (R Foundation for Statistical Computing, Vienna, Austria).  P values are assessed at the 
0.05 level throughout. 
Results 
The first patient was enrolled on the 6th of January 1999 and the study censored on the 1st December 
2013 for this analysis. There were 211 individuals, 187 individuals from FPC kindreds and 24 patients 
with HP. There were 80 pancreatic juice samples collected from 60 of these individuals; the remaining 
51 individuals only underwent imaging. (CONSORT diagram, Figure 13).  
 
 
 
 
 
 
 
 
 
 
Figure 13: CONSORT diagram for sub-groups of individuals undergoing screening using ERCP. 
Fifty-six of the ERCP procedures were in individuals from FPC kindred and 24 in HP patients. In the FPC 
cohort one individual underwent three ERCPs and five individuals underwent two ERCP procedures. 
In The HP cohort one patient underwent six ERCPs, one patient underwent five ERCPS and three 
underwent two ERCP procedures.    The demographic details of all patients are presented in Table  and 
the genetic background in patients associated with pancreas cancer syndromes and inherited 
pancreatitis is shown in Error! Reference source not found.17. 
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Table 17: Genetic background of patients with pancreatic cancer syndromes and inherited pancreatitis. 
Inherited Syndrome Syndrome variant or Mutation Individuals 
N = 60 
 
 
Familial Pancreatic Cancer 
Syndrome33, 124, 252 
Familial Pancreatic Cancer with unknown causative 
mutation (FPC)  
41 
Hereditary Non-Polyposis Colonic Carcinoma; 
Lynch Syndrome  (HNPCC) 
2 
Peutz-Jeghers Syndrome (PJS) 2 
Familial Atypical Multiple Malignant Melanoma 
(FAMMM) 
2 
Breast Cancer Type 2 (BRCA2) 1 
Hereditary Pancreatitis138, 140, 250 Cationic Trypsinogen 1(PRSS1), p.R122H  5 
Cationic Trypsinogen 1(PRSS1), p.N29I  5 
Familial Idiopathic Pancreatitis253 Serine Protease Inhibitor Kazal-Type 1 (SPINK1), 
p.N34S 
2 
 
A Trial Steering Committee review was undertaken in August 2008 after 34 ERCPs had been 
performed. There were seven (21%) cases of PEP, all seven in the FPC cohort which had had 16 ERCPs 
versus no cases of PEP in the HP cohort which had had 18 ERCPs (p= 0.0021). The study was suspended 
until the Committee completed a review of existing procedures. Changes were incorporated into 
Protocol version 2 (21st November 2008) and the study was recommenced on 28th November 2008.  
The new procedure now routinely employed soft-tipped wire insertion into the pancreatic duct and 
Table 16: Demographic data for individuals undergoing screening with ERCP. 
 
Variable 
Total 
Screening Group 
p 
FPC HP 
N = 60 N = 48 N = 12 - 
Age (years) Median (IQR) 54 (45.25-62) 53 (44.25-60) 61 (47.25-62) 0.216 
Gender 
Male 27 (45%) 22 (46%) 5 (42%) 
1.0000 
Female 33 (55%) 26 (54%) 7 (58%) 
Body Mass 
Index  
(Kg/m2) 
Median (IQR)  26.3 (24.4-31) 
27.95 (25-32.32) 
Missing in 6 
23.7 (22.6-24.6) 
Missing in 5 
0.004 
Smoking  
Never Smoked 33 (55%) 24 (50%) 9 (75%) 
0.1945 Previous/Curre
nt Smoker 
27 (45%) 24 (50%) 3 (25%) 
Alcohol 
(units/week) 
Median  
(IQR) 
5 (1-15) 
7 (2-15.5) 
Missing in 3 
0 (0-1) <0.001 
Diabetes 
Mellitus 
No 53 (88%) 47 (98%) 6 (50%) 
0.0001 
Yes 7 (12%) 1 (2%) 6 (50%) 
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prophylaxis with self-expelling 5-French plastic pancreatic stents and rectal diclofenac for FPC 
individuals.254, 255  Following the introduction of prophylaxis the incidence of PEP in FPC individuals fell 
to six (15.0%) of 40 procedures compared to 7 (43.8%) of 16 procedures without prophylaxis 
(p=0.0347).  Again there was no PEP in the six further ERCP procedures in the HP cohort performed 
after 2008 (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: A Time-Event waterfall plot for incidence of PEP among both cohorts. 
Endoscopic stent placement was attempted in all 40 cases of the FPC cohort but this was not possible 
in 13 (33%) due to tortuosity of the main pancreatic duct. Of these 13 cases without a stent one (7.7%) 
developed PEP. The deployment of the pancreatic stents was safe and well tolerated. Of the six cases 
of pancreatitis that had had prophylaxis, four individuals had had both stent and diclofenac, one had 
had a stent only and one had had diclofenac only.  PEP occurred in four out of 25 cases with dual 
prophylaxis (stent and diclofenac) compared to two out 15 cases with single prophylaxis (stent or 
diclofenac) (p=0.702). The only factor associated with PEP in FPC individuals, was the use of 
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prophylactic measures (Table 18). There was one severe case of pancreatitis and this occurred in the 
non-prophylaxis group; there were no deaths.  The median (IQR) length of hospital stay for patients 
with pancreatitis in the non-prophylaxis and prophylaxis groups was 5 (3-15) and 5 (0-10) days 
respectively (p=0.628). The only other ERCP related complication was one instance of duodenal 
perforation managed conservatively. By six weeks 24 (89%) of the stents were spontaneous expelled 
and the remaining three were removed uneventfully using upper gastrointestinal duodenoscopy.  
There were no instances of blocked stent or pathological migration. 
Table 18: Analysis of post-ERCP pancreatitis following 56 ERCP procedures performed in individuals from FPC kindreds. 
Factor 
ERCP procedures 
n = 56 
Post-ERCP 
pancreatitis 
n = 13 
Odds Ratio 
(95% CI) 
P-valueb 
Age (years)a,  
Median (IQR ) 
53  (44.75-60) 50  (42-54) 0.97 (0.92, 1.02) 0.1113 
Gender 
Female 30 9  (30%) 
0.43  (0.08, 1.84) 0.2238 
Male 26 4  (18%) 
Body Mass Index (Kg/m2)b,  
Median (IQR)  
26.9 (24.73, 31.35)d 29.8 (25.6, 35.6) 1.06 (0.99, 1.13) 0.0585 
Smoking  
Never Smoked 28 8  (29%) 
0.55 (0.12, 2.28) 0.5279 Previous/Current 
Smoker 
28 5  (18%) 
Alcohol intake  units/week 
Median (IQR)c 
5(1 - 15)e 7 (2 -20) 1.08  (0.98, 1.21) 0.5338 
Prophylaxis 
No 16 7  (44%) 
0.23  (0.06, 0.84) 
0.035 
 Yes 40 6  (15%) 
aOdds Ratio given for likelihood of developing post-ERCP pancreatitis if age is >median value. 
bOdds Ratio given for likelihood of developing post-ERCP pancreatitis if BMI is >median value. 
cOdds Ratio given for likelihood of developing post-ERCP pancreatitis if alcohol >median value. 
dMissing data in 6 cases. 
eMissing data in 3 cases. 
 
In summary during the whole period (1999-2013), PEP occurred in 13 (16.3%) instances following 
ERCP, all of which occurred following the 56 ERCPs in the FPC cohort (23.2%) and none in the HP cohort 
(p=0.0077).  
                                                          
b P-values presented are obtained from two-tailed Fisher or Mann Whitney U tests and are in general 
agreement with P-values obtained via Wald tests. 
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Screening outcomes 
Two patients with HP with positive pancreatic juice molecular tests had total pancreatectomy. The CT 
images did not show the presence of any malignant lesion. Both patients already had exocrine failure 
and also endocrine failure requiring insulin. The first patient had mutant KRAS (p.G12V), mutant p53 
(p.G245D) and CDKN2a promoter methylation >50%. The second patient had mutant KRAS (p.G12R), 
wild-type TP53 and CDKN2a promoter methylation of 17.6%.  In both cases histological examination 
of the resected pancreata revealed pancreatic intraepithelial neoplasia grades 1A, 1B and 2.   
Molecular analysis of pancreatic juice of one individual in the FPC cohort with a strong family history 
of pancreatic cancer (father, paternal uncle and two brothers all with pancreatic cancer) identified 
wild-type KRAS, mutant p53 (p.V225fs), and CDK2Na promoter methylation of 41.7%.  The pancreas-
specific CT did not shown any evidence of a tumour but EUS revealed a hypoechoic focus in the body 
of the pancreas.  EUS fine-needle aspiration was undertaken and cytology revealed nuclear atypia.  
Blinded molecular analysis of the cytology tissue revealed the same p53 mutation (p.V225fs).  Repeat 
EUS six weeks later however revealed normal imaging and fine-needle aspiration of the same area did 
not identify any abnormal cells on cytology.  Pancreatic juice molecular analysis was repeated  12 
months after the initial ERCP and this now identified wild-type KRAS, wild type TP53 and normal levels 
of CDK2Na promoter methylation (<12%).  Subsequent surveillance EUS examinations were normal. 
The individual remains under active follow-up 34 months after the original pancreas juice collection.  
Another individual from the FPC cohort had wild-type KRAS, mutant TP53 (p.L188P) and normal 
CDK2Na promoter methylation of 3.47%.  CT and EUS imaging were normal however and the individual 
remained under active follow-up 14 months after the original pancreas juice collection.  
Discussion 
Patient-related factors associated with a higher risk of PEP have commonly included age of 18-35 
years, a history of recurrent acute pancreatitis, a previous episode of PEP, and sphincter of Oddi 
dysfunction.255-258  This study has found that the risk of PEP in patients with HP undergoing screening 
by direct pancreatic cannulation for pancreatic juice collection following injection of secretin was very 
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low (no events in 23 procedures).  Two previous studies of interventional ERCP in patients with severe 
symptoms from HP have also suggested a low risk of PEP, but our study is the only one focussed on 
direct pancreatic duct cannulation and juice collection.259, 260   In marked contrast to the risk of PEP in 
patients with HP, the risk to patients with FPC was very high and this was much greater than might 
have been previously anticipated.254, 261, 262 
The difference in the risk of PEP between individuals from FPC kindreds and HP patients could not be 
explained by differences in age, gender, body mass index or smoking status. Individuals from FPC 
kindreds have normal sized ducts, which therefore would have predicted that this group would be at 
higher risk of PEP than those with a diseased pancreas. Patients with HP are much more likely to have 
diabetes mellitus as part of the disease.108, 250  FPC individuals had higher alcohol consumption than 
HP patients but this was not shown to be a contributory factor; patients with HP are likely to drink less 
alcohol because of medical advice from a young age.  The very low risk of PEP in patients with HP may 
be due to the fact that they are more likely to have dilated ducts along with marked pancreatic 
parenchymal fibrosis and atrophy and hence have less acinar tissue being exposed to trigger 
factors.250, 263  
Direct cannulation of a normal main pancreatic duct and aspiration of pancreatic juice following 
intravenous injection of secretin is the most likely cause of the PEP.264  Whilst the use of intravenous 
injection of secretin during ERCP in our study may have contributed to the high incidence of 
pancreatitis in the FPC group, a randomized double-blind controlled trial of intravenous secretin given 
immediately before ERCP has previously been shown to reduce the frequency of PEP from 15.1% in 
the placebo group to 8.7% in the secretin group265   
A significant reduction in PEP using either a self-expelling pancreatic stent or diclofenac has been 
confirmed by several recent pivotal studies and meta-analyses.266-269  In the current study the 
incidence of PEP in individuals from FPC kindreds was significantly reduced by using prophylaxis 
methods but the incidence is still too high in this group of patients to recommend continued use. 
Instead the EUROPAC Protocol has now adopted duodenal sampling following secretin injection to 
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determine molecular changes.236 It still needs to be established whether duodenal samples have loss 
of diagnostic sensitivity from (1) the effects of dilution, (2) interference by duodenal derived DNA and 
(3) contamination by gut flora. Because of this relative uncertainty and the minimal risk in HP patients 
the EUROPAC screening protocol continues to employ direct pancreatic duct cannulation and 
aspiration for pancreatic juice in this particular group.  
The clinical significance of molecular changes in pancreatic juice and duodenal samples needs to be 
further established. It is already known that KRAS mutations are often found in pancreatic juice from 
controls as well as those with chronic pancreatitis pancreatic cancer.139, 270  This study has also found 
one example of reversion of mutant to wild type TP53 and high CDK2Na promoter methylation 
reduction to normal levels with repeat sampling on observation. Despite the high theoretical risk of 
pancreatic cancer in FPC kindreds, the yield from current screening programmes is low.  An analysis 
of 988 individuals from FPC kindreds undergoing screening identified only 25 (2.5%) patients who had 
resection: due to high-grade dysplasia in 23 and early pancreatic cancer in the remaining two.271  The 
improvements in protocols from the EUROPAC and other screening programmes should encourage a 
higher participation by clinicians and patients at high risk from pancreatic cancer. 
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5.4 – Demographics of Heidelberg Samples 
Seventy two tissue samples were obtained from The University of Heidelberg, all were samples of 
cystic neoplasms from resected pancreata obtained between 2000 – 2005.  These samples were 
received frozen and subsequently prepared as described in Chapter 4.  Forty two samples were 
randomly selected to be used in ion torrent analysis.  The number was based on 20 ion torrent chips 
with 4 chips to be utilised in experimental design.  Demographic data are therefore presented for the 
total cohort of samples (n=72) and the ion torrent subset for which mutational data were obtained 
(n=41, one sample did not yield sufficient DNA for ion torrent analysis).  Below are presented a 
CONSORT diagram and table comparing the Ion Torrent Cohort to the Total Sample (PB = 
pancreatobiliary).  
 
 
 
Figure 15: CONSORT diagram of Ion Torrent samples, PB = pancreatobiliary, MCN = mucinous cystic neoplasm. 
 
Frozen Tissue 
72 
Ion Torrent 
42 
No Sequence 
 1 
Uncertain 
5 
CP 
6 
MCN 
2 
Normal 
3 
IPMN 
22 
Mixed 
4 
PB 
2 
Oncocytic 
1 
Intestinal 
8 
Gastric 
7 
PDAC 
3 
Storage 
 30 
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Table 19: Demographics of Ion Torrent cohort vs. total sample. 
Variable 
 
Total Sample  Ion Torrent Cohort  
Median Age (years) 63.35 (IQR: 53.18 – 69.25) 
n=72 
65.50 (IQR: 61.15 – 71.30) 
n=41 
Median Survival (months) 33.48 (IQR: 18.07 – 50.76) 
n=56 
36.57 (IQR: 19.40 – 54.10) 
n=35 
Gender (M:F) 36:36  
n=72 
25:16 
n=41 
Deaths  12 (16.7%)a 
n=72 
10 (24.4%)b 
n=41 
HEIDELBERG HISTOLOGY n=72 n=41 
Cystadenoma 14 (19.4%) 5 (12.2%) 
IPMN 27 (37.5%) 7 (17.1%) 
IPMC 27 (37.5%) 26 (63.4%) 
NET 1 (1.4%) 0  
PDAC 3 (4.2%) 3 (7.3%) 
LOCATION OF TUMOUR n=70 n=40 
Body 9 (12.5%) 5 (12.2%) 
Head 34 (47.2%) 20 (48.8%) 
Tail 17 (23.6%) 10 (24.4%) 
Whole Pancreas 10 (13.9%) 5 (12.2%) 
SMOKING STATUS n=72 n=41 
Former 10 (13.8%) 7 (17.1%) 
Never 52 (72.2%) 27 (65.9%) 
Current 10 (13.8%) 7 (17.1%) 
ALCOHOL n=71 n=41 
Daily 14 (19.4%) 8 (19.5%) 
Former 1 (1.4%) 1 (2.4%) 
Never 25 (34.7%) 16 (39.0%) 
Occasional 31 (43.1%) 15 (36.9%) 
DIABETES n=72 n=41 
No 59 (81.9%) 30 (73.2%) 
Diet controlled 3 (4.2%) 3 (7.3%) 
Insulin Controlled 5 (6.9%) 4 (9.8%) 
Tablet 5 (6.9%) 4 (9.8%) 
WEIGHT LOSS n=71 n=41 
Yes 28 (38.9%) 19 (46.3%) 
No 43 (59.7%) 22 (53.7%) 
a3 deaths were post-operative 
b1 death was post-operative 
 
Age 
This is defined as the age of the patient at the time of resection, in years.  
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Survial 
The number of whole months following resection for which data is available. 
Gender 
Defined as male or female. 
 
Death 
A simple ‘yes’ or ‘no’ if the patient is known to have survived up to 5yrs following resection.  If the 
patient is lost to follow-up they are presumed to be alive for the purposes of statistical analyses.  
Histology 
Can be defined as ‘Heidelberg Histology’ which is the definitive tissue diagnosis based upon formal 
assessment of the resected specimen in toto; or ‘Liverpool Histology’ which is the working histological 
diagnosis based upon independent blinded assessment of a small fragment of the resected specimen 
by a single pathologist in Liverpool.  Described as cystadenoma, intraductal papillary mucinous 
neoplasm (IPMN), intraductal papillary mucinous neoplasm containing cancer (IPMC), neuroendocrine 
tumour (NET) or pancreatic ductal adenocarcinoma (PDAC). 
Stage of Tumour 
Given in the format Ta Nb Mc where: 
T = Tumour invasion and ‘a’ is presented as a number from 0-3 (0 is also known as tis). 
N = Nodal status and ‘b’ is given as 0 (no nodes involved) or 1 (lymph nodes contain cancer). 
M = Metastatic spread and ‘c’ is given as 0 (no identified metastases) or 1 (distant metastases 
present). 
Thus an early cancer may be T1N0M0 and an advanced cancer with metastases may be T3N1M1.  See 
Appendix D for the WHO Classification for Histological Grading in Pancreatic Cancer (6th Edition). 
Location of Tumour 
This is the anatomical site of the resected tumour within the pancreas as taken from the pathological 
description of the specimen provided by Heidelberg.  It was described as head, body, tail or whole 
pancreas. 
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Smoking Status 
Self-reported status of the patient in terms of tobacco use, described as either: current smoker; 
former smoker (stopped >12 months previously) or; never smoked.  Quantity and duration of 
smoking history data were not available. 
Alcohol 
Self-reported status of the patient in terms of alcohol consumption, described as: drinking >1 unit 
daily; >1 unit occasionally; former drinker of >1 unit occasionally (having stopped >12 months 
previously) or; life-long abstinence (1 unit or less and only occasionally).  
Diabetes mellitus 
Recorded as the presence or absence of a diagnosis of diabetes mellitus at the time of resection.  This 
is described in terms of the modality of treatment which the patient was receiving for their diabetes 
at the time of resection: No diabetes present; diet controlled diabetes; insulin controlled diabetes or; 
tablet (metformin or other anti-hyperglycaemic agent) controlled diabetes. 
Weight Loss 
This is defined as the presence or absence of self-reported unintentional weight loss at the time of 
resection.  Numeric values were not available. 
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5.5 - Tissue Staining Results 
As described in Chapter 4 the tissue slides prepared from the Heidelberg tissue first underwent 
examination after staining with Haematoxylin and Eosin.  Over the following pages examples of H&E 
and then IHC stained tissue will be presented. Confirmation of histological diagnoses was made in 
conjunction with Professor Fiona Campbell, Consultant Histopathologist, Royal Liverpool & 
Broadgreen University Hospital. 
H&E and IHC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: IPMN showing extravasated mucus and calcification, low power H&E (CYST016). 
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Figure 17: The same image (CYST 016) under medium magnification, H&E. 
 
Figure 18: The same image (CYST 016) under high magnification showing scanty epithelial cells, suitable for IHC, H&E. 
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Figure 19: Colloid cancer under low magnification, CYST 014. 
 
Figure 20: Same image (CYST 014) under medium magnification, H&E.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
v 
A 
v 
C 
v 
D 
v Figure 21: PanIN (black arrow) within IPMN (blue arrow) (CYST 029) under low (A); medium (B); high (C) and highest (D) magnification, H&E.  Normal duct arrowed in yellow.  
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Figure 22: Oncocytic IPMN (CYST 023), low 
magnification, H&E. 
Figure 23: Oncocytic IPMN (CYST 023), medium 
magnification, H&E. 
Figure 24: Oncocytic IPMN (CYST 023), high 
magnification, H&E. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
Figure 25: IHC for CYST 010 after MUC 1 (A); MUC 2 (B); MUC 5AC (C) and MUC 6 (D), H&E. 
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5.6 - Histology 
For each of the 41 samples selected, sub-division (a) was sectioned for H&E staining (p.44) and 
submitted to expert assessment by a single Professor of pancreatic histopathology (Professor Fiona 
Campbell).  This process was performed whilst blinded to the histology reports from Heidelberg. 
Table 20 displays the histological assessment made in Liverpool compared to the actual histological 
result as described by Heidelberg.  It must be remembered when comparing these data that the 
histological diagnosis made in Heidelberg was made in light of the clinical details of each patient from 
whom the specimens were resected, as well as having the entire resected specimen available for 
microscopic analysis.  In contrast at Liverpool we had a third of a core of representative tissue provided 
by Heidelberg with no accompanying patient details.  Therefore in a number of cases the Liverpool 
pathologist felt that the tissue sample she had to analyse was insufficient for a diagnosis to be made.   
Table 20: Comparison of Liverpool vs. Heidelberg histology. 
 Heidelberg Histology 
IPMN PDAC Cystadenoma TOTAL 
Li
ve
rp
o
o
l H
is
to
lo
gy
 IPMN  19 1 2 22 
PDAC 2 1 - 3 
MCN - - 2 2 
CP 6 - - 6 
Normal 3 - - 3 
Uncertain 3 1 1 5 
TOTAL 33 3 5 41 
 
On the basis of the Liverpool histology diagnosis those specimens thought to represent IPMN (n=21) 
were submitted for IHC analysis (p.46).  In addition as control samples 4 further specimens were 
included from the Ion Torrent group (1 PDAC, 1 CP and 2 MCN) along with 4 samples collected from 
patients in the Royal Liverpool University Hospital (“RLUH 1-4”) for whom a certain diagnosis of IPMN 
had been made.  In accordance with the protocol outlined in Chapter 4 these samples then underwent 
IHC analysis for MUC 1, MUC 2, MUC 5AC and MUC 6.  The stained slides were then reported as 
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‘positive’ or ‘negative’ for each of the antibodies.  On the basis of this they were classified by epithelial 
sub-type using the key shown in Table 21.  These samples are displayed in Table 22. 
Table 21: Key for determining epithelial subtype of IPMN using MUC stains.  The shaded boxes are positive stain. 
 MUC1 MUC2 MUC5AC MUC6 
Gastric     
Intestinal     
Pancreatobiliary     
Oncocytic     
 
Table 22: IHC Results for the Ion Torrent cohort. 
Sample ID Histological Diagnosis Grade of Dysplasia Epithelial Subtype 
CYST001 IPMN IGD Gastric 
CYST003 IPMN IGD Intestinal 
CYST004 IPMN IGD Intestinal 
CYST006 IPMN LGD Mixed 
CYST009 IPMN HGD Mixed 
CYST010 IPMN Colloid Intestinal 
CYST012 IPMN Colloid Intestinal 
CYST014 IPMN Colloid Intestinal 
CYST016 IPMN LGD Gastric 
CYST021 IPMN Colloid Intestinal 
CYST023 IPMN HGD Oncocytic 
CYST024 IPMN Uncertain Uncertain 
CYST029 IPMN LGD Gastric 
CYST030 IPMN IGD Mixed 
CYST035 IPMN LGD Intestinal 
CYST038 IPMN LGD Mixed 
CYST048 IPMN IGD Gastric 
CYST054 IPMN LGD Gastric 
CYST059 IPMN LGD Gastric 
CYST062 IPMN LGD Gastric 
CYST073 IPMN LGD Pancreatobiliary 
CYST002 CP - - 
CYST017 PDAC Malignant Pancreatobiliary 
CYST063 MCN - - 
CYST065 MCN - - 
RLUH01 IPMN - Mixed 
RLUH02 IPMN - Gastric 
RLUH03 IPMN - Pancreatobiliary 
RLUH04 IPMN - Gastric 
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Epithelial Subtype 
As can be seen from Table , 21 samples from Heidelberg had identifiable IPMN epithelial sub-types.  
Survival data was subsequently found to be available for 18: 5 gastric sub-type; 7 intestinal; 2 
pancreatobiliary; 1 oncocytic and 3 mixed.  Kaplan-Meier analysis of survival by epithelial subtype 
amongst the Ion Torrent cohort did not have the power to show any significant difference (p=0.343, 
Log Rank), Figure 26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Kaplan-Meier plot to demonstrate survival by epithelial subtype. 
p = 0.343 
χ2 = 4.499 
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Comparison was made between each of the MUC stains and overall survival, data for which was 
available in 18 cases (85.7%).  In addition each of the MUC stains were analysed for correlation with 
age, gender, tumour status (T0 – T3), Nodal Status (N0 – N1), presence of metastases (M0 – M1), 
resection margin (R0 – R1), primary or recurrent cancer, the location of the tumour within the pancreas, 
diabetes, smoking, alcohol, weight loss, presence of peritoneal metastases and grade of dysplasia 
(Low, Moderate, High).   
MUC 1  
Of 21 samples 7 (33.3%) were found to be MUC1 positive. 
No statistically significant difference was established between gender, median age tumour status, 
nodal status, presence of metastases, resection margin, the location of the tumour within the 
pancreas, diabetes, smoking, alcohol, weight loss, presence of peritoneal metastases and grade of 
dysplasia.  However, given the small numbers there is insufficient power to conclude no relationships. 
There was a significant likelihood that MUC1 positive samples were associated with recurrent 
tumours, p=0.030, Table 23. 
Table 23: MUC 1 results. 
 MUC1  
Negative Positive p. 
Gender Female 7 2 
0.32 Male 7 5 
Tumour Status Unknown 6 4 
0.31 
0 0 1 
1 2 0 
2 1 0 
3 5 3 
Nodal Status Unknown 6 3 
0.25 
0 5 4 
1 3 0 
Metastases Unknown 7 3 
0.64 
0 6 4 
1 1 0 
Resection Margin Unknown 5 3 
0.31 
0 9 3 
1 0 1 
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Primary or Secondary 
Tumour 
Unknown 0 1 
0.03 
Primary 14 4 
Recurrence 0 2 
Location of Tumour Unknown 0 1 
0.23 
Body 1 2 
Head 4 2 
Tail 5 2 
Whole 4 0 
Diabetes None 12 5 
0.73 
Insulin 1 1 
Metformin 1 1 
Smoker Former 3 0 
0.09 
No 10 4 
Yes 1 3 
Alcohol Daily 4 1 
0.74 
Former 1 0 
No 4 3 
Occasionally 5 3 
Weight loss No 8 3 
0.44 Yes 6 4 
Peritoneal metastases No 13 7 
0.67 Yes 1 0 
Grade of Dysplasia Cancer 3 1 
0.17 
HGD 0 2 
IGD 3 2 
LGD 8 2 
 
There was no significant difference in overall survival between those patients who were MUC1 
positive compared to those who were negative, p=0.455 (Log Rank), Figure 27.  Survival data were not 
obtained for 1 MUC 1 positive patient and 2 MUC 1 negative patients. 
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Figure 27: Kaplan-Meier survival analysis of MUC 1. 
MUC 2  
Of 21 samples 11 (52.3%) were found to be MUC 2 positive. 
No statistically significant difference was established between median age tumour status, nodal 
status, presence of metastases, resection margin, primary or recurrent cancer, the location of the 
tumour within the pancreas, diabetes, smoking, alcohol, weight loss, presence of peritoneal 
metastases and grade of dysplasia. 
There was a significant difference between the number of males and females who were found to be 
MUC 2 positive, p=0 .024, Table 24.   
p = 0.445 
χ2 = 0.559 
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Table 24: MUC 2 results. 
 
MUC 2  
Negative Positive p. 
Gender Female 7 2 
0.02 Male 3 9 
Tumour Status Unknown 5 4 
0.53 
0 0 1 
1 1 1 
2 1 0 
3 3 5 
Nodal Status Unknown 5 4 
0.16 
0 5 4 
1 0 3 
Metastases Unknown 6 4 
0.64 
0 4 6 
1 0 1 
Resection Margin Unknown 5 3 
0.38 
0 4 8 
1 1 0 
Primary or Secondary 
Tumour 
Unknown 1 0 
0.56 
Primary 8 10 
Recurrence 1 1 
Location of Tumour Unknown 1 0 
0.28 
Body 1 2 
Head 1 5 
Tail 4 3 
Whole 3 1 
Diabetes Unknown 9 8 
0.36 
Insulin 0 2 
Metformin 1 1 
Smoker Former 1 2 
0.45 
No 8 6 
Yes 1 3 
Alcohol Daily 2 3 
0.22 
Former 1 0 
No 5 2 
Occasionally 2 6 
Weight loss No 5 6 
0.59 Yes 5 5 
Peritoneal metastases No 10 10 
0.52 Yes 0 1 
Grade of Dysplasia Cancer 1 3 
0.22 
HGD 1 1 
IGD 1 4 
LGD 7 3 
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There was borderline significant difference in overall survival between those patients who were MUC 
2 positive compared to those who were negative, p=0.054 (Log Rank), Figure 28.  Survival data were 
not obtained for 1 MUC 2 positive patient and 2 MUC 2 negative patients. 
 
 
 
Figure 28: Kaplan-Meier survival analysis of MUC 2. 
MUC 5AC  
Of 21 samples 20 (95.2%) were found to be MUC5AC positive. 
No statistically significant difference was established between gender, median age tumour status, 
nodal status, presence of metastases, resection margin, primary or recurrent cancer, the location of 
the tumour within the pancreas, diabetes, smoking, alcohol, weight loss, presence of peritoneal 
metastases and grade of dysplasia, Table 25. 
p = 0.054 
χ2 = 3.717 
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No significant difference in overall survival could be established when those patients who were 
MUC5AC positive were compared to those who were negative, p=0.416 (Log Rank), Figure 29.  Survival 
data were unavailable for 3 patients who were MUC 5AC positive. 
 
 
Table 25: MUC 5AC Results. 
 MUC 5AC  
Negative Positive p. 
Gender Female 0 9 
0.57 Male 1 11 
Tumour Status Unknown 0 9 
0.91 
0 0 1 
1 0 2 
2 0 1 
3 1 7 
Nodal Status Unknown 0 9 
0.25 
0 0 9 
1 1 2 
Metastases Unknown 0 10 
0.91 
0 1 9 
1 0 1 
Resection Margin Unknown 0 8 
0.92 
0 1 11 
1 0 1 
Primary or Secondary 
Tumour 
Unknown 0 1 
0.92 
Primary 1 17 
Recurrence 0 2 
Location of Tumour Unknown 0 1 
0.35 
Body 0 3 
Head 0 6 
Tail 0 7 
Whole 1 3 
Diabetes Unknown 1 16 
0.88 
Insulin 0 2 
Metformin 0 2 
Smoker Former 0 3 
0.77 
No 1 13 
Yes 0 4 
Alcohol Daily 0 5 
0.64 
Former 0 1 
No 0 7 
Occasionally 1 7 
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Weight loss No 0 11 
0.48 Yes 1 9 
Peritoneal metastases No 1 19 
0.95 Yes 0 1 
Grade of Dysplasia Cancer 1 3 
0.22 
HGD 0 2 
IGD 0 5 
LGD 0 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Kaplan-Meier survival analysis of MUC 5AC. 
 
 
 
p = 0.416 
χ2 = 0.662 
AC 
1 
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MUC6 
Of 21 samples 9 (42.9%) were found to be MUC6 positive. 
No statistically significant difference could be established between gender, median age tumour status, 
nodal status, presence of metastases, resection margin, primary or recurrent cancer, the location of 
the tumour within the pancreas, diabetes, smoking, alcohol, weight loss, and presence of peritoneal 
metastases.  MUC6 did appear to differentiate between the different grades of dysplasia, p = 0.05, 
Table 26. 
Table 26: MUC 6 Results. MUC6  
Negative Positive p. 
Gender Female 3 6 
0.07 Male 9 3 
Tumour Status Unknown 3 6 
0.72 
0 1 0 
1 1 1 
2 1 0 
3 6 2 
Nodal Status Unknown 3 6 
0.38 
0 6 3 
1 3 0 
Metastases Unknown 4 6 
0.73 
0 7 3 
1 1 0 
Resection Margin Unknown 0 5 
0.31 
0 9 3 
1 0 1 
Primary or Secondary 
Tumour 
Unknown 0 1 
0.10 
Primary 12 6 
Recurrence 0 2 
Location of Tumour Unknown 0 1 
0.20 
Body 2 1 
Head 5 1 
Tail 2 5 
Whole 3 1 
Diabetes Unknown 9 8 
0.44 
Insulin 1 1 
Metformin 2 0 
Smoker Former 3 0 
0.27 
No 7 7 
Yes 2 2 
Alcohol Daily 4 1 0.46 
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Former 1 0 
No 3 4 
Occasionally 4 4 
Weight loss No 7 4 
0.42 Yes 5 5 
Peritoneal metastases No 11 9 
0.57 Yes 1 0 
Grade of Dysplasia Cancer 4 0 
0.05 
HGD 0 2 
IGD 4 1 
LGD 4 6 
 
There was no significant difference in overall survival between those patients who were MUC6 
positive compared to those who were negative, p=0.612 (Log Rank), Figure 30. 
 
 
 
Figure 30: Kaplan-Meier survival analysis of MUC 6. 
p = 0.612 
χ2 = 0.272 
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Comparison with Mutations 
Each of the four MUC stains were analysed for any significant correlation with the presence of 
mutations which were identified following Ion Torrent analysis.  The results of these analyses are given 
in 5.7 - Ion Torrent Analysis.   
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5.7 - Ion Torrent Analysis 
As described in Chapter 4 the DNA extracted from 41 tissue samples was sequenced for mutations in 
exons 5, 6, 7 and 8 of TP53 using the Ion Torrent next generation sequencer.  The results are presented 
here.  When comparing the various mutations against MUC stains these results include 21 samples of 
IPMN previously described AND two samples analysed which were deemed to represent mucinous 
cystic neoplasm (MCN) histologically in Liverpool, a total of 23. 
Data Acquired  
Reads were analysed for each of the 10 repeats per sample and mutations were identified if they were 
present in >9% and <15% or reads at each base.  The average fragment length per sample (i.e. median 
value from 10 repeats) is given in Appendix E along with the average depth of reads of each fragment. 
The median values for each read of fragment across all 41 samples are given below in Table 27, the 
median values given are those for all 410 reads. 
Table 27: Average depth of reads across every sample analysed using Ion Torrent. 
Fragment Median read 
Depth  
E5F1 6439.5 
E5F2 4852.5 
E5F3 6823.5 
E6 254.5 
E7F1 4117.25 
E7F2 5445.75 
E8F1 3134.25 
E8F2 478.5 
 
Twenty-four mutations were identified amongst the 41 samples: 14 from exon 5; 0 from exon 6; 4 
from exon 7 and; 6 from exon 8.  In an effort to avoid erroneous mutations being detected I set a 
threshold for counting a mutation as ‘real’ if it was detected in more than two repeats (barcodes) of 
the same sample AND in loci where the minimum depth of coverage was 20 reads.  Thus in order to 
be counted the minimum requirement would be that the mutation occurred in 2/20 reads (10%) AND 
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in at least 2 of the repeats.  In cases where the mutation was observed but did not meet the above 
criteria, they were recorded as ‘possible’ mutations. 
Exon 5 of TP53 
Four of the 14 mutations identified occurred in at least three different samples: p.K132Q; p.M160L; 
p.K164R and; p.K164T.  The relative frequencies of mutations found in exon 5 are expressed in Table 
.    In two cases mutations were identified which did not fulfil the inclusion criteria outlined above 
and have been listed as ‘possible’ mutations. 
Table 28: Frequency of mutations detected by exon. 
Exon p. Notation g. Notation Occurrences 
(n=41) 
Published Somatic Count 
5 
Y126D 7578554  A>C 1 6 
L130F 7578542  G>A 2 15 
K132Q 7578536  T>G 4 19 
P153A 7578473  G>C 1 3 
G154R 7578470  C>G 1 0 
T155P 7578467  T>G 1 23 
A159P 7578455  C>G 2 31 
M160L 7578452  T>G 10 5 
M160I 7578450  C>T 0 3 (Possible Mutation) 
K164R 7578439  T>C 9 2 
K164T 7578439  T>G 3 2 
M169I 7578423  C>T 0 13 (Possible Mutation) 
E171G 7578418  T>C 2 8 
C176S 7578404  A>T 1 20 
7 
V216A 7578202  A>G 1 0 
V217G 7578199  A>C 1 0 
S240N 7577562  C>T 2 4 
I251L 7577530  T>G 10 6 
8 
L264R 7577147  A>C 7 7 
E271G 7577126  T>C 9 5 
E271A 7577126  T>G 1 2 
E271V 7577126  T>A 1 0 
R273H 7577120  C>T 4 851 
P278S 7577106  G>A 1 91 
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Each of the mutations identified were analysed against overall survival using the Kaplan-Meier 
method with Log-rank used to measure significance. None of the mutations were found to 
significantly affect survival.  The analyses for the four mutations present in >3 cases are reproduced 
in Figures 31 – 34. 
 
 
Figure 31: Kaplan-Meier survival analysis by mutant or wild type p.K132Q. 
p = 0.70 
χ2 = 0.300 
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Figure 32: Kaplan-Meier survival analysis by mutant or wild type p.M160L. 
 
 
 
 
p = 0.15 
χ2 = 2.676 
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Figure 33: Kaplan-Meier survival analysis by mutant or wild type p.K164R. 
p = 0.66 
χ2 = 0.769 
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Figure 34: Kaplan-Meier survival analysis by mutant or wild type p.K164T. 
In addition each of these mutations were assessed for any relationship to demographic factors (age, 
alcohol, smoking, diabetes) and pathological factors (tumour status, nodal status, presence of 
metastases, weight loss, epithelial sub-type) as well as the MUC staining described in 4.2.1 - 
Immunohistochemistry Methods.  These analyses are presented in Tables 29 – 32. 
 
 
 
 
p = 0.73 
χ2 = 0.864 
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Table 29: Results for p.K132Q. 
p.K132Q 
Variable Wild Type Mutant p. 
Gender Female 15 1 .488 
Male 22 3 
MUC1 Negative 13 3 .316 
Positive 7 0 
MUC2 Negative 11 1 .466 
Positive 9 2 
MUC5AC Negative 1 0 .870 
Positive 19 3 
MUC6 Negative 10 2 .534 
Positive 10 1 
Epithelial 
subtype 
Unknown 19 1 .514 
Gastric 6 1 
Intestinal 5 2 
Mixed 4 0 
Oncocytic 1 0 
Pancreatobiliary 2 0 
Tumour Status 0 10 0 .205 
1 1 1 
2 1 0 
3 12 2 
Nodal Status 0 19 1 .156 
1 5 2 
Mets 0 20 3 .770 
1 2 0 
Resection Margin 0 23 3 .531 
1 2 1 
2 1 0 
Primary or 
Secondary 
Tumour 
Unknown 1 0 .735 
Primary 32 4 
Recurrence 4 0 
Location of 
Tumour 
Unknown 1 0 .666 
Body 5 0 
Head 18 2 
Tail 8 2 
Whole 5 0 
Diabetes None 27 3 .612 
Diet 3 0 
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Insulin 3 1 
Metformin 4 0 
Smoker Former 5 2 .154 
No 25 2 
Yes 7 0 
Alcohol Unknown 1 0 .370 
Daily 6 2 
Former 1 0 
No 16 0 
Occasionally 13 2 
Weight loss No 18 4 .072 
Yes 19 0 
Peritoneal mets No 36 4 .902 
Yes 1 0 
Grade of 
Dysplasia 
Unknown 19 1 .666 
Cancer 3 1 
HGD 2 0 
IGD 4 1 
LGD 9 1 
 
Table 30: Results for p.M160L. 
p.M160L 
Variable Wild 
Type 
Mutant p. 
Gender Female 12 4 .612 
Male 19 6 
MUC1 Negative 11 5 .130 
Positive 7 0 
MUC2 Negative 10 2 .455 
Positive 8 3 
MUC5AC Negative 0 1 .217 
Positive 18 4 
MUC6 Negative 8 4 .185 
Positive 10 1 
Epithelial 
subtype 
Unknown 15 5 .605 
Gastric 5 2 
Intestinal 4 3 
Mixed 4 0 
Oncocytic 1 0 
Pancreatobiliary 2 0 
Tumour Status 0 9 1 .037 
1 0 2 
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2 0 1 
3 9 5 
Nodal Status 0 14 6 .429 
1 4 3 
Mets 0 16 7 .547 
1 1 1 
Resection Margin 0 19 7 .805 
1 2 1 
2 1 0 
Primary or 
Secondary 
Tumour 
Unknown 1 0 .399 
Primary 26 10 
Recurrence 4 0 
Location of 
Tumour 
Unknown 1 0 .597 
Body 5 0 
Head 15 5 
Tail 7 3 
Whole 3 2 
Diabetes None 20 10 .183 
Diet 3 0 
Insulin 4 0 
Metformin 4 0 
Smoker Former 6 1 .555 
No 19 8 
Yes 6 1 
Alcohol Unknown 0 1 .331 
Daily 5 3 
Former 1 0 
No 13 3 
Occasionally 12 3 
Weight loss No 18 4 .264 
Yes 13 6 
Peritoneal mets No 31 9 .244 
Yes 0 1 
Grade of 
Dysplasia 
Unknown 15 5   
Cancer 3 1 .842 
HGD 2 0 
IGD 3 2 
LGD 8 2 
 
 
 
 
 
P a g e  | 131 
 
 
Table 31: Results for p.K164R. 
p.K164R 
Variable Wild 
Type 
Mutant p. 
Gender Female 14 2 .220 
Male 18 7 
MUC1 Negative 14 2 .352 
Positive 5 2 
MUC2 Negative 11 1 .261 
Positive 8 3 
MUC5AC Negative 1 0 .826 
Positive 18 4 
MUC6 Negative 9 3 .329 
Positive 10 1 
Epithelial 
subtype 
Unknown 15 5 .627 
Gastric 7 0 
Intestinal 5 2 
Mixed 3 1 
Oncocytic 1 0 
Pancreatobiliary 1 1 
Tumour Status 0 7 3 .843 
1 1 1 
2 1 0 
3 10 4 
Nodal Status 0 15 5 .332 
1 4 3 
Mets 0 15 8 .453 
1 2 0 
Resection Margin 0 18 8 .432 
1 3 0 
2 1 0 
Primary or 
Secondary 
Tumour 
Unknown 1 0 .859 
Primary 28 8 
Recurrence 3 1 
Location of 
Tumour 
Unknown 1 0 .597 
Body 3 2 
Head 15 5 
Tail 8 2 
Whole 5 0 
Diabetes None 25 5 .048 
Diet 3 0 
Insulin 1 3 
Metformin 3 1 
Smoker Former 5 2 .762 
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No 22 5 
Yes 5 2 
Alcohol Unknown 1 0 .277 
Daily 8 0 
Former 1 0 
No 10 6 
Occasionally 12 3 
Weight loss No 20 2 .038 
Yes 12 7 
Peritoneal mets No 31 9 .780 
Yes 1 0 
Grade of 
Dysplasia 
Unknown 15 5 .501 
Cancer 2 2 
HGD 2 0 
IGD 4 1 
LGD 9 1 
 
Table 32: Results for p.K164T. 
p.K164T 
Variable Wild 
Type 
Mutant p. 
Gender Female 16 0 .216 
Male 22 3 
MUC1 Negative 16 0 .304 
Positive 6 1 
MUC2 Negative 12 0 .478 
Positive 10 1 
MUC5AC Negative 1 0 .957 
Positive 21 1 
MUC6 Negative 12 0 .478 
Positive 10 1 
Epithelial 
subtype 
Unknown 18 2 .639 
Gastric 7 0 
Intestinal 7 0 
Mixed 3 1 
Oncocytic 1 0 
Pancreatobiliary 2 0 
Tumour Status 0 8 2 .706 
1 2 0 
2 1 0 
3 13 1 
Nodal Status 0 17 3 .390 
1 7 0 
Mets 0 20 3 .770 
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1 2 0 
Resection Margin 0 23 3 .774 
1 3 0 
2 1 0 
Primary or 
Secondary 
Tumour 
Unknown 1 0 .799 
Primary 33 3 
Recurrence 4 0 
Location of 
Tumour 
Unknown 1 0 .750 
Body 4 1 
Head 19 1 
Tail 9 1 
Whole 5 0 
Diabetes None 28 2 .491 
Diet 3 0 
Insulin 4 0 
Metformin 3 1 
Smoker Former 7 0 .590 
No 25 2 
Yes 6 1 
Alcohol Unknown 1 0 .806 
Daily 8 0 
Former 1 0 
No 15 1 
Occasionally 13 2 
Weight loss No 20 2 .556 
Yes 18 1 
Peritoneal mets No 37 3 .927 
Yes 1 0 
Grade of 
Dysplasia 
Unknown 18 2 .131 
Cancer 4 0 
HGD 1 1 
IGD 5 0 
LGD 10 0 
The only findings of significance were an association between increased tumour status and the 
presence of p.M160L (p=.037) and weight loss was more likely in patients who expressed p.K164R 
mutation (p=.038).  There was also a predisposition to diabetes amongst those who had mutant 
p.K164R (p=0.48).  However, in all of these cases correction for multiple testing would make these 
differences insignificant. 
Exon 6 of TP53 
No mutations were demonstrated to occur in exon 6. 
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Exon 7 of TP53 
One of the 4 mutations identified occurred in at least three different samples: p.I251L.  The relative 
frequencies of mutations found in exon 7 are expressed in Table 28.     
Each of the mutations identified were analysed against overall survival using the Kaplan-Meier method 
with Log-rank used to measure significance. The presence pf p.I251L was not found to significantly 
affect survival. 
 
 
 
 
Figure 35: Kaplan-Meier survival analysis by mutant or wild type p.I251L. 
 
p = 0.905 
χ2 = 0.518 
4 3 2 1 
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In addition p.I251L was assessed for any relationship to demographic factors (age, alcohol, smoking, 
and diabetes) and pathological factors (tumour status, nodal status, presence of metastases, weight 
loss, and epithelial sub-type) as well as the MUC staining described in 4.2.1 - Immunohistochemistry 
Methods.  These analyses are presented in Table 33. 
Table 33: Results for p.I251L. 
p.I251L 
Variable Wild 
Type 
Mutant p. 
Gender Female 14 2 .148 
Male 17 8 
MUC1 Negative 14 2 .352 
Positive 5 2 
MUC2 Negative 11 1 .261 
Positive 8 3 
MUC5AC Negative 1 0 .826 
Positive 18 4 
MUC6 Negative 9 3 .329 
Positive 10 1 
Epithelial 
subtype 
Unknown 14 6 .622 
Gastric 6 1 
Intestinal 6 1 
Mixed 2 2 
Oncocytic 1 0 
Pancreatobiliary 2 0 
Tumour Status 0 6 4 .242 
1 2 0 
2 0 1 
3 11 3 
Nodal Status 0 14 6 .668 
1 5 2 
Mets 0 16 7 .510 
1 2 0 
Resection Margin 0 20 6 .789 
1 2 1 
2 1 0 
Primary or 
Secondary 
Tumour 
Unknown 1 0 .848 
Primary 27 9 
Recurrence 3 1 
Location of 
Tumour 
Unknown 1 0 .928 
Body 4 1 
Head 14 6 
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Tail 8 2 
Whole 4 1 
Diabetes None 22 8 .288 
Diet 3 0 
Insulin 2 2 
Metformin 4 0 
Smoker Former 6 1 .006 
No 23 4 
Yes 2 5 
Alcohol Unknown 1 0 .789 
Daily 5 3 
Former 1 0 
No 13 3 
Occasionally 11 4 
Weight loss No 17 5 .537 
Yes 14 5 
Peritoneal mets No 30 10 .756 
Yes 1 0 
Grade of 
Dysplasia 
Unknown 14 6 .145 
Cancer 4 0 
HGD 2 0 
IGD 2 3 
LGD 9 1 
The only finding of significance was an increased incidence of p.I251L being found in patients who 
declared themselves as current smokers (p=0.006). 
Exon 8 of TP53 
Three of the 6 mutations identified occurred in at least three different samples: p.L264R; p.E271G and; 
p.R273H.  The relative frequencies of mutations found in exon 8 are expressed in Table .     
Each of the mutations identified were analysed against overall survival using the Kaplan-Meier method 
with Log-rank used to measure significance. A single mutation, p.L264R, was found to significantly 
predict poor survival, p<0.001.   
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Figure 36: Kaplan-Meier survival analysis by mutant or wild type p.L264R. 
p <0.001 
χ2 = 19.023 
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Figure 37: Kaplan-Meier survival analysis by mutant or wild type p.E271G. 
p = 0.901 
χ2 = 0.359 
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Figure 38: Kaplan-Meier survival analysis by mutant or wild type p.R273H. 
In addition each of these mutations were assessed for any relationship to demographic factors (age, 
alcohol, smoking, diabetes) and pathological factors (tumour status, nodal status, presence of 
metastases, weight loss, and epithelial sub-type) as well as the MUC staining described in 4.2.1 - 
Immunohistochemistry Methods.  These analyses are presented Tables 34 - 36. 
Table 34: Results for p.L234R 
p.L264R 
Variable Wild 
Type 
Mutant p. 
Gender Female 14 2 .431 
Male 20 5 
MUC1 Negative 13 3 .316 
p = 0.085 
χ2 = 1.049 
0 0 
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Positive 7 0 
MUC2 Negative 11 1 .466 
Positive 9 2 
MUC5 Negative 1 0 .870 
Positive 19 3 
MUC6 Negative 10 2 .534 
Positive 10 1 
Epithelial 
subtype 
Unknown 15 5 .490 
Gastric 7 0 
Intestinal 5 2 
Mixed 4 0 
Oncocytic 1 0 
Pancreatobiliary 2 0 
Tumour Status 0 9 1 .216 
1 2 0 
2 1 0 
3 8 6 
Nodal Status 0 18 2 .005 
1 2 5 
Mets 0 19 4 .050 
1 0 2 
Resection Margin 0 19 7 .495 
1 3 0 
2 1 0 
Primary or 
Secondary 
Tumour 
Unknown 1 0 .556 
Primary 29 7 
Recurrence 4 0 
Location of 
Tumour 
Unknown 1 0 .836 
Body 4 1 
Head 16 4 
Tail 8 2 
Whole 5 0 
Diabetes None 25 5 .807 
Diet 3 0 
Insulin 3 1 
Metformin 3 1 
Smoker Former 6 1 .943 
No 22 5 
Yes 6 1 
Alcohol Unknown 1 0 .846 
Daily 7 1 
Former 1 0 
No 12 4 
Occasionally 13 2 
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Weight loss No 17 5 .271 
Yes 17 2 
Peritoneal mets No 34 6 .171 
Yes 0 1 
Grade of 
Dysplasia 
Unknown 15 5 .468 
Cancer 3 1 
HGD 2 0 
IGD 4 1 
LGD 10 0 
 
Table 35: Results for p.E271G. 
p.E271G 
Variable Wild 
Type 
Mutant p. 
Gender Female 14 2 .220 
Male 18 7 
MUC1 Negative 12 4 .508 
Positive 6 1 
MUC2 Negative 11 1 .131 
Positive 7 4 
MUC5 Negative 1 0 .783 
Positive 17 5 
MUC6 Negative 9 3 .545 
Positive 9 2 
Epithelial 
subtype 
Unknown 16 4 .710 
Gastric 6 1 
Intestinal 4 3 
Mixed 3 1 
Oncocytic 1 0 
Pancreatobiliary 2 0 
Tumour Status 0 8 2 .094 
1 0 2 
2 1 0 
3 11 3 
Nodal Status 0 16 4 .241 
1 4 3 
Mets 0 17 6 .490 
1 1 1 
Resection Margin 0 18 8 .432 
1 3 0 
2 1 0 
Primary or 
Secondary 
Tumour 
Unknown 1 0 .859 
Primary 28 8 
Recurrence 3 1 
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Location of 
Tumour 
Unknown 1 0 .376 
Body 5 0 
Head 14 6 
Tail 7 3 
Whole 5 0 
Diabetes None 25 5 .048 
Diet 3 0 
Insulin 1 3 
Metformin 3 1 
Smoker Former 4 3 .251 
No 23 4 
Yes 5 2 
Alcohol Unknown 1 0 .925 
Daily 6 2 
Former 1 0 
No 13 3 
Occasionally 11 4 
Weight loss No 18 4 .400 
Yes 14 5 
Peritoneal mets No 31 9 .780 
Yes 1 0 
Grade of 
Dysplasia 
Unknown 16 4 .754 
Cancer 3 1 
HGD 2 0 
IGD 3 2 
LGD 8 2 
 
Table 36: Results for p.R273H. 
p.R273H 
Variable Wild 
Type 
Mutant p. 
Gender Female 14 2 .512 
Male 23 2 
MUC1 Negative 14 2 .684 
Positive 6 1 
MUC2 Negative 11 1 .466 
Positive 9 2 
MUC5 Negative 1 0 .870 
Positive 19 3 
MUC6 Negative 10 2 .534 
Positive 10 1 
Epithelial 
subtype 
Unknown 19 1 .818 
Gastric 6 1 
Intestinal 6 1 
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Mixed 3 1 
Oncocytic 1 0 
Pancreatobiliary 2 0 
Tumour Status 0 10 0 .571 
1 2 0 
2 1 0 
3 12 2 
Nodal Status 0 20 0 .060 
1 5 2 
Mets 0 21 2 .843 
1 2 0 
Resection Margin 0 24 2 .848 
1 3 0 
2 1 0 
Primary or 
Secondary 
Tumour 
Unknown 1 0 .735 
Primary 32 4 
Recurrence 4 0 
Location of 
Tumour 
Unknown 1 0 .870 
Body 5 0 
Head 18 2 
Tail 9 1 
Whole 4 1 
Diabetes None 27 3 .612 
Diet 3 0 
Insulin 3 1 
Metformin 4 0 
Smoker Former 6 1 .614 
No 24 3 
Yes 7 0 
Alcohol Unknown 1 0 .031 
Daily 8 0 
Former 0 1 
No 15 1 
Occasionally 13 2 
Weight loss No 20 2 .639 
Yes 17 2 
Peritoneal mets No 36 4 .902 
Yes 1 0 
Grade of 
Dysplasia 
Unknown 19 1 .475 
Cancer 3 1 
HGD 2 0 
IGD 5 0 
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LGD 8 2 
 
In addition to the association between poor survival and p.L264R there was also an increased 
likelihood of patients with p.L264R having lymph node involvement (p=0.005) and metastases 
(p=0.050).  This may well explain the poor overall survival.  An increased incidence of diabetes was 
demonstrated amongst patients with p.E271G, p=0.048, after Bonferroni correction. 
Samples with 2 or more concurrent mutations 
 
Overall, of the 41 samples for whom Ion Torrent data is available, 18 had two or more concurrent 
mutations (Figure 39).  When those patients with ≥2 mutations are compared to those with <2 there 
is no discernible difference in survival using the Kaplan-Meier method, p=0.921 (Figure 40).  Similarly, 
even when the similar analysis is performed using only those patients who have 2 or more concurrent 
mutations consisting solely among the 8 commonest mutations there is no difference (p=0.348). 
 
Figure 39: Graphical representation of number of samples with concurrent mutations. 
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Figure 40: Kaplan-Meier analysis of survival when comparing those samples with < or equal to 2 concurrent mutations and 
>2. 
 
 
p = 0.921 
χ2 = 0.010 
≥ 2 
< 2 
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Figure 41: Kaplan-Meier analysis of survival when comparing concurrent mutations from among the 8 identified in greater 
than 3 samples using Ion Torrent. 
 
 
 
  
p = 0.384 
χ2 = 0.759 
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5.8 - Analysis of Individuals who Died 
During the five years of follow-up 10 of the 41 patients (23%) in the Ion Torrent cohort died.  One of 
these patients (CYST035) was recorded as a post-operative death following complications.  The 
median age of these individuals was 68.40 years (IQR: 59.08 – 73.08), a comparative analysis of the 
demographics and pathological data for those patients who survived versus those patients who did 
not can be found in Table 37. 
Table 37: Results by samples who have survived vs. those who have not. 
Variable Alive or Dead p. 
alive dead 
Male or 
Female 
Female 13 3 0.39 
Male 18 7 
MUC1 Negative 12 4 0.51 
Positive 6 1 
MUC2 Negative 12 0 0.01 
Positive 6 5 
MUC5 Negative 0 1 0.22 
Positive 18 4 
MUC6 Negative 8 4 0.19 
Positive 10 1 
Epithelial 
subtype 
Unknown 15 5 0.20 
Gastric 7 0 
Intestinal 3 4 
Mixed 3 1 
Oncocytic 1 0 
Pancreatobiliary 2 0 
Tumour 
Status 
0 10 0 0.01 
1 2 0 
2 1 0 
3 5 9 
Nodal Status 0 17 3 <0.005 
1 1 6 
Mets 0 16 7 0.12 
1 0 2 
Resection 
Margin 
0 18 8 0.80 
1 2 1 
2 1 0 
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Primary or 
Secondary 
Tumour 
Unknown 1 0 0.40 
Primary 26 10 
Recurrence 4 0 
Location of 
Tumour 
Unknown 1 0 0.89 
Body 3 2 
Head 15 5 
Tail 8 2 
Whole 4 1 
Diabetes None 22 8 0.79 
Diet 3 0 
Insulin 3 1 
Metformin 3 1 
Smoker Former 6 1 0.56 
No 19 8 
Yes 6 1 
Alcohol Unknown 0 1 0.40 
Daily 7 1 
Former 1 0 
No 12 4 
Occasion 11 4 
Weight loss No 16 6 0.46 
Yes 15 4 
Peritoneal 
mets 
No 31 9 0.24 
Yes 0 1 
median age (IQR) 64.8                
(60.70 - 
69.70) 
68.4                     
(59.08 - 
73.08) 
0.736 
 
Corresponding Kaplan-Meier analyses found that the only factors which affected survival were: 
increased nodal status (p=0.002) and the presence of metastases (p<0.005).  These curves are 
demonstrated in Figures 42 and 43.  Table 38 displays the demographic and pathological data for these 
10 patients as well as their mutational status for each of the 8 most common mutations found among 
the Ion Torrent cohort. 
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Figure 42: Kaplan-Meier analysis of survival when comparing different nodal status (TNM classification: N0-N1) for samples 
from the Ion Torrent cohort. 
 
 
 
 
 
 
p = 0.002 
χ2 = 9.737 
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Figure 43: Kaplan-Meier analysis of survival when comparing different metastasis status (TNM classification: M0-M1) for 
samples from the Ion Torrent cohort. 
Of the 9 patients who died of pancreatic cancer, 6 had p.L264R mutation.  Only one other patient was 
found to have this mutation (CYST063) who was lost to follow-up and so survival data cannot be 
obtained.  As a consequence of these data, and having proven using Kaplan-Meier’s method that 
p.L264R is significantly associated with survival we can calculate the sensitivity and specificity to this 
mutation to predict death by 5 years as follows: 
 
 
Survival to 5 years  
Yes No TOTALS 
p.L264R 
Mutant  1 6 7 
Wild Type 30 4 34 
 TOTALS 31 10 41 
p <0.001 
χ2 = 28.407 
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Sensitivity = 0.6 (95%CI: 0.27 – 0.86); Specificity = 0.97 (95%CI: 0.81 – 1); Positive Predictive Value = 
0.86 (95%CI: 0.42 – 0.99). 
Of the four patients who were wild-type for p.L264R but died, one (CYST035) died as a consequence 
of post-operative complications.  The remaining three patients (CYST009, CYST010, CYST025) died of 
pancreatic cancer.  It is worth noting, however, that one of these patients (CYST009) was ‘borderline’ 
for expression of p.L264R.  The expressed percentage of reads which were mutant was 7.83%, below 
the 9% threshold defined in my methods. 
If we remove CYST035 as a post-operative death and also exclude CYST063 as lost to follow-up (the 
only patient among the Ion Torrent cohort to be so) we find: 
 Survival to 5 years  
Yes No TOTALS 
p.L264R 
Mutant  0 6 6 
Wild Type 30 3 33 
 TOTALS 30 9 39 
Sensitivity = 0.67 (95%CI: 0.30 – 0.91); Specificity = 1 (95%CI: 0.86 – 1); Positive Predictive Value = 1 
(95%CI: 0.52 – 1).
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Table 38: Individual data for those samples coming from patients who have died. 
CYST - 7 9 10 14 15 18 21 22 25 35
Age (Yrs) 75 72 46 65 32 66 64 71 72 78
Gender Male Male Male Male Male Male Female Female Female Male
Survival (months) 12 39 54 27 43 47 12 36 19 1 (post-op)
HD histology IPMC IPMC IPMC IPMC IPMC IPMC IPMC IPMC PDAC IPMN 
LV Histology PDAC IPMN IPMN IPMN CP CP IPMN CP PDAC IPMN
MUC1 - Positive Negative Negative - - Negative - - Negative
MUC2 - Positive Positive Positive - - Positive - - Positive
MUC5AC - Positive Patchy Pos Positive - - Positive - - Positive
MUC6 - Positive Negative Negative - - Negative - - Negative
Epithelial subtype - Mixed Mixed Intestinal - - Intestinal - - Intestinal
Tumour Status 3 3 3 3 3 3 3 3 3
Nodal Status 1 0 1 1 1 1 1 0 0
Mets 1 0 0 0 0 0 1 0 0
Resection Margin 0 0 0 0 0 0 0 0 1
Primary or Secondary Primary Primary Primary Primary Primary Primary Primary Primary Primary Primary
Location Head Body Whole Tail Head Head Tail Head Head Body
Diabetes Metformin None None Insulin None None None None None None
Smoker No No No Former No No No No No Yes
Alcohol Occasion Occasion Occasion Occasion No No No No Unknown Daily
Weight Loss No No Yes No Yes No No Yes Yes No
Peritoneal mets No No No No No No Yes No No No
Dysplasia - HGD Cancer Cancer - - IGD - - LGD
K132Q W/T W/T W/T Mutant W/T W/T W/T W/T W/T W/T
M160L W/T W/T Mutant W/T Mutant W/T Mutant Mutant Mutant W/T
K164R W/T W/T W/T Mutant Mutant Mutant W/T W/T W/T W/T
K164T W/T Mutant W/T W/T W/T W/T W/T W/T W/T W/T
I251L W/T W/T W/T W/T Mutant W/T W/T Mutant W/T Mutant
E271G Mutant W/T W/T Mutant Mutant W/T W/T W/T W/T W/T
R273H W/T W/T W/T Mutant Mutant W/T W/T W/T W/T W/T
L264R Mutant W/T W/T Mutant Mutant Mutant Mutant Mutant W/T W/T
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5.9 - Validation 
Once I had identified the significance on the p.L264R mutation I needed to try and develop a cheaper 
and easier method to detect it to enhance the clinical usefulness of p.L264R as a prognostic marker. 
Given that I now had a single mutation I set about trying to create primers for use in a simple nested 
real time PCR which would be specific for this mutation.  I could then use those samples which have 
been found to have the mutation on Ion Torrent analysis as the positive control when validating the 
PCR. 
I used a simple primer design tool to design six sets of primers (three wild type and three mutant) 
which would create firstly a long fragment (739 bp) as round 1 and then using the amplified product 
of round one either a short product in round 2 (426 bp) or a long product in round 2 (711 bp). 
These primers are detailed in Appendix F. 
To ensure that I remained blinded to avoid any bias the next set of experiments were designed by me 
but performed by a laboratory colleague, Dr Li Yan.  I provided the extracted DNA, diluted to 10G for 
14 individuals – five who had p.L264R mutation identified using the ion torrent, seven who had been 
identified as wild type for p.L164R and one which was borderline.  Dr Yan was not aware which 
samples were which and all experimental steps were completed in exactly the same manner for the 
six samples. 
The first round of standard PCR was optimised by Dr Li Yan using the primers I designed with an 
annealing temperature of 55°C and melting temperature of 76°C.  The product was then run on an 
electrophoresis gel, the bands cut and extracted as detailed in 4.3.5 - Extraction and Purification. 
This extracted amplified product was then processed in two separate real time PCR experiments using 
both the ‘short’ primers and the ‘long’ primers in round 2.  Short Product PCR was optimised with an 
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annealing temperature of 50°C and a melting temperature of 79°C.  The Long Product PCR was 
optimised with an annealing temperature of 50°C and a melting temperature of 76°C. 
The resultant real-time PCR results confirmed that the mutation specific primers were able to detect 
the mutation in the three known mutant samples.  The ratio of the cycle thresholds for wild type and 
mutant primers was more clearly demonstrated when the amplified product from round 1 had 
undergone PCR with the ‘short’ product primers in round 2.  Accordingly we were now able to perform 
a simple two-step analysis using this technique on DNA extracted from the remaining samples which 
had not been analysed using the ion torrent. 
The ARMS PCR was conducted three times for each of the Ion Torrent samples using both the wild 
type and mutation specific primers.  The cycle threshold values for each PCR were then averaged and 
plotted on a scatter graph with a line of best fit calculated where more mutant values are below the 
gradient than above but which precludes the most wild type samples.  The gradient of this line was 
given as +0.5318, Figure 44.
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Figure 44: Analysis of wild type and mutant cycle thresholds for validation comparing unknown ‘Liverpool’ samples with Ion Torrent.
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Using this value a receiver-operator curve (ROC) was generated by calculating sensitivity and 1-
specificity for each threshold value generated by ARMS and extrapolated using the following formula: 
W/T Ct x 0.53185 x c 
Where ‘c’ was given as Ct from 40 – 20 in values decreasing by 0.5. 40, 39.5, 39 etc…  The resultant 
value was then subtracted from the ARMS generated mutant cycle threshold (Mt Ct).  If the value was 
negative then the sample was called MUTANT.  If positive (i.e calculated W/T Ct < Mut Ct) then the 
sample was called WILD TYPE.  For each resultant value sensitivity and specificity could be calculated 
using the descriptors: 
Mutant + Dead = True Positive (TP) 
Mutant + Alive = False Positive (FP) 
Wild Type + Dead = False Negative (FN) 
Wild Type + Alive = True Negative (TN) 
Sensitivity and Specificity can be readily calculated using: 
Sensitivity = TP / (TP+FN)  
Sensitivity = TN / (TN+FN) 
The resultant data were plotted to create a ROC using SPSS (Figure 45) with an area under the curve 
calculated at 0.79.  From this curve the optimum W/T cycle threshold can be calculated as the point 
which is maximally sensitive and specific (calculated to lie between 0.66 – 0.83 sensitivity and 0.61 – 
0.82 specificity).  This correlates to a W/T Ct of 33.5 cycles. 
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Figure 45: ROC analysis for validation data. 
 
The final formula is then described as: 
IF Mut Ct < (W/T Ct x 0.5138) + 33.5 = Mutant Sample 
IF Mut Ct > (W/T Ct x 0.5138) + 33.5 = Wild Type Sample. 
Using this formula applied to the original average Ct readings for each sample they have been 
designated as mutant or wild type and compared against each other for survival using the Kaplan-
Meier Method (Figure 46).  As can be seen, there is still a significant difference in survival between 
those individuals described as mutant using mutation specific PCR and those described as wild type, 
p=0.005. 
AUC = 0.79 
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Figure 46: Kaplan-Meir analysis of survival for PCR detected p.L264R mutations among all Heidelberg samples. 
Following from this, and as a form of validation, I have produced a separate Kaplan-Meir analysis 
comparing only those samples which were not included in the original Ion Torrent cohort.  As can be 
seen from Figure 47 a further three p.L264R mutations were identified, of which 2 died. 
p <0.001 
χ2 = 9.404 
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Wild Type 27 22 13 7 3 0 
Mutant 3 0 0 0 0 0 
 
Figure 47: Kaplan-Meir analysis of survival for PCR detected p.L264R mutations among all Heidelberg samples. 
 
 
Liverpool data 
Finally, work was undertaken to perform these mutation specific PCR experiments upon historically 
resected samples of IPMN from the Liverpool Pancreas Biomedical Research Unit biobank (between 
2004 and 2008) which have been stored at -150°C. 
This analysis was once again performed in a blinded fashion with the lab work being undertaken by a 
post-doctoral researcher who was blinded to the histological and survival data.  Seven samples were 
identified, 4 of which were IPMN with concurrent cancer (IPMC) and 3 which were benign IPMN.  Using 
p <0.001 
χ2 = 22.542 
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the methods and formula previously described these samples were analysed to identify their p.L264R 
mutational status.  Only two samples were found to be Wild Type, both of these were found in 
histologically identified malignant IPMN.  The numbers are obviously small and survival analyses does 
not reveal any significance between those mutant or wild type samples (p=0.897), Figure 48. 
 
 
Figure 48: Kaplan-Meier survival analyses for p.L264R mutation among 7 Liverpool samples. 
 
Clearly greater numbers are needed and this is work is being undertaken at the time of writing this 
thesis.  The one point of potential significance is that the only sample which was histologically 
malignant and yet survived was wild type for p.L264R.  All malignant IPMN which were mutant for 
p.L264R died within 5 years of their resection.
p = 0.897 
χ2 = 0.104 
Figure 48: Nested PCR results for Liverpool samples using previously defined cut-off.
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Chapter 6 
CONCLUSIONS 
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6 - Conclusions 
1) p.L264R in tissue predicts survival (p<0.005). 
2) Those malignant IPMN which did not have p.L264R were less likely to have nodal spread 
suggesting that whilst p.L264R is not the trigger for malignancy it may facilitate lymphatic 
spread and could be a target for palliative or adjuvant chemotherapy. 
3) The exact role of p.L264R remains unclear, it is likely to promote binding to MDM2. 
4) Limiting dilution is a successful method of removing replicated PCR error from samples 
undergoing whole genome sequencing. 
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7 - Discussion 
General 
Cystic lesions of the pancreas are an increasing phenomenon – it’s likely that their incidence is 
unchanged but that their rate of detection improves with more sophisticated cross-sectional 
imaging.100, 102, 272-276  In addition more and more people are undergoing such imaging for a variety of 
diagnostic reasons and so the incidental finding of IPMNs is set to increase.31, 277  In one institution in 
the USA, 356 such lesions were detected over 7 years – the most frequent indications for CT scan were 
genitourinary complaints and chest pain.32 
There are numerous current published guidelines for the management of such lesions but pancreatic 
specialists are still unable to determine with any degree of confidence which of these pose a significant 
risk to the patient and which can be safely observed or even discharged from ‘active’ follow-up.31, 115, 
148, 277-285 
As demonstrated, a policy of resection of all such lesions is not feasible given the volume of IPMN 
detected but also would create levels of morbidity and mortality which are quite unacceptable when 
taken in the context of the likelihood of malignant progression.95, 286-291 
Ideally a form of functional imaging, such as PET-CT, would be the best way of assessing the malignant 
potential of individual IPMN, such trials are underway, and in the future they may well play an 
important role in the algorithm for the management of incidental IPMN.292-295 At present however 
each pancreatic unit relies on their own interpretation of the Sendai criteria resulting in different rates 
of resection for both malignant and benign IPMN.  New work suggests that there may be benefit in 
the addition of a secretin enhanced MRI in the determination of small BD-IPMN.296 
When imaging cannot reliably reveal the information required to make a clinical decision further, 
invasive investigations must be considered.  Clearly the role of serum CA19-9 has been proven in 
pancreatic malignancy, there are of course certain exceptions such as those who carry the Lewis 
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antibody, but even this stalwart of pancreatic malignancy is proving contentious as a marker for 
IPMN.297-299  Further serum markers, most frequently a CEA level of >110ng/mL, have been suggested 
as predictors of malignancy.299, 300 
Pancreatic juice (usually obtained at ERCP) has been shown to contain markers that can indicate early 
pancreatic cancer, until recently it formed the basis of screening for the EUROPAC study.  The problem 
with this approach is the significant risk of harm (either PEP or perforation) which is incurred by virtue 
of the procedure.249 
The Goggins’ group has shown that pancreatic juice can be reliably collected from within the 
duodenum of an individual thus negating the risk associated with ERCP.236, 301  The controversy remains 
as to the effect of duodenal contamination with both bacterial and ingested DNA, however the very 
fact that pancreatic DNA can be separated suggests that future collection of pancreatic juice may well 
be possible with minimal risk to the patient. By definition, whatever the sub-type of IPMN there will 
always be communication with the main pancreatic duct thus there will be DNA material from the 
IPMN within the pancreatic juice. There is, of course, the possibility that the detected DNA may well 
be a product of ‘natural’ apoptosis of damaged cells which have sloughed off into the main pancreatic 
duct.  This may carry mutation resulting in a false positive finding which would be difficult to avoid. 
A more direct approach to obtaining cystic fluid may be via an endoscopic fine-needle aspiration (EUS-
FNA).  This has been shown in the past to be roughly 70% accurate for the diagnosis of IPMN but as a 
technique it is still not advocated in the current (2012) Sendai criteria for the management of side 
branch IPMN.104, 302  The cytological benefit of obtaining this fluid is based purely in the detection of 
atypical or malignant cells, since on the morphological characteristics alone it is impossible to 
distinguish between IPMN and MCN.303-305  Work is currently underway at the University of Pittsburgh 
to identify molecular markers which may herald malignancy within cyst fluid but to date, other than 
association between cyst size and KRAS there has been no breakthrough.62, 306, 307 
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This study has shown that the detection of p.L264R in tissue is associated with poor survival, it would 
follow therefore that if this mutation were to be detected in the pancreatic juice of an individual with 
an IPMN that their IPMN has undergone malignant transformation and the benefit of resection is likely 
to be minimal or, more optimistically, that the surgery was too late in the collected samples – so 
equivalent patients should be operated on earlier.   
The question of clinical application may therefore be posited away from diagnosis and rather to 
prognosis.  If a resected IPMN is subsequently found to be p.L264R mutant this information, in 
conjunction with TNM staging may be evidence enough to confirm the need for adjuvant 
chemotherapy. 
MUC Status  
Mucin protein staining, particularaly MUC1, has been variously associated with a good prognosis in 
gastric and pancreatic ductal cancer;308, 309 but also a poor prognosis in high grade lymphoma;310 renal 
cell carcinoma;311 breast cancer;312 ovarian cancer;313  cholangiocarcinoma;314 and colorectal cancer 
associated with HNPCC.315 
MUC1 has been implicated in the devlopment of PanIN lesions and has also been shown to be 
associated with epidermal growth factor receptor tyrosine kinases, therefore postulated to promote 
cell adhesion and possibly stimulate metastases.316  Among the 21 samples which were stained for 
MUC1 there was no discernable correlation between tumour status or metastases, similiarily there is 
probably no significant correlation between the presence of MUC1 and whether or not the tumour is 
recurrent as only two samples within the cohort were recurrent tumours. 
MUC2 has also been shown to be associated with positive survival outcomes in gastric 
adenocarcinoma and has been shown to differentiate between mucinous and tubular subtypes of 
colorectal carcinoma.317, 318  Interestingly MUC2 is the only MUC protein to have been shown to have 
discernable differences in expression depending on an individuals race.319 
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It is likley that the gender bias displayed in MUC 2 and MUC 6 may be artefactual and represents the 
danger of multiple testing though there was no obvious gender bias in MUC 5 samples. 
In this work MUC 6 is perhaps associated with lower grade dysplasia (p=0.05) but I would only have 
expected MUC 6 to be present in the oncocytic subtype.  In my cohort MUC 6 was positive in 9, 
including the oncocytic sample (CYST023) thus suggesting that 8 of the remainig samples were ‘mixed’ 
IPMN with an element of oncoytic epithelium present.   This raises the question of whether the 
conventional wisdom that IPMN should be graded in line with the most ‘sinister’ subtype 
(gastric>intestinal>pancreatobiliary>oncocytic) holds true in all cases as this cohort includes 8 cases 
which should therefore be classed as oncocytic. 
Samples which were MUC 2 positive did have a tendency towards significance for survival (p=0.054) 
which is difficult to explain in the context of a lack of association between grade of dysplasia or TNM 
status. 
In essence, within the confines of this work, the MUC staining was more useful for delineating the 
epithelial sub-type of IPMN rather than displaying any significant prognostic associations. 
Mutational Analyses 
The initial assessment of those individuals with p.M160L mutation suggested a trend towards 
increasing tumour status (Table 30), however when tumour status is defined as high (>T2) or low 
(≤T2) there is no difference (4/13 vs. 5/14, p=0.78). 
My research suggested a relationship between p.I251L and smoking (8 out of 14 current or ex-smokers 
were found to have the mutation compared to 4/27 non-smokers, p=0.06).  In 2002 researchers in 
California confirmed that there are a greater percentage of p53 mutations in smokers lung cancer 
(30%) versus non-smokers lung cancer (12%).320  These mutations were clustered between codons 
254-249 however.  Furthermore, it has long been established that the most common p53 mutations 
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associated with smoking are G>T transversions, whereas p.I251L is the opposite transversion (A>C).210  
This mutation has been previously reported in stomach and bladder cancers.321  In gastric cancer, 
research on smoking mediated p53 mutational status has focussed on codon 72 and the interaction 
with Helicobacter pylori.322  There is insufficient evidence, due to the small numbers involved in this 
sample, to accurately assess the likelihood of smoking being a causative factor in IPMN development, 
this is born out in a recent large scale retrospective analysis of 446 patients.323  Certainly we have not 
demonstrated an association between smoking and maligant progression, nor indeed survival. 
An association has been suggested between diabetes and the p.E271G mutation in this work.  Among 
8 diabetics who were undergoing treatment (either with insulin therapy or oral anti-hyperglycaemic 
agents) 4 (50%) were found to express the mutation compared to 5 out of 30 (17%) non-diabetics, 
p=0.048).  Little has been proven with regards to the relatonship between p53 and diabetes, research 
conducted in obese mice have uncovered a p53-dependent senescence response in fat cells; this 
response ultimately engendered insulin resistance.172, 198  Diabetes was not independently shown to 
be a significant co-factor for survival, grade of dysplasia or severity of tumour (TNM stage). 
Mutations 
The following data has been collated from the IARC p53 databse 
(http://p53.iarc.fr/TP53GeneVariations.aspx). 
p.K132Q (c.394A>C) 
On the basis of yeast functional assays this is a loss of function mutation as with the promoters of 
p53R2, NOXA, GAD45 and AIP this mutation gives less than 10% of wild type activity. 
This mutation was first described in a B-cell lymphoma and has been described as a somatic mutation 
in pancreatic adenocarcinoma on one occasion, the mutation has been shown to be present in the 
pancreatic cancer cell line PSN1.324,325  Of the 4 occurrences in my Ion Torrent samples 3 were IPMC 
and 1 IPMN.  One case died at 26.86 months.  Two of the IPMN were intestinal subtype and one gastric.  
The IPMC was a mucinous adenocarcinoma.   
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Unpublished work at the University of Florida is attempting to prove the hypothesis that p.K164 is 
essential for transferring p53 out of the nucleus and into the cytoplasm of the cell 
(http://cur.aa.ufl.edu/Data/Sites/5/media/symposium2013/symposium-book-2013-final.pdf). 
p.M160L (c.478A>C) 
On the basis of yeast functional assays this is not a loss of function mutation as with the promoters of 
p53R2 and NOXA it results in greater than wild type activity and for the promoters of GAD45 and AIP 
greater than 70% activity. 
This mutation was first described in a MALT (Mucosal Associated Lymphoid Tissue)-lymphoma and has 
also been described as a somatic mutation in cholangiocarcinoma but is not known to be present in 
any cell lines.326-328  Of the 10 occurrences in my sample 8 were IPMC, 1 PDAC and only one IPMN. Five 
of the cases died with a median survival of 35.73 months. It is thought that p.M160L may be a mutation 
which adversely affects the DNA binding domain of p53 by altering the β-sheet in the core of the 
domain.329 
p.K164R (c.491A>G) 
On the basis of yeast functional assays this is not a loss of function mutation as with the promoters 
of p53R2 and NOXA it results in greater than wild type activity and for the promoters of GAD45 and 
AIP greater than 50% activity. 
This mutation was first reported in colorectal cancer and has been described in pancreatic cancer 
twice and in one case of liver-fluke associated cholangiocarcinoma.330-334 Of the 9 occurrences in my 
sample all were malignant IPMN (IPMC), three of whom died with a median survival of 43 months.  
Interestingly all three of those who died also carried the p.L264R mutation and all of those who 
survived were wild type for p.L164R.  Work in 2008 suggested that mutation at codon 164 may lead 
to loss of acetylation which will reduce the ability of p53 to activate p.21 and also blocks the 
interaction of p53 and MDM2.335  As a consequence the p53 will be activated regardless of its 
phosphorylation status. 
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p.K164T (c.491A>C) 
On the basis of yeast functional assays this is not a loss of function mutation as with the promoters of 
p53R2 and NOXA it results in greater than wild type activity and for the promoters of GAD45 and AIP 
greater than 40% activity. 
This mutation was first reported in an ovarian cancer and has never been described in pancreatic or 
biliary cancers.336  Of the 3 occurrences in my sample all were malignant mixed IPMN 1 died at 38.6 
months.  Little is understood about this mutation and there are currently no published hypotheses for 
the possible action on the p53 molecule. 
p.I251L (c.751A>C) 
On the basis of yeast functional assays this is a loss of function mutation as  with the promoters of 
NOXA, GAD45 and AIP it gives less than 10% of wild type activity and with p53R2 promoter only 25%   
activity. 
This mutation was first reported in a gastric cancer but has never been described in pancreatic or 
biliary cancer.337  This mutation is known to be present in three separate stomach cancer cell-lines: 
MK28, MK7 and MK24.338, 339  Amongst the 10 occurrences in my sample, 9 were IPMC and one benign.  
One patient died at 35 months and another died of post-operative complications.  No specific work 
has been published which looks at this mutation, however the I251 position is known to be an area of 
hydrophobic binding for the molecule RelA-associated inhibitor which has been shown to interact with 
p53 by inhibiting the DNA-binding activity.340 
p.L264R (c.791T>G) 
On the basis of yeast functional assays this is not a loss of function mutation as with the promoters of 
p53R2, NOXA, GAD45 and AIP it gives greater than 10% of wild type activity. 
First described in colorectal cancer, this mutation has been identified to have occurred in pancreatic 
cancer on one occasion and is also known to be present in the cell line TK-10.139, 341, 342  As described 
in chapter 5, this is the only mutation which demonstrated a significant association with survival.  
There have been so specific publications, to date, which have looked at the function of p.L264R 
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specifically.  A study of ribozyme mediated modification of p53 mRNA in lung cancer demonstrated 
that even when codon 264 was targeted there was no suppression of cell growth.343 
p.L264 forms part of the linker which bridges the S9–S10 β-sheets of p53 and mutation of this site has 
been shown to give increased MDM2-dependent ubiquitination of p53.344  
p.E271G (c.812A>G) 
On the basis of yeast functional assays this is not a loss of function mutation as with the promoters of 
p53R2, NOXA, GAD45 and AIP it gives greater than 70% activity. 
This mutation was first described in a mouth cancer and has never previously been reported in 
pancreatic or biliary cancer.345  Of the 9 cases in my sample p.E271G never occurred as a sole mutation 
and 8 of the cases were IPMC with one IPMN.  Three cases died with a median survival of 26.8 months.  
E271 is known to be one the two important glutamate residues which bind to damaged DNA via PARP-
1 leading to inhibited nuclear export of p53 and apoptosis.329 
p.R273H (c.818G>A) 
On the basis of yeast functional assays this is a loss of function mutation as with the promoters of 
NOXA, GAD45 and AIP promoters it gives less than 10% activity and for p53R2 just 16% activity. 
The most common mutation described in p53, R273H was first described in lung cancer in 1990.346  It 
has since been discovered to occur in 50 different cancers as well as 80 cell lines and 54 reported 
germline mutations are available in the literature.  R273H has been identified to have occurred in 14 
different pancreatic tumours.333, 347-359  Amongst the 4 occurrences of this mutation in my sample, 2 
were benign IPMN who both survived and 2 were IPMC and who both died with a median survival of 
34.95 months.  R273 mutations are known to adversely affect p53 function in two major ways: the 
mutation change the protein confirmation which prevents the formation of the functional tetramer 
and;360 asserts a ‘transdominance’ effect which promotes propagation of the mutant p53 in favour of 
the wild type protein.361 
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Limitations 
The number of samples in this work is small, yet these data are compelling.  The concern that there 
may be a geographical bias to the development of this somatic mutation is negated by the detection 
of p.L264R in samples obtained from Liverpool – with similar survival outcomes.  Whether or not this 
mutation is caused by specific environmental stresses is still open – though we have looked at 
diabetes, alcohol and smoking insofar as the data we hold has allowed. 
If such a mutation can be demonstrated to be a product of or accentuated by external factors then 
where possible advice should be given to avoid such precursors.  
Immunohistochemistry confirmed the subtype of IPMN (gastric, intestinal, oncocytic, 
pancreatobiliary) used within the study but did not bear any correlation with survival, nor the 
expression of p.L264R.   
It is apparent from an assessment of the median depth of reads per exon (Table 27) that Exon 6 had a 
relative paucity of reads – this may well be the reason that none of the mutations detected using the 
whole genome sequence method were located in exon 6.    It is already known, however, that 
mutations are comparatively less common in Exon 6 compared to 5, 7 and 8 as can be seen in Figure  
49 taken from the IARC p53 database. 
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Figure 49: Frequency of mutations of p53 by exon. 
Initially I was concerned that my method of ‘blind’ dissection of the samples provided from Heidelberg 
would mean that mutational analyses would not reflect the neoplasm present.  In fact, as can be seen 
from the fact that many of the samples processed were felt to represent benign conditions (such as 
chronic pancreatitis) the fact that p53 mutations were detected in ‘normal’ paraneoplastic tissue adds 
weight to the idea of a ‘field theory’ of mutational change surrounding the initial neoplastic focus.362  
The surrounding cells are harbouring mutations in readiness for malignant transformation before they 
have been phenotypically altered. 
A final point to be made in terms of limitation of this work would be to raise the suggestion that the 
somatic p.L264R mutation may well be a geographic phenomenon – certainly the results among (an 
admittedly smaller) Liverpool selection of patients do not bear the same startling  significance as the 
German cohort, although the same trend is seen.  I do not think that this diminishes the significance 
of the work, even if the results are subsequently found to be applicable to German patients there is 
still the potential for a significant benefit. 
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Summary 
There are relatively few reports of mutations at codon 264 of p53 (45 at the time of writing). However, 
p.L264R has been seen previously in renal cell cancer and exists in cell line (TK-10) which may provide 
access to future studies to try and discover the effect of this mutation on the overall function of the 
p53 protein. The suggestion from the literature is that this mutation may act chiefly to increase binding 
of p53 to MDM2344, which combined with its maintained activity in promoting expression of essential 
genes involved in survival in conditions of stress (p53R2, NOXA, GAD45 and AIP) may imply that the 
mutation does not prevent the survival promoting functions of p53 but instead attenuates the 
functions that require high levels of the protein (such as induction of apoptosis). This in turn would 
imply that p.L264R would be a well-tolerated mutation offering a pre-malignant lesion the opportunity 
to develop further, with a continuing requirement for other p53 mutations in order for the lesion to 
finally develop into a carcinoma. 
The work of Goggins et.al. at Johns Hopkins has shown that it is possible to detect lesions from 
pancreatic cysts in duodenal aspirate, indeed in Liverpool our own experience with duodenal aspirate 
has yielded similar results (p.89).363  It is feasible, therefore, so suggest that further work could be 
aimed at detecting p.L264R in duodenal aspirate of individuals with CT proven IPMN to prospectively 
prove correlation with p.L264R and outcomes. 
Whether the future role of p.L264R is destined to be a screening tool, a therapeutic target or a 
prognostic marker there is sufficient weight of evidence within this thesis to advocate further 
investigation into the role of thesis SNP in the pathogenesis of IPMN associated pancreatic cancer.  I 
remain firmly committed to my prediction that the cure for pancreatic cancer will be found in 
epigenetics not the operating theatre.  To misquote Paracelsus: 
“There can be no surgeon who is not also a scientist”.  
P a g e  | 187 
 
 
 
 
 
 
Chapter 8 
REFERENCES 
 
  
P a g e  | 188 
 
 
8 - References  
1. UK CR. Pancreatic Cancer Incidence Statistics.  2013 17/05/2013 [cited 2014 28/05/2014]; 
Available from: http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/pancreas/incidence/ 
2. Mayor S. One year cancer survival rates in England remain poor despite national strategies, 
report finds. BMJ. 2011; 342: d1374. 
3. UK CR. Pancreatic Cancer Survival Statistics.  2012 03/09/2012 [cited 2014 28/05/2014]; 
Available from: http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/pancreas/survival/pancreatic-cancer-survival-statistics#source1 
4. Mishra MV, Keith SW, Shen X, Ad VB, Champ CE, Biswas T. Primary Pancreatic Lymphoma: A 
Population-based Analysis Using the SEER Program. American journal of clinical oncology. 2011. 
5. Murakami H, Tsuchiya K, Nishimura H, Ushikubi F, Atsumi K, Seki M, et al. [Hereditary 
pancreatitis]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology. 1983; 
80(4): 1031-5. 
6. Starling N, Cunningham D. Survival from cancer of the pancreas in England and Wales up to 
2001. British journal of cancer. 2008; 99 Suppl 1: S24-5. 
7. Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, et al. Survival and prognosis of invasive 
intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal 
adenocarcinoma. Pancreas. 2008; 36(1): 50-5. 
8. Niedergethmann M, Grutzmann R, Hildenbrand R, Dittert D, Aramin N, Franz M, et al. 
Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas 
(IPMN): a 10-year experience. World journal of surgery. 2008; 32(10): 2253-60. 
9. Goldstein J, Benharroch D, Sion-Vardy N, Arish A, Levy I, Maor E. Solid cystic and papillary 
tumor of the pancreas with oncocytic differentiation. Journal of surgical oncology. 1994; 56(1): 63-7. 
10. Tajiri H, Yoshimori M, Nakamura K, Ozaki H, Taylor WF, Go VL. [Clinicopathological study on 
carcinoma of the pancreas operated on at the Mayo Clinic and the National Cancer Center Hospital--
a comparison of the diagnostic process in both institutions and an analysis of survival rates]. Nihon 
Gan Chiryo Gakkai shi. 1987; 22(3): 566-72. 
11. Maire F, Sauvanet A, Couvelard A, Rebours V, Vullierme MP, Lebtahi R, et al. Recurrence after 
surgical resection of gastrinoma: who, when, where and why? European journal of gastroenterology 
& hepatology. 2012; 24(4): 368-74. 
12. Grygiel K, Szmidt J, Jelenska M, Pawlak K. Surgical treatment of hyperinsulinism during the 
course of pancreatic cancer (insulinoma) - one center experience. Polski przeglad chirurgiczny. 2012; 
84(1): 31-6. 
13. Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ. Glucagonoma and the 
glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. Clinical 
endocrinology. 2011; 74(5): 593-8. 
14. Elshafie O, Grant C, Al-Hamdani A, Jain R, Woodhouse N. VIPoma Crisis: Immediate and life 
saving reduction of massive stool volumes on starting treatment with octreotide. Sultan Qaboos 
University medical journal. 2011; 11(1): 104-7. 
15. Evans J, Chapple A, Salisbury H, Corrie P, Ziebland S. "It can't be very important because it 
comes and goes"--patients' accounts of intermittent symptoms preceding a pancreatic cancer 
diagnosis: a qualitative study. BMJ open. 2014; 4(2): e004215. 
16. Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, et al. Exocrine pancreatic 
cancer: symptoms at presentation and their relation to tumour site and stage. Clinical & translational 
oncology : official publication of the Federation of Spanish Oncology Societies and of the National 
Cancer Institute of Mexico. 2005; 7(5): 189-97. 
P a g e  | 189 
 
 
17. Gobbi PG, Bergonzi M, Comelli M, Villano L, Pozzoli D, Vanoli A, et al. The prognostic role of 
time to diagnosis and presenting symptoms in patients with pancreatic cancer. Cancer epidemiology. 
2013; 37(2): 186-90. 
18. Silverman DT. Risk factors for pancreatic cancer: a case-control study based on direct 
interviews. Teratogenesis, carcinogenesis, and mutagenesis. 2001; 21(1): 7-25. 
19. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon 
carcinoma. Science. 1981; 212(4490): 53-5. 
20. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a 
biochemical marker in the diagnosis of pancreatic cancer. European journal of surgical oncology : the 
journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 
2007; 33(3): 266-70. 
21. Gui JC, Yan WL, Liu XD. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic 
cancer: a meta-analysis. Clinical and experimental medicine. 2014; 14(2): 225-33. 
22. Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, Nishihara S, et al. Lewis and secretor 
gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer 
patients. Cancer research. 1998; 58(3): 512-8. 
23. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of 
carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer research. 1987; 47(20): 
5501-3. 
24. Yeo C, Yeo, TP, Hruban, RH, et. al., editor. Cancer of the Pancreas. 7th ed. Philadelphia: 
Lippincott Williams & Wilkins; 2004. 
25. Procacci C, Graziani R, Bicego E, Bergamo-Andreis IA, Mainardi P, Zamboni G, et al. Intraductal 
mucin-producing tumors of the pancreas: imaging findings. Radiology. 1996; 198(1): 249-57. 
26. Megibow AJ, Lombardo FP, Guarise A, Carbognin G, Scholes J, Rofsky NM, et al. Cystic 
pancreatic masses: cross-sectional imaging observations and serial follow-up. Abdominal imaging. 
2001; 26(6): 640-7. 
27. Long EE, Van Dam J, Weinstein S, Jeffrey B, Desser T, Norton JA. Computed tomography, 
endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic 
cancer. Surgical oncology. 2005; 14(2): 105-13. 
28. Vargas R, Nino-Murcia M, Trueblood W, Jeffrey RB, Jr. MDCT in Pancreatic adenocarcinoma: 
prediction of vascular invasion and resectability using a multiphasic technique with curved planar 
reformations. AJR American journal of roentgenology. 2004; 182(2): 419-25. 
29. Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT, Gines MA, et al. Preoperative staging 
and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic 
ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. The 
American journal of gastroenterology. 2004; 99(3): 492-501. 
30. Winter JM, Cameron JL, Lillemoe KD, Campbell KA, Chang D, Riall TS, et al. Periampullary and 
pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. 
Annals of surgery. 2006; 243(5): 673-80; discussion 80-3. 
31. Sachs T, Pratt WB, Callery MP, Vollmer CM, Jr. The incidental asymptomatic pancreatic lesion: 
nuisance or threat? Journal of gastrointestinal surgery : official journal of the Society for Surgery of 
the Alimentary Tract. 2009; 13(3): 405-15. 
32. Bruzoni M, Johnston E, Sasson AR. Pancreatic incidentalomas: clinical and pathologic 
spectrum. American journal of surgery. 2008; 195(3): 329-32; discussion 32. 
33. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 
2007; 56(8): 1134-52. 
34. Shore S, Raraty MG, Ghaneh P, Neoptolemos JP. Review article: chemotherapy for pancreatic 
cancer. Alimentary pharmacology & therapeutics. 2003; 18(11-12): 1049-69. 
35. Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM, et al. Adjuvant therapy 
in pancreatic cancer: historical and current perspectives. Annals of oncology : official journal of the 
European Society for Medical Oncology / ESMO. 2003; 14(5): 675-92. 
P a g e  | 190 
 
 
36. Sultana A, Cox T, Ghaneh P, Neoptolemos JP. Adjuvant therapy for pancreatic cancer. Recent 
results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 
2012; 196: 65-88. 
37. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, et al. Systematic 
review, including meta-analyses, on the management of locally advanced pancreatic cancer using 
radiation/combined modality therapy. British journal of cancer. 2007; 96(8): 1183-90. 
38. Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, et al. Extended neoadjuvant 
chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative 
outcomes and survival. Annals of surgical oncology. 2014; 21(5): 1530-7. 
39. Chen KT, Devarajan K, Milestone BN, Cooper HS, Denlinger C, Cohen SJ, et al. Neoadjuvant 
chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does 
time interval between radiotherapy and surgery matter? Annals of surgical oncology. 2014; 21(2): 662-
9. 
40. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. Current standards of 
surgery for pancreatic cancer. The British journal of surgery. 2004; 91(11): 1410-27. 
41. Birkmeyer JD, Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL, Fisher ES. Effect of hospital 
volume on in-hospital mortality with pancreaticoduodenectomy. Surgery. 1999; 125(3): 250-6. 
42. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume 
and surgical mortality in the United States. The New England journal of medicine. 2002; 346(15): 1128-
37. 
43. Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN. Relationship between 
hospital volume and late survival after pancreaticoduodenectomy. Surgery. 1999; 126(2): 178-83. 
44. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 
pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. Journal of 
gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2006; 10(9): 
1199-210; discussion 210-1. 
45. Chen T, Wang H, Song Y, Li X, Wang J. POSSUM and P-POSSUM as predictors of postoperative 
morbidity and mortality in patients undergoing hepato-biliary-pancreatic surgery: a meta-analysis. 
Annals of surgical oncology. 2013; 20(8): 2501-10. 
46. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. Influence of 
resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation 
and/or chemotherapy in the ESPAC-1 randomized controlled trial. Annals of surgery. 2001; 234(6): 
758-68. 
47. Ghaneh P, Neoptolemos JP. Conclusions from the European Study Group for Pancreatic 
Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer. Surgical 
oncology clinics of North America. 2004; 13(4): 567-87, vii-viii. 
48. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy 
with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: 
a randomized controlled trial. JAMA : the journal of the American Medical Association. 2007; 297(3): 
267-77. 
49. de Castro SM, Houwert JT, Lagarde SM, Reitsma JB, Busch OR, van Gulik TM, et al. Evaluation 
of POSSUM for patients undergoing pancreatoduodenectomy. World journal of surgery. 2009; 33(7): 
1481-7. 
50. Debinska I, Smolinska K, Osiniak J, Paluszkiewicz P. The possum scoring system and complete 
blood count in the prediction of complications after pancreato-duodenal area resections. Polski 
przeglad chirurgiczny. 2011; 83(1): 10-8. 
51. Gallacher PJ RN, Duxbury M, et al. The evaluation of the POSSUM scoring system in the 
prediction of morbidity following pancreaticoduodenectomy. British Journal of Surgery. 2011; 98 
(Suppl. 3): 44. 
52. Khan AW, Shah SR, Agarwal AK, Davidson BR. Evaluation of the POSSUM scoring system for 
comparative audit in pancreatic surgery. Digestive surgery. 2003; 20(6): 539-45. 
P a g e  | 191 
 
 
53. Knight BC, Kausar A, Manu M, Ammori BA, Sherlock DJ, O'Reilly DA. Evaluation of surgical 
outcome scores according to ISGPS definitions in patients undergoing pancreatic resection. Digestive 
surgery. 2010; 27(5): 367-74. 
54. Pratt W, Joseph S, Callery MP, Vollmer CM, Jr. POSSUM accurately predicts morbidity for 
pancreatic resection. Surgery. 2008; 143(1): 8-19. 
55. Tamijmarane A, Bhati CS, Mirza DF, Bramhall SR, Mayer DA, Wigmore SJ, et al. Application of 
Portsmouth modification of physiological and operative severity scoring system for enumeration of 
morbidity and mortality (P-POSSUM) in pancreatic surgery. World journal of surgical oncology. 2008; 
6: 39. 
56. Zhang Y, Fu L, Zhang ZD, Li ZJ, Liu XB, Hu WM, et al. Evaluation of POSSUM in predicting post-
operative morbidity in patients undergoing pancreaticoduodenectomy. The Journal of international 
medical research. 2009; 37(6): 1859-67. 
57. Lahat G, Ben Haim M, Nachmany I, Sever R, Blachar A, Nakache R, et al. Pancreatic 
incidentalomas: high rate of potentially malignant tumors. Journal of the American College of 
Surgeons. 2009; 209(3): 313-9. 
58. Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, Falconi M, et al. Branch-duct intraductal 
papillary mucinous neoplasms: observations in 145 patients who underwent resection. 
Gastroenterology. 2007; 133(1): 72-9; quiz 309-10. 
59. Spinelli KS, Fromwiller TE, Daniel RA, Kiely JM, Nakeeb A, Komorowski RA, et al. Cystic 
pancreatic neoplasms: observe or operate. Annals of surgery. 2004; 239(5): 651-7; discussion 7-9. 
60. Richards MA. Trends and inequalities in survival for 20 cancers in England and Wales 1986-
2001: population-based analyses and clinical commentaries. Foreword. British journal of cancer. 2008; 
99 Suppl 1: S1. 
61. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, et al. An 
illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal 
papillary mucinous neoplasms. The American journal of surgical pathology. 2004; 28(8): 977-87. 
62. Khalid A, Zahid M, Finkelstein SD, LeBlanc JK, Kaushik N, Ahmad N, et al. Pancreatic cyst fluid 
DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointestinal endoscopy. 
2009; 69(6): 1095-102. 
63. Sawai H, Okada Y, Funahashi H, Matsuo Y, Tanaka M, Manabe T. Immunohistochemical 
analysis of molecular biological factors in intraductal papillary-mucinous tumors and mucinous cystic 
tumors of the pancreas. Scandinavian journal of gastroenterology. 2004; 39(11): 1159-65. 
64. Traverso LW, Moriya T, Hashimoto Y. Intraductal papillary mucinous neoplasms of the 
pancreas: making a disposition using the natural history. Current gastroenterology reports. 2012; 
14(2): 106-11. 
65. Logan SE, Voet RL, Tompkins RK. The malignant potential of mucinous cysts of the pancreas. 
The Western journal of medicine. 1982; 136(2): 157-62. 
66. Verbeke CS. Intraductal papillary-mucinous neoplasia of the pancreas: Histopathology and 
molecular biology. World journal of gastrointestinal surgery. 2010; 2(10): 306-13. 
67. Cellier C, Cuillerier E, Palazzo L, Rickaert F, Flejou JF, Napoleon B, et al. Intraductal papillary 
and mucinous tumors of the pancreas: accuracy of preoperative computed tomography, endoscopic 
retrograde pancreatography and endoscopic ultrasonography, and long-term outcome in a large 
surgical series. Gastrointestinal endoscopy. 1998; 47(1): 42-9. 
68. Furukawa T, Kloppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, Horii A, et al. 
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. 
Virchows Archiv : an international journal of pathology. 2005; 447(5): 794-9. 
69. Terris B, Dubois S, Buisine MP, Sauvanet A, Ruszniewski P, Aubert JP, et al. Mucin gene 
expression in intraductal papillary-mucinous pancreatic tumours and related lesions. The Journal of 
pathology. 2002; 197(5): 632-7. 
P a g e  | 192 
 
 
70. Furukawa T, Takahashi T, Kobari M, Matsuno S. The mucus-hypersecreting tumor of the 
pancreas. Development and extension visualized by three-dimensional computerized mapping. 
Cancer. 1992; 70(6): 1505-13. 
71. Werner J, Fritz S, Buchler MW. Intraductal papillary mucinous neoplasms of the pancreas-a 
surgical disease. Nature reviews Gastroenterology & hepatology. 2012; 9(5): 253-9. 
72. Talamini MA, Pitt HA, Hruban RH, Boitnott JK, Coleman J, Cameron JL. Spectrum of cystic 
tumors of the pancreas. American journal of surgery. 1992; 163(1): 117-23; discussion 23-4. 
73. Takasu N, Kimura W, Moriya T, Hirai I, Takeshita A, Kamio Y, et al. Intraductal papillary-
mucinous neoplasms of the gastric and intestinal types may have less malignant potential than the 
pancreatobiliary type. Pancreas. 2010; 39(5): 604-10. 
74. Shi C, Hruban RH. Intraductal papillary mucinous neoplasm. Human pathology. 2012; 43(1): 1-
16. 
75. Fernandez-del Castillo C, Adsay NV. Intraductal papillary mucinous neoplasms of the pancreas. 
Gastroenterology. 2010; 139(3): 708-13, 13 e1-2. 
76. Mino-Kenudson M, Fernandez-del Castillo C, Baba Y, Valsangkar NP, Liss AS, Hsu M, et al. 
Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor 
epithelial subtypes. Gut. 2011; 60(12): 1712-20. 
77. Adsay NV, Merati K, Basturk O, Iacobuzio-Donahue C, Levi E, Cheng JD, et al. Pathologically 
and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation 
of an "intestinal" pathway of carcinogenesis in the pancreas. The American journal of surgical 
pathology. 2004; 28(7): 839-48. 
78. Luttges J, Zamboni G, Longnecker D, Kloppel G. The immunohistochemical mucin expression 
pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and 
determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. The 
American journal of surgical pathology. 2001; 25(7): 942-8. 
79. Basturk O, Khayyata S, Klimstra DS, Hruban RH, Zamboni G, Coban I, et al. Preferential 
expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms 
highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic 
carcinogenesis. The American journal of surgical pathology. 2010; 34(3): 364-70. 
80. Yonezawa S, Taira M, Osako M, Kubo M, Tanaka S, Sakoda K, et al. MUC-1 mucin expression 
in invasive areas of intraductal papillary mucinous tumors of the pancreas. Pathology international. 
1998; 48(4): 319-22. 
81. Terada T, Nakanuma Y. Expression of mucin carbohydrate antigens (T, Tn and sialyl Tn) and 
MUC-1 gene product in intraductal papillary-mucinous neoplasm of the pancreas. American journal of 
clinical pathology. 1996; 105(5): 613-20. 
82. Karasaki H, Mizukami Y, Tokusashi Y, Koizumi K, Ishizaki A, Imai K, et al. Localization of the 
most severely dysplastic/invasive lesions and mucin phenotypes in intraductal papillary mucinous 
neoplasm of the pancreas. Pancreas. 2011; 40(4): 588-94. 
83. Maker AV, Katabi N, Gonen M, DeMatteo RP, D'Angelica MI, Fong Y, et al. Pancreatic cyst fluid 
and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. 
Annals of surgical oncology. 2011; 18(1): 199-206. 
84. Klimstra DS. Cystic, mucin-producing neoplasms of the pancreas: the distinguishing features 
of mucinous cystic neoplasms and intraductal papillary mucinous neoplasms. Seminars in diagnostic 
pathology. 2005; 22(4): 318-29. 
85. Handra-Luca A, Flejou JF, Rufat P, Corcos O, Belghiti J, Ruszniewski P, et al. Human pancreatic 
mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared 
with intraductal papillary-mucinous adenoma. Histopathology. 2006; 48(7): 813-21. 
86. Satoh K, Shimosegawa T, Moriizumi S, Koizumi M, Toyota T. KRAS mutation and p53 protein 
accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas. 1996; 12(4): 
362-8. 
P a g e  | 193 
 
 
87. Wada K. p16 and p53 gene alterations and accumulations in the malignant evolution of 
intraductal papillary-mucinous tumors of the pancreas. Journal of hepato-biliary-pancreatic surgery. 
2002; 9(1): 76-85. 
88. Kawahira H, Kobayashi S, Kaneko K, Asano T, Ochiai T. p53 protein expression in intraductal 
papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy. Hepato-
gastroenterology. 2000; 47(34): 973-7. 
89. Amato E, Molin MD, Mafficini A, Yu J, Malleo G, Rusev B, et al. Targeted next-generation 
sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the 
pancreas. The Journal of pathology. 2014; 233(3): 217-27. 
90. Sasaki M, Sugio K, Kuwabara Y, Koga H, Nakagawa M, Chen T, et al. Alterations of tumor 
suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer. Annals of 
nuclear medicine. 2003; 17(3): 189-96. 
91. Biankin AV, Biankin SA, Kench JG, Morey AL, Lee CS, Head DR, et al. Aberrant p16(INK4A) and 
DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with 
invasive ductal adenocarcinoma. Gut. 2002; 50(6): 861-8. 
92. Fritz S, Buchler MW, Werner J. [Surgical therapy of intraductal papillary mucinous neoplasms 
of the pancreas]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 2012; 83(2): 130-5. 
93. Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, et al. Intraductal 
papillary mucinous neoplasms of the pancreas: an updated experience. Annals of surgery. 2004; 
239(6): 788-97; discussion 97-9. 
94. Wada K, Kozarek RA, Traverso LW. Outcomes following resection of invasive and noninvasive 
intraductal papillary mucinous neoplasms of the pancreas. American journal of surgery. 2005; 189(5): 
632-6; discussion 7. 
95. Salvia R, Crippa S, Falconi M, Bassi C, Guarise A, Scarpa A, et al. Branch-duct intraductal 
papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut. 2007; 56(8): 1086-
90. 
96. Abe K, Suda K, Arakawa A, Yamasaki S, Sonoue H, Mitani K, et al. Different patterns of 
p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic 
intraepithelial neoplasia. Pancreas. 2007; 34(1): 85-91. 
97. Conlon KC. Intraductal papillary mucinous tumors of the pancreas. Journal of clinical oncology 
: official journal of the American Society of Clinical Oncology. 2005; 23(20): 4518-23. 
98. Fernandez-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL. 
Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic 
patients. Arch Surg. 2003; 138(4): 427-3; discussion 33-4. 
99. Sarr MG, Murr M, Smyrk TC, Yeo CJ, Fernandez-del-Castillo C, Hawes RH, et al. Primary cystic 
neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and 
unanswered questions. Journal of gastrointestinal surgery : official journal of the Society for Surgery 
of the Alimentary Tract. 2003; 7(3): 417-28. 
100. Khan S, Sclabas G, Reid-Lombardo KM. Population-based epidemiology, risk factors and 
screening of intraductal papillary mucinous neoplasm patients. World journal of gastrointestinal 
surgery. 2010; 2(10): 314-8. 
101. Lee CJ, Scheiman J, Anderson MA, Hines OJ, Reber HA, Farrell J, et al. Risk of malignancy in 
resected cystic tumors of the pancreas < or =3 cm in size: is it safe to observe asymptomatic patients? 
A multi-institutional report. Journal of gastrointestinal surgery : official journal of the Society for 
Surgery of the Alimentary Tract. 2008; 12(2): 234-42. 
102. Yoon WJ, Ryu JK, Lee JK, Woo SM, Lee SH, Park JK, et al. Extrapancreatic malignancies in 
patients with intraductal papillary mucinous neoplasm of the pancreas: prevalence, associated 
factors, and comparison with patients with other pancreatic cystic neoplasms. Annals of surgical 
oncology. 2008; 15(11): 3193-8. 
P a g e  | 194 
 
 
103. Woo SM, Ryu JK, Lee SH, Yoon WJ, Kim YT, Yoon YB. Branch duct intraductal papillary 
mucinous neoplasms in a retrospective series of 190 patients. The British journal of surgery. 2009; 
96(4): 405-11. 
104. Tanaka M, Fernandez-Del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International 
consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 
2012; 12(3): 183-97. 
105. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary 
pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nature genetics. 1996; 14(2): 
141-5. 
106. Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, et al. Mutations in the gene encoding 
the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nature genetics. 
2000; 25(2): 213-6. 
107. Ravnik-Glavac M, Glavac D, di Sant' Agnese P, Chernick M, Dean M. Cystic fibrosis gene 
mutations detected in hereditary pancreatitis. Pflugers Archiv : European journal of physiology. 1996; 
431(6 Suppl 2): R191-2. 
108. Grocock CJ, Rebours V, Delhaye MN, Andren-Sandberg A, Weiss FU, Mountford R, et al. The 
variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families. 
Gut. 2010; 59(3): 357-63. 
109. Lynch HT, Fitzsimmons ML, Smyrk TC, Lanspa SJ, Watson P, McClellan J, et al. Familial 
pancreatic cancer: clinicopathologic study of 18 nuclear families. The American journal of 
gastroenterology. 1990; 85(1): 54-60. 
110. MacDermott RP, Kramer P. Adenocarcinoma of the pancreas in four siblings. 
Gastroenterology. 1973; 65(1): 137-9. 
111. Reimer RR, Fraumeni JF, Jr., Ozols RF, Bender R. Pancreatic cancer in father and son. Lancet. 
1977; 1(8017): 911. 
112. Ehrenthal D, Haeger L, Griffin T, Compton C. Familial pancreatic adenocarcinoma in three 
generations. A case report and a review of the literature. Cancer. 1987; 59(9): 1661-4. 
113. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: improvements in our understanding of 
genetics and screening. The international journal of biochemistry & cell biology. 2004; 36(8): 1386-92. 
114. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, et al. Frequent detection of 
pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012; 142(4): 796-804; 
quiz e14-5. 
115. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer 
of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased 
risk for familial pancreatic cancer. Gut. 2013; 62(3): 339-47. 
116. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, et al. Five years of prospective 
screening of high-risk individuals from families with familial pancreatic cancer. Gut. 2009; 58(10): 
1410-8. 
117. Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, et al. The yield of first-time 
endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. 
The American journal of gastroenterology. 2009; 104(9): 2175-81. 
118. Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, et al. Clinical and genetic 
characteristics of hereditary pancreatitis in Europe. Clinical gastroenterology and hepatology : the 
official clinical practice journal of the American Gastroenterological Association. 2004; 2(3): 252-61. 
119. Whitcomb DC. Hereditary pancreatitis: a model for understanding the genetic basis of acute 
and chronic pancreatitis. Pancreatology. 2001; 1(6): 565-70. 
120. Vitone LJ, Greenhalf W, Howes NR, Neoptolemos JP. Hereditary pancreatitis and secondary 
screening for early pancreatic cancer. Rocz Akad Med Bialymst. 2005; 50: 73-84. 
121. de las Heras-Castano G, Castro-Senosiain B, Fontalba A, Lopez-Hoyos M, Sanchez-Juan P. 
Hereditary pancreatitis: clinical features and inheritance characteristics of the R122C mutation in the 
P a g e  | 195 
 
 
cationic trypsinogen gene (PRSS1) in six Spanish families. JOP : Journal of the pancreas. 2009; 10(3): 
249-55. 
122. Sossenheimer MJ, Aston CE, Preston RA, Gates LK, Jr., Ulrich CD, Martin SP, et al. Clinical 
characteristics of hereditary pancreatitis in a large family, based on high-risk haplotype. The Midwest 
Multicenter Pancreatic Study Group (MMPSG). The American journal of gastroenterology. 1997; 92(7): 
1113-6. 
123. Rebours V, Boutron-Ruault MC, Schnee M, Ferec C, Le Marechal C, Hentic O, et al. The natural 
history of hereditary pancreatitis: a national series. Gut. 2009; 58(1): 97-103. 
124. Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, et al. Clinical and genetic 
characteristics of hereditary pancreatitis in Europe. Clinical gastroenterology and hepatology : the 
official clinical practice journal of the American Gastroenterological Association. 2004; 2(3): 252-61. 
125. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between 
mutations of the cystic fibrosis gene and idiopathic pancreatitis. The New England journal of medicine. 
1998; 339(10): 653-8. 
126. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, et al. 
Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut. 2007; 56(10): 
1460-9. 
127. Klein AP, Beaty TH, Bailey-Wilson JE, Brune KA, Hruban RH, Petersen GM. Evidence for a major 
gene influencing risk of pancreatic cancer. Genetic epidemiology. 2002; 23(2): 133-49. 
128. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of 
pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003; 124(5): 1292-9. 
129. McFaul CD, Greenhalf W, Earl J, Howes N, Neoptolemos JP, Kress R, et al. Anticipation in 
familial pancreatic cancer. Gut. 2006; 55(2): 252-8. 
130. Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthai E, et al. German national case 
collection for familial pancreatic cancer (FaPaCa): ten years experience. Familial cancer. 2011; 10(2): 
323-30. 
131. Eberle MA, Pfutzer R, Pogue-Geile KL, Bronner MP, Crispin D, Kimmey MB, et al. A new 
susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. 
American journal of human genetics. 2002; 70(4): 1044-8. 
132. Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Dowen S, et al. Palladin 
mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS medicine. 
2006; 3(12): e516. 
133. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, et al. Prospective 
risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer research. 2004; 64(7): 2634-8. 
134. Bartsch DK, Gress TM, Langer P. Familial pancreatic cancer-current knowledge. Nature reviews 
Gastroenterology & hepatology. 2012; 9(8): 445-53. 
135. Lynch HT, Brand RE, Deters CA, Fusaro RM. Update on familial pancreatic cancer. Current 
gastroenterology reports. 2001; 3(2): 121-8. 
136. Hruban RH, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Falatko F, et al. Familial 
pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology 
/ ESMO. 1999; 10 Suppl 4: 69-73. 
137. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during 
the genetic evolution of pancreatic cancer. Nature. 2010; 467(7319): 1114-7. 
138. Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nature reviews 
Cancer. 2013; 13(1): 66-74. 
139. Yan L, McFaul C, Howes N, Leslie J, Lancaster G, Wong T, et al. Molecular analysis to detect 
pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology. 2005; 128(7): 2124-30. 
140. Greenhalf W, Grocock C, Harcus M, Neoptolemos J. Screening of high-risk families for 
pancreatic cancer. Pancreatology. 2009; 9(3): 215-22. 
141. Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new 
clinical approaches. Cell. 2012; 148(1-2): 21-3. 
P a g e  | 196 
 
 
142. Hunt GC, Faigel DO. Assessment of EUS for diagnosing, staging, and determining resectability 
of pancreatic cancer: a review. Gastrointestinal endoscopy. 2002; 55(2): 232-7. 
143. Bronstein YL, Loyer EM, Kaur H, Choi H, David C, DuBrow RA, et al. Detection of small 
pancreatic tumors with multiphasic helical CT. AJR American journal of roentgenology. 2004; 182(3): 
619-23. 
144. Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other 
cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a 
prospective cohort study. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 2012; 30(9): 958-64. 
145. Lindor NM, Petersen GM, Spurdle AB, Thompson B, Goldgar DE, Thibodeau SN. Pancreatic 
cancer and a novel MSH2 germline alteration. Pancreas. 2011; 40(7): 1138-40. 
146. Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, et al. PALB2 
mutations in familial breast and pancreatic cancer. Familial cancer. 2011; 10(2): 225-31. 
147. Harinck F, Canto MI, Schulick R, Goggins M, Poley JW, Fockens P, et al. Surveillance in 
individuals at high risk of pancreatic cancer: too early to tell? Gut. 2010; 59(7): 1005; author reply 6-
7. 
148. Nair RM, Barthel JS, Centeno BA, Choi J, Klapman JB, Malafa MP. Interdisciplinary 
management of an intraductal papillary mucinous neoplasm of the pancreas. Cancer control : journal 
of the Moffitt Cancer Center. 2008; 15(4): 322-33. 
149. Ahmad NA, Lewis JD, Siegelman ES, Rosato EF, Ginsberg GG, Kochman ML. Role of endoscopic 
ultrasound and magnetic resonance imaging in the preoperative staging of pancreatic 
adenocarcinoma. The American journal of gastroenterology. 2000; 95(8): 1926-31. 
150. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, et al. Screening for early 
pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clinical gastroenterology 
and hepatology : the official clinical practice journal of the American Gastroenterological Association. 
2006; 4(6): 766-81; quiz 665. 
151. Kim JH, Hong SS, Kim YJ, Kim JK, Eun HW. Intraductal papillary mucinous neoplasm of the 
pancreas: differentiate from chronic pancreatits by MR imaging. European journal of radiology. 2012; 
81(4): 671-6. 
152. Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of 
serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and 
cholangiocarcinoma. Digestive diseases and sciences. 2011; 56(8): 2491-6. 
153. Grocock CJ, Vitone LJ, Harcus MJ, Neoptolemos JP, Raraty MG, Greenhalf W. Familial 
pancreatic cancer: a review and latest advances. Advances in medical sciences. 2007; 52: 37-49. 
154. Lane DP. Cell immortalization and transformation by the p53 gene. Nature. 1984; 312(5995): 
596-7. 
155. Vousden KH, Lane DP. p53 in health and disease. Nature reviews Molecular cell biology. 2007; 
8(4): 275-83. 
156. Eshuis WJ, van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, Kuipers EJ, et al. Therapeutic 
delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary 
drainage. Annals of surgery. 2010; 252(5): 840-9. 
157. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential 
mediator of p53 tumor suppression. Cell. 1993; 75(4): 817-25. 
158. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site 
for human p53 protein complexes. Molecular and cellular biology. 1992; 12(6): 2866-71. 
159. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B, et al. Further 
characterisation of the p53 responsive element--identification of new candidate genes for trans-
activation by p53. Oncogene. 1997; 14(1): 85-94. 
160. Bourdon JC, Renzing J, Robertson PL, Fernandes KN, Lane DP. Scotin, a novel p53-inducible 
proapoptotic protein located in the ER and the nuclear membrane. The Journal of cell biology. 2002; 
158(2): 235-46. 
P a g e  | 197 
 
 
161. Okorokov AL, Sherman MB, Plisson C, Grinkevich V, Sigmundsson K, Selivanova G, et al. The 
structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. The EMBO 
journal. 2006; 25(21): 5191-200. 
162. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009; 
458(7242): 1127-30. 
163. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochimica et biophysica acta. 2009; 
1787(5): 414-20. 
164. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, 
and clinical use. Cold Spring Harbor perspectives in biology. 2010; 2(1): a001008. 
165. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-frequency developmental 
abnormalities in p53-deficient mice. Current biology : CB. 1995; 5(8): 931-6. 
166. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient 
embryos exhibit exencephaly. Nature genetics. 1995; 10(2): 175-80. 
167. Hu W, Feng Z, Teresky AK, Levine AJ. p53 regulates maternal reproduction through LIF. Nature. 
2007; 450(7170): 721-4. 
168. Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, et al. Central role of p53 in the suntan 
response and pathologic hyperpigmentation. Cell. 2007; 128(5): 853-64. 
169. McGowan KA, Li JZ, Park CY, Beaudry V, Tabor HK, Sabnis AJ, et al. Ribosomal mutations cause 
p53-mediated dark skin and pleiotropic effects. Nature genetics. 2008; 40(8): 963-70. 
170. Matheu A, Maraver A, Serrano M. The Arf/p53 pathway in cancer and aging. Cancer research. 
2008; 68(15): 6031-4. 
171. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, et al. Delayed ageing through 
damage protection by the Arf/p53 pathway. Nature. 2007; 448(7151): 375-9. 
172. Minamino T, Orimo M, Shimizu I, Kunieda T, Yokoyama M, Ito T, et al. A crucial role for adipose 
tissue p53 in the regulation of insulin resistance. Nature medicine. 2009; 15(9): 1082-7. 
173. Liu P, Xu B, Cavalieri TA, Hock CE. Pifithrin-alpha attenuates p53-mediated apoptosis and 
improves cardiac function in response to myocardial ischemia/reperfusion in aged rats. Shock. 2006; 
26(6): 608-14. 
174. Morrison RS, Kinoshita Y, Johnson MD, Guo W, Garden GA. p53-dependent cell death signaling 
in neurons. Neurochemical research. 2003; 28(1): 15-27. 
175. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, et al. p53 mediates cellular dysfunction 
and behavioral abnormalities in Huntington's disease. Neuron. 2005; 47(1): 29-41. 
176. Bretaud S, Allen C, Ingham PW, Bandmann O. p53-dependent neuronal cell death in a DJ-1-
deficient zebrafish model of Parkinson's disease. Journal of neurochemistry. 2007; 100(6): 1626-35. 
177. Culmsee C, Mattson MP. p53 in neuronal apoptosis. Biochemical and biophysical research 
communications. 2005; 331(3): 761-77. 
178. Duan W, Ding H, Subler MA, Zhu WG, Zhang H, Stoner GD, et al. Lung-specific expression of 
human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic 
mice. Oncogene. 2002; 21(51): 7831-8. 
179. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harbor perspectives in 
biology. 2010; 2(2): a001107. 
180. Bourdon JC, Laurenzi VD, Melino G, Lane D. p53: 25 years of research and more questions to 
answer. Cell death and differentiation. 2003; 10(4): 397-9. 
181. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 
1991; 253(5015): 49-53. 
182. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408(6810): 307-10. 
183. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell growth 
& differentiation : the molecular biology journal of the American Association for Cancer Research. 
2001; 12(7): 337-49. 
184. Smith ML, Fornace AJ, Jr. Genomic instability and the role of p53 mutations in cancer cells. 
Current opinion in oncology. 1995; 7(1): 69-75. 
P a g e  | 198 
 
 
185. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical 
oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 
1995; 13(4): 1009-22. 
186. Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, et al. miR-34a, miR-29c and 
miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009; 23(6): 1159-
63. 
187. Dolezalova D, Mraz M, Barta T, Plevova K, Vinarsky V, Holubcova Z, et al. MicroRNAs regulate 
p21(Waf1/Cip1) protein expression and the DNA damage response in human embryonic stem cells. 
Stem Cells. 2012; 30(7): 1362-72. 
188. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is 
a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993; 75(4): 805-16. 
189. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of 
cyclin kinases. Nature. 1993; 366(6456): 701-4. 
190. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992; 358(6381): 15-6. 
191. Ortiz-Hidalgo C, De La Vega G, Aguirre-Garcia J. The histopathology and biologic prognostic 
factors of Barrett's esophagus: a review. Journal of clinical gastroenterology. 1998; 26(4): 324-33. 
192. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. The New 
England journal of medicine. 1993; 329(18): 1318-27. 
193. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nature reviews Cancer. 2002; 2(8): 
594-604. 
194. Vousden KH. Activation of the p53 tumor suppressor protein. Biochimica et biophysica acta. 
2002; 1602(1): 47-59. 
195. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3): 323-31. 
196. Ambs S, Hussain SP, Marrogi AJ, Harris CC. Cancer-prone oxyradical overload disease. IARC 
scientific publications. 1999; (150): 295-302. 
197. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated 
selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996; 379(6560): 88-
91. 
198. Brady CA, Attardi LD. p53 at a glance. Journal of cell science. 2010; 123(Pt 15): 2527-32. 
199. Tasdemir E, Chiara Maiuri M, Morselli E, Criollo A, D'Amelio M, Djavaheri-Mergny M, et al. A 
dual role of p53 in the control of autophagy. Autophagy. 2008; 4(6): 810-4. 
200. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, et al. Regulation 
of autophagy by cytoplasmic p53. Nature cell biology. 2008; 10(6): 676-87. 
201. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004; 432(7015): 316-23. 
202. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation 
of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005; 
434(7035): 907-13. 
203. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a 
candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 434(7035): 864-70. 
204. Kenzelmann Broz D, Attardi LD. In vivo analysis of p53 tumor suppressor function using 
genetically engineered mouse models. Carcinogenesis. 2010; 31(8): 1311-8. 
205. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. 
Nature reviews Cancer. 2001; 1(3): 233-40. 
206. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes & development. 1998; 12(19): 
2984-91. 
207. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel JS, et al. Mice 
deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 
356(6366): 215-21. 
208. Vousden KH, Ryan KM. p53 and metabolism. Nature reviews Cancer. 2009; 9(10): 691-700. 
P a g e  | 199 
 
 
209. Weissmueller S, Manchado E, Saborowski M, Morris JPt, Wagenblast E, Davis CA, et al. Mutant 
p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell. 
2014; 157(2): 382-94. 
210. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor 
gene: clues to cancer etiology and molecular pathogenesis. Cancer research. 1994; 54(18): 4855-78. 
211. Kim TG, Chen J, Sadoshima J, Lee Y. Jumonji represses atrial natriuretic factor gene expression 
by inhibiting transcriptional activities of cardiac transcription factors. Molecular and cellular biology. 
2004; 24(23): 10151-60. 
212. Kim E, Deppert W. Transcriptional activities of mutant p53: when mutations are more than a 
loss. Journal of cellular biochemistry. 2004; 93(5): 878-86. 
213. Pan WH, Chen JW, Fann C, Jou YS, Wu SY. Linkage analysis with candidate genes: the Taiwan 
young-onset hypertension genetic study. Human genetics. 2000; 107(3): 210-5. 
214. Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-
responsive genes cannot induce apoptosis. Molecular and cellular biology. 1996; 16(9): 4961-71. 
215. Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 
mutants with impaired apoptotic function. Molecular and cellular biology. 1996; 16(9): 4952-60. 
216. Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, et al. Gain-of-
function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. 
Oncogene. 2014; 33(12): 1601-8. 
217. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nature 
reviews Cancer. 2003; 3(2): 117-29. 
218. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell 
death and differentiation. 2003; 10(4): 404-8. 
219. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals 
over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009; 458(7235): 223-
7. 
220. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional 
activation of p53-target genes. Nature. 1994; 370(6486): 220-3. 
221. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53 and cancer-associated 
mutants. Advances in cancer research. 2007; 97: 1-23. 
222. Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer 
mutants. Oncogene. 2007; 26(15): 2226-42. 
223. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochemical and biophysical 
research communications. 2005; 331(3): 834-42. 
224. Slee EA, O'Connor DJ, Lu X. To die or not to die: how does p53 decide? Oncogene. 2004; 23(16): 
2809-18. 
225. Li HH, Li AG, Sheppard HM, Liu X. Phosphorylation on Thr-55 by TAF1 mediates degradation 
of p53: a role for TAF1 in cell G1 progression. Molecular cell. 2004; 13(6): 867-78. 
226. Hidalgo M. Pancreatic cancer. The New England journal of medicine. 2010; 362(17): 1605-17. 
227. Boschman CR, Stryker S, Reddy JK, Rao MS. Expression of p53 protein in precursor lesions and 
adenocarcinoma of human pancreas. The American journal of pathology. 1994; 145(6): 1291-5. 
228. Rhim AD, Stanger BZ. Molecular biology of pancreatic ductal adenocarcinoma progression: 
aberrant activation of developmental pathways. Progress in molecular biology and translational 
science. 2010; 97: 41-78. 
229. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, et al. 
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic 
intraepithelial neoplasia tissue microarray. Modern pathology : an official journal of the United States 
and Canadian Academy of Pathology, Inc. 2003; 16(9): 902-12. 
230. Morton JP, Jamieson NB, Karim SA, Athineos D, Ridgway RA, Nixon C, et al. LKB1 
haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-
dependent growth arrest. Gastroenterology. 2010; 139(2): 586-97, 97 e1-6. 
P a g e  | 200 
 
 
231. Weissmuller T, Glover LE, Fennimore B, Curtis VF, MacManus CF, Ehrentraut SF, et al. HIF-
dependent regulation of AKAP12 (gravin) in the control of human vascular endothelial function. The 
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 
2014; 28(1): 256-64. 
232. Sato Y, Mukai M, Sasaki M, Kitao A, Yoneda N, Kobayashi D, et al. Intraductal papillary-
mucinous neoplasm of the pancreas associated with polycystic liver and kidney disease. Pathology 
international. 2009; 59(3): 201-4. 
233. Ihrler S, Weiler C, Hirschmann A, Sendelhofert A, Lang S, Guntinas-Lichius O, et al. Intraductal 
carcinoma is the precursor of carcinoma ex pleomorphic adenoma and is often associated with 
dysfunctional p53. Histopathology. 2007; 51(3): 362-71. 
234. Adsay NV. Intraductal papillary mucinous neoplasms of the pancreas: pathology and 
molecular genetics. Journal of gastrointestinal surgery : official journal of the Society for Surgery of 
the Alimentary Tract. 2002; 6(5): 656-9. 
235. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, et al. MicroRNA array analysis finds 
elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from 
healthy and disease controls. Clinical cancer research : an official journal of the American Association 
for Cancer Research. 2013; 19(13): 3600-10. 
236. Kanda M, Knight S, Topazian MD, Syngal S, Farrell J, Lee JH, et al. Mutant GNAS detected in 
duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of 
pancreatic cysts. Gut. 2012. 
237. Fritz S, Klauss M, Bergmann F, Hackert T, Hartwig W, Strobel O, et al. Small (Sendai Negative) 
Branch-Duct IPMNs: Not Harmless. Annals of surgery. 2012; 256(2): 313-20. 
238. Bassi C, Stocken DD, Olah A, Friess H, Buckels J, Hickey H, et al. Influence of surgical resection 
and post-operative complications on survival following adjuvant treatment for pancreatic cancer in 
the ESPAC-1 randomized controlled trial. Digestive surgery. 2005; 22(5): 353-63. 
239. Carter R, Stocken DD, Ghaneh P, Bramhall SR, Olah A, Kelemen D, et al. Longitudinal quality of 
life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset 
analysis of the ESPAC-1 data. International journal of cancer Journal international du cancer. 2009; 
124(12): 2960-5. 
240. Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, et al. Pancreatic cancer 
hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Journal of the 
National Cancer Institute. 2014; 106(1): djt347. 
241. Neoptolemos JP, Kerr DJ, Beger H, Link K, Pederzoli P, Bassi C, et al. ESPAC-1 trial progress 
report: the European randomized adjuvant study comparing radiochemotherapy, 6 months 
chemotherapy and combination therapy versus observation in pancreatic cancer. Digestion. 1997; 
58(6): 570-7. 
242. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of 
adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in 
patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized 
trial. JAMA : the journal of the American Medical Association. 2012; 308(2): 147-56. 
243. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant 
chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: 
a randomized controlled trial. JAMA : the journal of the American Medical Association. 2010; 304(10): 
1073-81. 
244. Manchester KL. Value of A260/A280 ratios for measurement of purity of nucleic acids. 
BioTechniques. 1995; 19(2): 208-10. 
245. Huberman JA. Importance of measuring nucleic acid absorbance at 240 nm as well as at 260 
and 280 nm. BioTechniques. 1995; 18(4): 636. 
246. Glasel JA. Validity of nucleic acid purities monitored by 260nm/280nm absorbance ratios. 
BioTechniques. 1995; 18(1): 62-3. 
P a g e  | 201 
 
 
247. Manchester KL. Use of UV methods for measurement of protein and nucleic acid 
concentrations. BioTechniques. 1996; 20(6): 968-70. 
248. DeAngelis MM, Wang DG, Hawkins TL. Solid-phase reversible immobilization for the isolation 
of PCR products. Nucleic acids research. 1995; 23(22): 4742-3. 
249. Nicholson JA, Greenhalf W, Jackson R, Cox TF, Butler JV, Hanna T, et al. Incidence of Post-ERCP 
Pancreatitis From Direct Pancreatic Juice Collection in Hereditary Pancreatitis and Familial Pancreatic 
Cancer Before and After the Introduction of Prophylactic Pancreatic Stents and Rectal Diclofenac. 
Pancreas. 2015; 44(2): 260-5. 
250. Whitcomb DC, Larusch J, Krasinskas AM, Klei L, Smith JP, Brand RE, et al. Common genetic 
variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. 
Nature genetics. 2012. 
251. Bradley EL, 3rd. A clinically based classification system for acute pancreatitis. Summary of the 
International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch 
Surg. 1993; 128(5): 586-90. 
252. McFaul CD, Greenhalf W, Earl J, Howes N, Neoptolemos JP, Kress R, et al. Anticipation in 
familial pancreatic cancer. Gut. 2006; 55(2): 252-8. 
253. Threadgold J, Greenhalf W, Ellis I, Howes N, Lerch MM, Simon P, et al. The N34S mutation of 
SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause 
the disease. Gut. 2002; 50(5): 675-81. 
254. Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD. A meta-analysis of rectal 
NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008; 57(9): 1262-7. 
255. Singh P, Das A, Isenberg G, Wong RC, Sivak MV, Jr., Agrawal D, et al. Does prophylactic 
pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of 
controlled trials. Gastrointestinal endoscopy. 2004; 60(4): 544-50. 
256. Raty S, Sand J, Pulkkinen M, Matikainen M, Nordback I. Post-ERCP pancreatitis: reduction by 
routine antibiotics. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the 
Alimentary Tract. 2001; 5(4): 339-45; discussion 45. 
257. Singh P, Gurudu SR, Davidoff S, Sivak MV, Jr., Indaram A, Kasmin FE, et al. Sphincter of Oddi 
manometry does not predispose to post-ERCP acute pancreatitis. Gastrointestinal endoscopy. 2004; 
59(4): 499-505. 
258. Choudari CP, Nickl NJ, Fogel E, Lehman GA, Sherman S. Hereditary pancreatitis: clinical 
presentation, ERCP findings, and outcome of endoscopic therapy. Gastrointestinal endoscopy. 2002; 
56(1): 66-71. 
259. Dever JB, Irani S, Brandabur J, Traverso LW, Kozarek R. Outcomes of interventional ERCP in 
hereditary pancreatitis. Journal of clinical gastroenterology. 2010; 44(1): 46-51. 
260. Freeman ML. Role of pancreatic stents in prevention of post-ERCP pancreatitis. JOP : Journal 
of the pancreas. 2004; 5(5): 322-7. 
261. Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, et al. A randomized trial 
of rectal indomethacin to prevent post-ERCP pancreatitis. The New England journal of medicine. 2012; 
366(15): 1414-22. 
262. Ito K, Fujita N, Kanno A, Matsubayashi H, Okaniwa S, Nakahara K, et al. Risk factors for post-
ERCP pancreatitis in high risk patients who have undergone prophylactic pancreatic duct stenting: a 
multicenter retrospective study. Intern Med. 2011; 50(24): 2927-32. 
263. Nicholson JA, Greenhalf W, Jackson R, Cox TF, Butler JV, Hanna T, et al. Incidence of Post-ERCP 
Pancreatitis From Direct Pancreatic Juice Collection in Hereditary Pancreatitis and Familial Pancreatic 
Cancer Before and After the Introduction of Prophylactic Pancreatic Stents and Rectal Diclofenac. 
Pancreas. 9000; Publish Ahead of Print: 10.1097/MPA.0000000000000246. 
264. Zhou W, Li Y, Zhang Q, Li X, Meng W, Zhang L, et al. Risk factors for postendoscopic retrograde 
cholangiopancreatography pancreatitis: a retrospective analysis of 7,168 cases. Pancreatology. 2011; 
11(4): 399-405. 
P a g e  | 202 
 
 
265. Jowell PS, Branch MS, Fein SH, Purich ED, Kilaru R, Robuck G, et al. Intravenous synthetic 
secretin reduces the incidence of pancreatitis induced by endoscopic retrograde 
cholangiopancreatography. Pancreas. 2011; 40(4): 533-9. 
266. Ohhashi T, Azuma T, Roddie IC. Effect of potassium on adrenergic nerve endings in bovine 
mesenteric lymphatics. Journal of the autonomic nervous system. 1983; 8(3): 205-11. 
267. Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, et al. Pancreatic stents for 
prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointestinal 
endoscopy. 2011; 73(2): 275-82. 
268. Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, et al. A randomized trial 
of rectal indomethacin to prevent post-ERCP pancreatitis. The New England journal of medicine. 2012; 
366(15): 1414-22. 
269. Sethi S, Sethi N, Wadhwa V, Garud S, Brown A. A meta-analysis on the role of rectal diclofenac 
and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography 
pancreatitis. Pancreas. 2014; 43(2): 190-7. 
270. Furuya N, Kawa S, Akamatsu T, Furihata K. Long-term follow-up of patients with chronic 
pancreatitis and KRAS gene mutation detected in pancreatic juice. Gastroenterology. 1997; 113(2): 
593-8. 
271. Bartsch DK, Gress TM, Langer P. Familial pancreatic cancer--current knowledge. Nature 
reviews Gastroenterology & hepatology. 2012; 9(8): 445-53. 
272. Kamisawa T, Tu Y, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Malignancies associated with 
intraductal papillary mucinous neoplasm of the pancreas. World journal of gastroenterology : WJG. 
2005; 11(36): 5688-90. 
273. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG. Frequency of 
extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications 
for management. Annals of surgery. 2010; 251(1): 64-9. 
274. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, et al. [Extrapancreatic tumors in intraductal 
papillary mucinous neoplasm of the pancreas]. The Korean journal of gastroenterology = Taehan 
Sohwagi Hakhoe chi. 2009; 54(3): 162-6. 
275. Baumgaertner I, Corcos O, Couvelard A, Sauvanet A, Rebours V, Vullierme MP, et al. 
Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary 
mucinous neoplasms of the pancreas: a case-control study. The American journal of gastroenterology. 
2008; 103(11): 2878-82. 
276. Choi MG, Kim SW, Han SS, Jang JY, Park YH. High incidence of extrapancreatic neoplasms in 
patients with intraductal papillary mucinous neoplasms. Arch Surg. 2006; 141(1): 51-6; discussion 6. 
277. Kent TS, Jr CM, Callery MP. Intraductal papillary mucinous neoplasm and the pancreatic 
incidentaloma. World journal of gastrointestinal surgery. 2010; 2(10): 319-23. 
278. Sawhney MS, Al-Bashir S, Cury MS, Brown A, Chuttani R, Pleskow DK, et al. International 
consensus guidelines for surgical resection of mucinous neoplasms cannot be applied to all cystic 
lesions of the pancreas. Clinical gastroenterology and hepatology : the official clinical practice journal 
of the American Gastroenterological Association. 2009; 7(12): 1373-6. 
279. Tanno S, Nakano Y, Nishikawa T, Nakamura K, Sasajima J, Minoguchi M, et al. Natural history 
of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: 
long-term follow-up results. Gut. 2008; 57(3): 339-43. 
280. Buscaglia JM, Shin EJ, Giday SA, Kapoor S, Dunbar KB, Eloubeidi MA, et al. Awareness of 
guidelines and trends in the management of suspected pancreatic cystic neoplasms: survey results 
among general gastroenterologists and EUS specialists. Gastrointestinal endoscopy. 2009; 69(4): 813-
20, quiz 20 e1-17. 
281. Del Chiaro M, Verbeke C, Salvia R, Kloppel G, Werner J, McKay C, et al. European experts 
consensus statement on cystic tumours of the pancreas. Digestive and liver disease : official journal of 
the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2013; 
45(9): 703-11. 
P a g e  | 203 
 
 
282. Farnell MB. Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the 
pancreas. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the 
Alimentary Tract. 2008; 12(3): 414-6. 
283. Goh BK. Sendai Consensus Guidelines for Branch-duct IPMN: Guidelines Are Just Guidelines. 
Annals of surgery. 2015; 262(2): e65. 
284. Nguyen AH, Toste PA, Farrell JJ, Clerkin BM, Williams J, Muthusamy VR, et al. Current 
recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may 
overlook some patients with cancer. Journal of gastrointestinal surgery : official journal of the Society 
for Surgery of the Alimentary Tract. 2015; 19(2): 258-65. 
285. Vege SS, Ziring B, Jain R, Moayyedi P. American gastroenterological association institute 
guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. 
Gastroenterology. 2015; 148(4): 819-22; quize12-3. 
286. Kloppel G. Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas. 
Hepato-gastroenterology. 1998; 45(24): 1981-5. 
287. Traverso LW, Peralta EA, Ryan JA, Jr., Kozarek RA. Intraductal neoplasms of the pancreas. 
American journal of surgery. 1998; 175(5): 426-32. 
288. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, et al. Intraductal papillary-
mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell 
differentiation and KRAS, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Archiv : an 
international journal of pathology. 1994; 425(4): 357-67. 
289. Siech M, Tripp K, Schmidt-Rohlfing B, Mattfeldt T, Gorich J, Beger HG. Intraductal papillary 
mucinous tumor of the pancreas. American journal of surgery. 1999; 177(2): 117-20. 
290. Poultsides GA, Reddy S, Cameron JL, Hruban RH, Pawlik TM, Ahuja N, et al. Histopathologic 
basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated 
invasive adenocarcinoma of the pancreas. Annals of surgery. 2010; 251(3): 470-6. 
291. Salvia R, Fernandez-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani W, et al. Main-
duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and 
long-term survival following resection. Annals of surgery. 2004; 239(5): 678-85; discussion 85-7. 
292. Xiao SY. Intraductal papillary mucinous neoplasm of the pancreas: an update. Scientifica. 
2012; 2012: 893632. 
293. Pedrazzoli S, Sperti C, Pasquali C, Bissoli S, Chierichetti F. Comparison of International 
Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous 
neoplasms of the pancreas. Annals of surgery. 2011; 254(6): 971-6. 
294. Takanami K, Hiraide T, Tsuda M, Nakamura Y, Kaneta T, Takase K, et al. Additional value of 
FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal 
papillary mucinous neoplasms of the pancreas with mural nodules. Annals of nuclear medicine. 2011; 
25(7): 501-10. 
295. Takanami K, Yamada T, Tsuda M, Takase K, Ishida K, Nakamura Y, et al. Intraductal papillary 
mucininous neoplasm of the bile ducts: multimodality assessment with pathologic correlation. 
Abdominal imaging. 2011; 36(4): 447-56. 
296. Rastegar N, Matteoni-Athayde LG, Eng J, Takahashi N, Tamm EP, Mortele KJ, et al. Incremental 
value of secretin-enhanced magnetic resonance cholangiopancreatography in detecting ductal 
communication in a population with high prevalence of small pancreatic cysts. European journal of 
radiology. 2015; 84(4): 575-80. 
297. Fujino Y, Matsumoto I, Ueda T, Toyama H, Kuroda Y. Proposed new score predicting 
malignancy of intraductal papillary mucinous neoplasms of the pancreas. American journal of surgery. 
2007; 194(3): 304-7. 
298. Fritz S, Hackert T, Hinz U, Hartwig W, Buchler MW, Werner J. Role of serum carbohydrate 
antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal 
papillary mucinous neoplasm of the pancreas. The British journal of surgery. 2011; 98(1): 104-10. 
P a g e  | 204 
 
 
299. Kawai M, Uchiyama K, Tani M, Onishi H, Kinoshita H, Ueno M, et al. Clinicopathological 
features of malignant intraductal papillary mucinous tumors of the pancreas: the differential diagnosis 
from benign entities. Arch Surg. 2004; 139(2): 188-92. 
300. Kanno A, Satoh K, Hirota M, Hamada S, Umino J, Itoh H, et al. Prediction of invasive carcinoma 
in branch type intraductal papillary mucinous neoplasms of the pancreas. Journal of gastroenterology. 
2010; 45(9): 952-9. 
301. Doyle CJ, Yancey K, Pitt HA, Wang M, Bemis K, Yip-Schneider MT, et al. The proteome of 
normal pancreatic juice. Pancreas. 2012; 41(2): 186-94. 
302. Emerson RE, Randolph ML, Cramer HM. Endoscopic ultrasound-guided fine-needle aspiration 
cytology diagnosis of intraductal papillary mucinous neoplasm of the pancreas is highly predictive of 
pancreatic neoplasia. Diagnostic cytopathology. 2006; 34(7): 457-62. 
303. Jani N, Dewitt J, Eloubeidi M, Varadarajulu S, Appalaneni V, Hoffman B, et al. Endoscopic 
ultrasound-guided fine-needle aspiration for diagnosis of solid pseudopapillary tumors of the 
pancreas: a multicenter experience. Endoscopy. 2008; 40(3): 200-3. 
304. Burford H, Baloch Z, Liu X, Jhala D, Siegal GP, Jhala N. E-cadherin/beta-catenin and CD10: a 
limited immunohistochemical panel to distinguish pancreatic endocrine neoplasm from solid 
pseudopapillary neoplasm of the pancreas on endoscopic ultrasound-guided fine-needle aspirates of 
the pancreas. American journal of clinical pathology. 2009; 132(6): 831-9. 
305. Layfield LJ, Cramer H. Fine-needle aspiration cytology of intraductal papillary-mucinous 
tumors: a retrospective analysis. Diagnostic cytopathology. 2005; 32(1): 16-20. 
306. Rockacy M, Khalid A. Update on pancreatic cyst fluid analysis. Annals of gastroenterology : 
quarterly publication of the Hellenic Society of Gastroenterology. 2013; 26(2): 122-7. 
307. Rockacy MJ, Zahid M, McGrath KM, Fasanella KE, Khalid A. Association between KRAS 
mutation, detected in pancreatic cyst fluid, and long-term outcomes of patients. Clinical 
gastroenterology and hepatology : the official clinical practice journal of the American 
Gastroenterological Association. 2013; 11(4): 425-9. 
308. Kamoshida S, Tsutsumi Y. Expression of MUC-1 glycoprotein in plasma cells, follicular dendritic 
cells, myofibroblasts and perineurial cells: immunohistochemical analysis using three monoclonal 
antibodies. Pathology international. 1998; 48(10): 776-85. 
309. Pantano F, Baldi A, Santini D, Vincenzi B, Borzomati D, Vecchio FM, et al. MUC2 but not MUC5 
expression correlates with prognosis in radically resected pancreatic cancer patients. Cancer biology 
& therapy. 2009; 8(11): 996-9. 
310. Rassidakis GZ, Goy A, Medeiros LJ, Jiang Y, Thomaides A, Remache Y, et al. Prognostic 
Significance of MUC-1 Expression in Systemic Anaplastic Large Cell Lymphoma. Clinical Cancer 
Research. 2003; 9(6): 2213-20. 
311. Leroy X, Zerimech F, Zini L, Copin MC, Buisine MP, Gosselin B, et al. MUC1 expression is 
correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. American 
journal of clinical pathology. 2002; 118(1): 47-51. 
312. Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, et al. Evaluation 
of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant 
chemotherapy for breast cancer. Annals of oncology : official journal of the European Society for 
Medical Oncology / ESMO. 2013; 24(9): 2316-24. 
313. Engelstaedter V, Heublein S, Schumacher AL, Lenhard M, Engelstaedter H, Andergassen U, et 
al. Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients. BMC cancer. 
2012; 12: 600. 
314. Park SY, Roh SJ, Kim YN, Kim SZ, Park HS, Jang KY, et al. Expression of MUC1, MUC2, MUC5AC 
and MUC6 in cholangiocarcinoma: prognostic impact. Oncology reports. 2009; 22(3): 649-57. 
315. You JF, Hsieh LL, Changchien CR, Chen JS, Chen JR, Chiang JM, et al. Inverse effects of mucin 
on survival of matched hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer 
patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 
2006; 12(14 Pt 1): 4244-50. 
P a g e  | 205 
 
 
316. Li XH, Zheng HC, Wang ZG, Takahashi H, Yang XH, Guan YF, et al. The clinicopathological and 
prognostic significance of MUC-1 expression in Japanese gastric carcinomas: an immunohistochemical 
study of tissue microarrays. Anticancer research. 2008; 28(2A): 1061-7. 
317. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T, et al. Expression of 
MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. 
Clinical cancer research : an official journal of the American Association for Cancer Research. 1998; 
4(11): 2605-14. 
318. Baldus SE, Monig SP, Hanisch FG, Zirbes TK, Flucke U, Oelert S, et al. Comparative evaluation 
of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal 
adenocarcinoma. Histopathology. 2002; 40(5): 440-9. 
319. Manne U, Weiss HL, Grizzle WE. Racial differences in the prognostic usefulness of MUC1 and 
MUC2 in colorectal adenocarcinomas. Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2000; 6(10): 4017-25. 
320. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke 
carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002; 21(48): 
7435-51. 
321. LaRue H, Allard P, Simoneau M, Normand C, Pfister C, Moore L, et al. P53 point mutations in 
initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. 
Carcinogenesis. 2000; 21(1): 101-6. 
322. Malakar M, Devi KR, Phukan RK, Kaur T, Deka M, Puia L, et al. p53 codon 72 polymorphism 
interactions with dietary and tobacco related habits and risk of stomach cancer in Mizoram, India. 
Asian Pacific journal of cancer prevention : APJCP. 2014; 15(2): 717-23. 
323. Rezaee N, Khalifian S, Cameron JL, Pawlik TM, Hruban RH, Fishman EK, et al. Smoking is not 
associated with severe dysplasia or invasive carcinoma in resected intraductal papillary mucinous 
neoplasms. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the 
Alimentary Tract. 2015; 19(4): 656-65. 
324. De Re V, Carbone A, De Vita S, Gloghini A, Maestro R, Gasparotto D, et al. p53 protein over-
expression and p53 gene abnormalities in HIV-1-related non-Hodgkin's lymphomas. International 
journal of cancer Journal international du cancer. 1994; 56(5): 662-7. 
325. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, et al. Abnormalities of 
the p53 tumour suppressor gene in human pancreatic cancer. British journal of cancer. 1991; 64(6): 
1076-82. 
326. Du M, Peng H, Singh N, Isaacson PG, Pan L. The accumulation of p53 abnormalities is 
associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood. 1995; 86(12): 
4587-93. 
327. Sturm PD, Baas IO, Clement MJ, Nakeeb A, Johan G, Offerhaus A, et al. Alterations of the p53 
tumor-suppressor gene and KRAS oncogene in perihilar cholangiocarcinomas from a high-incidence 
area. International journal of cancer Journal international du cancer. 1998; 78(6): 695-8. 
328. Makower D, Rozenblit A, Kaufman H, Edelman M, Lane ME, Zwiebel J, et al. Phase II clinical 
trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with 
hepatobiliary tumors with correlative p53 studies. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2003; 9(2): 693-702. 
329. Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, et al. Isolation of temperature-
sensitive p53 mutations from a comprehensive missense mutation library. The Journal of biological 
chemistry. 2004; 279(1): 348-55. 
330. Shaw P, Tardy S, Benito E, Obrador A, Costa J. Occurrence of Ki-ras and p53 mutations in 
primary colorectal tumors. Oncogene. 1991; 6(11): 2121-8. 
331. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, et al. Pancreatic adenocarcinomas 
frequently show p53 gene mutations. The American journal of pathology. 1993; 142(5): 1534-43. 
P a g e  | 206 
 
 
332. Weyrer K, Feichtinger H, Haun M, Weiss G, Ofner D, Weger AR, et al. p53, Ki-ras, and DNA 
ploidy in human pancreatic ductal adenocarcinomas. Laboratory investigation; a journal of technical 
methods and pathology. 1996; 74(1): 279-89. 
333. Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, et al. Pancreatic tumours: 
molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine 
nonductal or endocrine tumorigenesis. British journal of cancer. 2001; 84(2): 253-62. 
334. Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al. Exome sequencing 
of liver fluke-associated cholangiocarcinoma. Nature genetics. 2012; 44(6): 690-3. 
335. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation Is Indispensable for p53 Activation. Cell. 
2008; 133(4): 612-26. doi:10.1016/j.cell.2008.03.025. 
336. Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, et al. p53 mutations 
and expression in ovarian cancers: correlation with overall survival. International journal of 
gynecological pathology : official journal of the International Society of Gynecological Pathologists. 
1999; 18(1): 29-41. 
337. Matozaki T, Sakamoto C, Suzuki T, Matsuda K, Uchida T, Nakano O, et al. p53 gene mutations 
in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer 
cells. Cancer research. 1992; 52(16): 4335-41. 
338. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue 
of Somatic Mutations in Cancer) database and website. British journal of cancer. 2004; 91(2): 355-8. 
339. Mashima T, Oh-hara T, Sato S, Mochizuki M, Sugimoto Y, Yamazaki K, et al. p53-defective 
tumors with a functional apoptosome-mediated pathway: a new therapeutic target. Journal of the 
National Cancer Institute. 2005; 97(10): 765-77. 
340. Tomoda K, Takahashi N, Hibi Y, Asamitsu K, Ishida H, Kondo T, et al. Molecular docking analysis 
of the protein-protein interaction between RelA-associated inhibitor and tumor suppressor protein 
p53 and its inhibitory effect on p53 action. Cancer science. 2008; 99(3): 615-22. 
341. Colomer A, Erill N, Verdu M, Roman R, Vidal A, Cordon-Cardo C, et al. Lack of p53 nuclear 
immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas. 
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society 
for Applied Immunohistochemistry. 2003; 11(2): 130-7. 
342. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 
tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and 
correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer research. 1997; 
57(19): 4285-300. 
343. Cai DW, Mukhopadhyay T, Roth JA. Suppression of lung cancer cell growth by ribozyme-
mediated modification of p53 pre-mRNA. Cancer gene therapy. 1995; 2(3): 199-205. 
344. Shimizu H, Burch LR, Smith AJ, Dornan D, Wallace M, Ball KL, et al. The conformationally 
flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose 
mutation increases ubiquitination of p53 in vivo. The Journal of biological chemistry. 2002; 277(32): 
28446-58. 
345. Chung KY, Mukhopadhyay T, Kim J, Casson A, Ro JY, Goepfert H, et al. Discordant p53 gene 
mutations in primary head and neck cancers and corresponding second primary cancers of the upper 
aerodigestive tract. Cancer research. 1993; 53(7): 1676-83. 
346. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, et al. Mutations in the p53 
gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. 
Oncogene. 1990; 5(10): 1603-10. 
347. Ruggeri B, Zhang SY, Klein-Szanto AJ. Molecular and cytogenetic alterations in human 
pancreatic cancer: the role of tumor suppressor genes. Progress in clinical and biological research. 
1992; 376: 245-60. 
348. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations 
in the p53 and KRAS genes in pancreatic cancer. International journal of cancer Journal international 
du cancer. 1994; 58(2): 185-91. 
P a g e  | 207 
 
 
349. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, et al. KRAS and p53 gene 
mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic 
lesions. Cancer research. 1994; 54(6): 1556-60. 
350. Hoshi T, Imai M, Ogawa K. Frequent KRAS mutations and absence of p53 mutations in mucin-
producing tumors of the pancreas. Journal of surgical oncology. 1994; 55(2): 84-91. 
351. Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S, et al. Association of 
p53 gene mutations with short survival in pancreatic adenocarcinoma. Japanese journal of cancer 
research : Gann. 1995; 86(2): 174-81. 
352. Chen J, Millar WJ. Are recent cohorts healthier than their predecessors? Health reports / 
Statistics Canada, Canadian Centre for Health Information = Rapports sur la sante / Statistique Canada, 
Centre canadien d'information sur la sante. 2000; 11(4): 9-23 (Eng); 9-6 (Fre). 
353. Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T, et al. Molecular 
pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression 
of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer. 1997; 79(4): 700-
16. 
354. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive 
pathways in pancreatic carcinoma. Cancer research. 1997; 57(9): 1731-4. 
355. Iwao T, Hanada K, Tsuchida A, Hirata M, Eguchi N, Kajiyama G. The establishment of a 
preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing 
with special attention to p53 mutations. Cancer. 1998; 82(8): 1487-94. 
356. Sorio C, Bonora A, Orlandini S, Moore PS, Capelli P, Cristofori P, et al. Successful xenografting 
of cryopreserved primary pancreatic cancers. Virchows Archiv : an international journal of pathology. 
2001; 438(2): 154-8. 
357. Kang S, Duan LH, Zhang JH, Guo W, Wang N, Li Y. [Association of p53 gene polymorphism with 
susceptibility to ovarian cancer]. Zhonghua fu chan ke za zhi. 2004; 39(11): 754-8. 
358. Bian Y, Matsubayashi H, Li CP, Abe T, Canto M, Murphy KM, et al. Detecting low-abundance 
p16 and p53 mutations in pancreatic juice using a novel assay: heteroduplex analysis of limiting 
dilution PCRs. Cancer biology & therapy. 2006; 5(10): 1392-9. 
359. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in 
human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321(5897): 1801-6. 
360. Stindt MH, Muller PA, Ludwig RL, Kehrloesser S, Dotsch V, Vousden KH. Functional interplay 
between MDM2, p63/p73 and mutant p53. Oncogene. 2014. 
361. Dong P, Tada M, Hamada J, Nakamura A, Moriuchi T, Sakuragi N. p53 dominant-negative 
mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clinical & 
experimental metastasis. 2007; 24(6): 471-83. 
362. Soto AM, Sonnenschein C. The tissue organization field theory of cancer: a testable 
replacement for the somatic mutation theory. BioEssays : news and reviews in molecular, cellular and 
developmental biology. 2011; 33(5): 332-40. 
363. Kanda M, Knight S, Topazian M, Syngal S, Farrell J, Lee J, et al. Mutant GNAS detected in 
duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of 
pancreatic cysts. Gut. 2012. 
 
 
  
P a g e  | 208 
 
 
Appendix A: Concentration of DNA obtained from each Heidelberg 
sample. 
CYST 0- 
Concentration of DNA (ng/uL) 
CYST 0- 
Concentration of DNA (ng/uL) 
Eluent 1 Eluent 2 Eluent 1 Eluent 2 
1 119 165 37 137.4 113.4 
2 2.1 2.9 38 46.8 33.7 
3 15.6 9 39 68.4 475.6 
4 10.6 7 40 73.1 71.7 
5 28.1 32.5 41 239.8 109.2 
6 15.9 21.3 42 136 240.8 
7 6.8 5.8 43 165.9 53.9 
8 30.6 31.7 44 13.9 44.4 
9 81 51.2 45 22.2 21.4 
10 125.6 76.7 46 8.7 19.8 
11 109.5 43.2 47 14.6 18.4 
12 119.7 73.5 48 15.9 17 
13 38.7 26.7 49 33.2 42.3 
14 6.9 3.2 50 32.2 43.7 
15 36.1 44.6 51 55.9 168.1 
16 11.8 12.4 52 37.5 42.3 
17 34.5 134.6 53 74.5 97 
18 39.3 1008.2 54 36.2 31.4 
19 4.1 4.7 55 3.2 1.4 
20 7.3 11.7 56 16.2 10.6 
21 24.1 14.6 57 69 37.2 
22 745 171.8 58 75.1 153.9 
23 87.3 126.3 59 55.5 69.6 
24 43.4 21.5 60 57 77.3 
25 71.4 37.8 61 12.4 9.3 
26 15.3 10 62 43.3 61 
27 348.5 33.9 63 38.5 30.3 
28 38.5 32.3 64 79.5 144.1 
29 91 68.2 65 59.7 76.6 
30 56.2 32.7 66 158 570 
31 1177.9 406.6 67 68.2 109.1 
32 68 125.9 68 128.6 130.5 
33 71 53.7 69 39.1 29.7 
34 72.4 96.5 70 28.9 35.4 
35 43.2 55.2 71 6.1 7.6 
36 54.1 70.8 72 53.6 45.4 
    73 11.3 13.9 
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Appendix B: KRAS primers used to confirm samples were at 10G. 
Forward control KRAS primer (5’TGACTGAATATAAACTTGTGGTAGTTGGCG3’) and  
Common Reverse KRAS primer (5’CTCATGAAAATGGTCAGAGAAACCTTTATC3’).  
Alanine (5’TATCGTCAAGGCACTCTTGCCTACGCCTG 3’);  
Valine (5’TATCGTCAAGGCACTCTTGCCTACGCCTA 3’);  
12 Aspartate (5’TATCGTCAAGGCACTCTTGCCTACGCCTT 3’);  
Serine (5’CTGAATATAAACTTGTGGTAGTTGGAGCCA 3’); 
 Arginine (5’CTGAATATAAACTTGTGGTAGTTGGAGTTC 3’);  
Cystine (5’CTGAATATAAACTTGTGGTAGTTGGAGCAT 3’).  
Use the appropriate common primer pair:  either Common Forward 
(5’GTACTGGTGGAGTATTTGATAGTGTATTAACC3’) or  
Common Reverse (5’CTCATGAAAATGGTCAGAGAAACCTTTATC3’). 
The PCR programme used for standard KRAS PCR (hot start, melting temp, annealing and binding 
temp etc.) 
Pre-Incubation: 
95oC for 10 minutes 
Amplification cycles (at least 60) consisting of: 
95oC for 10 seconds 
61 oC for 5 seconds 
72 oC for 5 seconds with a single fluorescence measurement at the end  
Melting Curve:  
95 oC for 5 seconds  
65 oC for 1 minute 
Then a slow ramp to 98 oC over a 10 minute period with continuous fluorescence measurement 
Cooling: 
40 oC  for 10 seconds then cooled to 2 oC  which was held. 
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Appendix C: List of individually created barcoded primers used for Ion 
Torrent. 
Oligo name Oligo sequence (5' to 3') Synthesis 
scale 
Exon 5 F1 A-1.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAACAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-1.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAACCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-1.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAGCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-1.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAATCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-1.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACACAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-1.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACCCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-1.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACGCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-1.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACTCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-1.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGACAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-1.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGCCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 P-1.1 CCT CTC TAT GGG CAG TCG GTG ATAAAC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-1.2 CCT CTC TAT GGG CAG TCG GTG ATAACC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-1.3 CCT CTC TAT GGG CAG TCG GTG ATAAGC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-1.4 CCT CTC TAT GGG CAG TCG GTG ATAATC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-1.5 CCT CTC TAT GGG CAG TCG GTG ATACAC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-1.6 CCT CTC TAT GGG CAG TCG GTG ATACCC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-1.7 CCT CTC TAT GGG CAG TCG GTG ATACGC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-1.8 CCT CTC TAT GGG CAG TCG GTG ATACTC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-1.9 CCT CTC TAT GGG CAG TCG GTG ATAGAC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-1.10 CCT CTC TAT GGG CAG TCG GTG ATAGCC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F2 A-1.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAAAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-1.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAACAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-1.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAGAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-1.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAATAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-1.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACAAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-1.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACCAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-1.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACGAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-1.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACTAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-1.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGAAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-1.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGCAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 P-1.1 CCT CTC TAT GGG CAG TCG GTG ATAAAA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-1.2 CCT CTC TAT GGG CAG TCG GTG ATAACA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-1.3 CCT CTC TAT GGG CAG TCG GTG ATAAGA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-1.4 CCT CTC TAT GGG CAG TCG GTG ATAATA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-1.5 CCT CTC TAT GGG CAG TCG GTG ATACAA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-1.6 CCT CTC TAT GGG CAG TCG GTG ATACCA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-1.7 CCT CTC TAT GGG CAG TCG GTG ATACGA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-1.8 CCT CTC TAT GGG CAG TCG GTG ATACTA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-1.9 CCT CTC TAT GGG CAG TCG GTG ATAGAA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-1.10 CCT CTC TAT GGG CAG TCG GTG ATAGCA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F3 A-1.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAATGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-1.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAACTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-1.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAGTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-1.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAATTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-1.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACATGG CCA TCT ACA AGC AGT CA  200N 
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Exon 5 F3 A-1.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACCTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-1.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACGTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-1.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACTTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-1.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGATGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-1.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGCTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 P-1.1 CCT CTC TAT GGG CAG TCG GTG ATAAAT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-1.2 CCT CTC TAT GGG CAG TCG GTG ATAACT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-1.3 CCT CTC TAT GGG CAG TCG GTG ATAAGT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-1.4 CCT CTC TAT GGG CAG TCG GTG ATAATT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-1.5 CCT CTC TAT GGG CAG TCG GTG ATACAT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-1.6 CCT CTC TAT GGG CAG TCG GTG ATACCT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-1.7 CCT CTC TAT GGG CAG TCG GTG ATACGT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-1.8 CCT CTC TAT GGG CAG TCG GTG ATACTT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-1.9 CCT CTC TAT GGG CAG TCG GTG ATAGAT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-1.10 CCT CTC TAT GGG CAG TCG GTG ATAGCT GGC CAT CTA CAA GCA GTC A  200N 
Exon 6 F A-1.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAACAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-1.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAACCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-1.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAGCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-1.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAATCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-1.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACACAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-1.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACCCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-1.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACGCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-1.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACTCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-1.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGACAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-1.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGCCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F P-1.1 CCT CTC TAT GGG CAG TCG GTG ATAAAC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-1.2 CCT CTC TAT GGG CAG TCG GTG ATAACC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-1.3 CCT CTC TAT GGG CAG TCG GTG ATAAGC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-1.4 CCT CTC TAT GGG CAG TCG GTG ATAATC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-1.5 CCT CTC TAT GGG CAG TCG GTG ATACAC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-1.6 CCT CTC TAT GGG CAG TCG GTG ATACCC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-1.7 CCT CTC TAT GGG CAG TCG GTG ATACGC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-1.8 CCT CTC TAT GGG CAG TCG GTG ATACTC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-1.9 CCT CTC TAT GGG CAG TCG GTG ATAGAC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-1.10 CCT CTC TAT GGG CAG TCG GTG ATAGCC AGG CCT CTG ATT CCT CAC T 200N 
Exon 7 F1 A-1.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAACCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-1.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAACCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-1.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAGCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-1.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAATCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-1.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACACCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-1.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACCCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-1.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACGCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-1.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACTCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-1.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGACCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-1.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGCCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 P-1.1 CCT CTC TAT GGG CAG TCG GTG ATAAAC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-1.2 CCT CTC TAT GGG CAG TCG GTG ATAACC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-1.3 CCT CTC TAT GGG CAG TCG GTG ATAAGC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-1.4 CCT CTC TAT GGG CAG TCG GTG ATAATC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-1.5 CCT CTC TAT GGG CAG TCG GTG ATACAC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-1.6 CCT CTC TAT GGG CAG TCG GTG ATACCC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-1.7 CCT CTC TAT GGG CAG TCG GTG ATACGC CTG CTT GCC ACA GGT CT  200N 
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Exon 7 F1 P-1.8 CCT CTC TAT GGG CAG TCG GTG ATACTC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-1.9 CCT CTC TAT GGG CAG TCG GTG ATAGAC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-1.10 CCT CTC TAT GGG CAG TCG GTG ATAGCC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F2 A-1.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAACCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-1.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAACCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-1.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAGCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-1.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAATCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-1.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACACCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-1.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACCCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-1.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACGCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-1.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACTCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-1.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGACCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-1.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGCCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 P-1.1 CCT CTC TAT GGG CAG TCG GTG ATAAAC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-1.2 CCT CTC TAT GGG CAG TCG GTG ATAACC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-1.3 CCT CTC TAT GGG CAG TCG GTG ATAAGC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-1.4 CCT CTC TAT GGG CAG TCG GTG ATAATC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-1.5 CCT CTC TAT GGG CAG TCG GTG ATACAC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-1.6 CCT CTC TAT GGG CAG TCG GTG ATACCC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-1.7 CCT CTC TAT GGG CAG TCG GTG ATACGC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-1.8 CCT CTC TAT GGG CAG TCG GTG ATACTC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-1.9 CCT CTC TAT GGG CAG TCG GTG ATAGAC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-1.10 CCT CTC TAT GGG CAG TCG GTG ATAGCC CTC ACC ATC ATC ACA CTG G  200N 
Exon 8 F1 A-1.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAATGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-1.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAACTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-1.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAGTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-1.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAATTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-1.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACATGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-1.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACCTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-1.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACGTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-1.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACTTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-1.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGATGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-1.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGCTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 P-1.1 CCT CTC TAT GGG CAG TCG GTG ATAAAT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-1.2 CCT CTC TAT GGG CAG TCG GTG ATAACT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-1.3 CCT CTC TAT GGG CAG TCG GTG ATAAGT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-1.4 CCT CTC TAT GGG CAG TCG GTG ATAATT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-1.5 CCT CTC TAT GGG CAG TCG GTG ATACAT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-1.6 CCT CTC TAT GGG CAG TCG GTG ATACCT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-1.7 CCT CTC TAT GGG CAG TCG GTG ATACGT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-1.8 CCT CTC TAT GGG CAG TCG GTG ATACTT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-1.9 CCT CTC TAT GGG CAG TCG GTG ATAGAT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-1.10 CCT CTC TAT GGG CAG TCG GTG ATAGCT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F2 A-1.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAAACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-1.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAACACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-1.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAAGACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-1.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAATACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-1.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACAACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-1.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACCACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-1.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACGACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-1.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGACTACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-1.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGAACT GGG ACG GAA CAG CTT TG  200N 
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Exon 8 F2 A-1.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGCACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 P-1.1 CCT CTC TAT GGG CAG TCG GTG ATAAAA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-1.2 CCT CTC TAT GGG CAG TCG GTG ATAACA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-1.3 CCT CTC TAT GGG CAG TCG GTG ATAAGA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-1.4 CCT CTC TAT GGG CAG TCG GTG ATAATA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-1.5 CCT CTC TAT GGG CAG TCG GTG ATACAA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-1.6 CCT CTC TAT GGG CAG TCG GTG ATACCA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-1.7 CCT CTC TAT GGG CAG TCG GTG ATACGA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-1.8 CCT CTC TAT GGG CAG TCG GTG ATACTA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-1.9 CCT CTC TAT GGG CAG TCG GTG ATAGAA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-1.10 CCT CTC TAT GGG CAG TCG GTG ATAGCA CTG GGA CGG AAC AGC TTT G  200N 
Exon 5 F1 A-2.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGGCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-2.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGTCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-2.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATACAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-2.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATCCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-2.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATGCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-2.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATTCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-2.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAACAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-2.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCACCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-2.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAGCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-2.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCATCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 P-2.1 CCT CTC TAT GGG CAG TCG GTG ATAGGC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-2.2 CCT CTC TAT GGG CAG TCG GTG ATAGTC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-2.3 CCT CTC TAT GGG CAG TCG GTG ATATAC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-2.4 CCT CTC TAT GGG CAG TCG GTG ATATCC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-2.5 CCT CTC TAT GGG CAG TCG GTG ATATGC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-2.6 CCT CTC TAT GGG CAG TCG GTG ATATTC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-2.7 CCT CTC TAT GGG CAG TCG GTG ATCAAC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-2.8 CCT CTC TAT GGG CAG TCG GTG ATCACC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-2.9 CCT CTC TAT GGG CAG TCG GTG ATCAGC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-2.10 CCT CTC TAT GGG CAG TCG GTG ATCATC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F2 A-2.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGGAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-2.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGTAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-2.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATAAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-2.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATCAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-2.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATGAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-2.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATTAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-2.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAAAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-2.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCACAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-2.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAGAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-2.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCATAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 P-2.1 CCT CTC TAT GGG CAG TCG GTG ATAGGA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-2.2 CCT CTC TAT GGG CAG TCG GTG ATAGTA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-2.3 CCT CTC TAT GGG CAG TCG GTG ATATAA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-2.4 CCT CTC TAT GGG CAG TCG GTG ATATCA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-2.5 CCT CTC TAT GGG CAG TCG GTG ATATGA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-2.6 CCT CTC TAT GGG CAG TCG GTG ATATTA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-2.7 CCT CTC TAT GGG CAG TCG GTG ATCAAA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-2.8 CCT CTC TAT GGG CAG TCG GTG ATCACA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-2.9 CCT CTC TAT GGG CAG TCG GTG ATCAGA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-2.10 CCT CTC TAT GGG CAG TCG GTG ATCATA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F3 A-2.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGGTGG CCA TCT ACA AGC AGT CA  200N 
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Exon 5 F3 A-2.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGTTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-2.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATATGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-2.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATCTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-2.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATGTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-2.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATTTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-2.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAATGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-2.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCACTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-2.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAGTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-2.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCATTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 P-2.1 CCT CTC TAT GGG CAG TCG GTG ATAGGT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-2.2 CCT CTC TAT GGG CAG TCG GTG ATAGTT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-2.3 CCT CTC TAT GGG CAG TCG GTG ATATAT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-2.4 CCT CTC TAT GGG CAG TCG GTG ATATCT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-2.5 CCT CTC TAT GGG CAG TCG GTG ATATGT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-2.6 CCT CTC TAT GGG CAG TCG GTG ATATTT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-2.7 CCT CTC TAT GGG CAG TCG GTG ATCAAT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-2.8 CCT CTC TAT GGG CAG TCG GTG ATCACT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-2.9 CCT CTC TAT GGG CAG TCG GTG ATCAGT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-2.10 CCT CTC TAT GGG CAG TCG GTG ATCATT GGC CAT CTA CAA GCA GTC A  200N 
Exon 6 F A-2.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGGCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-2.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGTCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-2.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATACAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-2.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATCCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-2.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATGCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-2.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATTCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-2.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAACAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-2.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCACCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-2.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAGCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-2.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCATCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F P-2.1 CCT CTC TAT GGG CAG TCG GTG ATAGGC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-2.2 CCT CTC TAT GGG CAG TCG GTG ATAGTC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-2.3 CCT CTC TAT GGG CAG TCG GTG ATATAC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-2.4 CCT CTC TAT GGG CAG TCG GTG ATATCC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-2.5 CCT CTC TAT GGG CAG TCG GTG ATATGC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-2.6 CCT CTC TAT GGG CAG TCG GTG ATATTC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-2.7 CCT CTC TAT GGG CAG TCG GTG ATCAAC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-2.8 CCT CTC TAT GGG CAG TCG GTG ATCACC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-2.9 CCT CTC TAT GGG CAG TCG GTG ATCAGC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-2.10 CCT CTC TAT GGG CAG TCG GTG ATCATC AGG CCT CTG ATT CCT CAC T 200N 
Exon 7 F1 A-2.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGGCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-2.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGTCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-2.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATACCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-2.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATCCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-2.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATGCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-2.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATTCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-2.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAACCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-2.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCACCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-2.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAGCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-2.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCATCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 P-2.1 CCT CTC TAT GGG CAG TCG GTG ATAGGC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-2.2 CCT CTC TAT GGG CAG TCG GTG ATAGTC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-2.3 CCT CTC TAT GGG CAG TCG GTG ATATAC CTG CTT GCC ACA GGT CT  200N 
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Exon 7 F1 P-2.4 CCT CTC TAT GGG CAG TCG GTG ATATCC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-2.5 CCT CTC TAT GGG CAG TCG GTG ATATGC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-2.6 CCT CTC TAT GGG CAG TCG GTG ATATTC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-2.7 CCT CTC TAT GGG CAG TCG GTG ATCAAC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-2.8 CCT CTC TAT GGG CAG TCG GTG ATCACC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-2.9 CCT CTC TAT GGG CAG TCG GTG ATCAGC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-2.10 CCT CTC TAT GGG CAG TCG GTG ATCATC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F2 A-2.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGGCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-2.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGTCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-2.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATACCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-2.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATCCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-2.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATGCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-2.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATTCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-2.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAACCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-2.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCACCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-2.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAGCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-2.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCATCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 P-2.1 CCT CTC TAT GGG CAG TCG GTG ATAGGC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-2.2 CCT CTC TAT GGG CAG TCG GTG ATAGTC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-2.3 CCT CTC TAT GGG CAG TCG GTG ATATAC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-2.4 CCT CTC TAT GGG CAG TCG GTG ATATCC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-2.5 CCT CTC TAT GGG CAG TCG GTG ATATGC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-2.6 CCT CTC TAT GGG CAG TCG GTG ATATTC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-2.7 CCT CTC TAT GGG CAG TCG GTG ATCAAC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-2.8 CCT CTC TAT GGG CAG TCG GTG ATCACC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-2.9 CCT CTC TAT GGG CAG TCG GTG ATCAGC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-2.10 CCT CTC TAT GGG CAG TCG GTG ATCATC CTC ACC ATC ATC ACA CTG G  200N 
Exon 8 F1 A-2.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGGTGA TTT CCT TAC TGC CTC TTGC  200N 
Exon 8 F1 A-2.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGTTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-2.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATATGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-2.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATCTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-2.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATGTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-2.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATTTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-2.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAATGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-2.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCACTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-2.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAGTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-2.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCATTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 P-2.1 CCT CTC TAT GGG CAG TCG GTG ATAGGT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-2.2 CCT CTC TAT GGG CAG TCG GTG ATAGTT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-2.3 CCT CTC TAT GGG CAG TCG GTG ATATAT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-2.4 CCT CTC TAT GGG CAG TCG GTG ATATCT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-2.5 CCT CTC TAT GGG CAG TCG GTG ATATGT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-2.6 CCT CTC TAT GGG CAG TCG GTG ATATTT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-2.7 CCT CTC TAT GGG CAG TCG GTG ATCAAT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-2.8 CCT CTC TAT GGG CAG TCG GTG ATCACT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-2.9 CCT CTC TAT GGG CAG TCG GTG ATCAGT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-2.10 CCT CTC TAT GGG CAG TCG GTG ATCATT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F2 A-2.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGGACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-2.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGAGTACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-2.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATAACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-2.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATCACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-2.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATGACT GGG ACG GAA CAG CTT TG  200N 
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Exon 8 F2 A-2.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGATTACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-2.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAAACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-2.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCACACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-2.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCAGACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-2.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCATACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 P-2.1 CCT CTC TAT GGG CAG TCG GTG ATAGGA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-2.2 CCT CTC TAT GGG CAG TCG GTG ATAGTA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-2.3 CCT CTC TAT GGG CAG TCG GTG ATATAA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-2.4 CCT CTC TAT GGG CAG TCG GTG ATATCA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-2.5 CCT CTC TAT GGG CAG TCG GTG ATATGA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-2.6 CCT CTC TAT GGG CAG TCG GTG ATATTA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-2.7 CCT CTC TAT GGG CAG TCG GTG ATCAAA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-2.8 CCT CTC TAT GGG CAG TCG GTG ATCACA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-2.9 CCT CTC TAT GGG CAG TCG GTG ATCAGA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-2.10 CCT CTC TAT GGG CAG TCG GTG ATCATA CTG GGA CGG AAC AGC TTT G  200N 
Exon 5 F1 A-3.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCACAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-3.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCCCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-3.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCGCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-3.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCTCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-3.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGACAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-3.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGCCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-3.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGGCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-3.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGTCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-3.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTACAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 A-3.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTCCAC TTG TGC CCT GAC TTT CA 200N 
Exon 5 F1 P-3.1 CCT CTC TAT GGG CAG TCG GTG ATCCAC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-3.2 CCT CTC TAT GGG CAG TCG GTG ATCCCC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-3.3 CCT CTC TAT GGG CAG TCG GTG ATCCGC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-3.4 CCT CTC TAT GGG CAG TCG GTG ATCCTC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-3.5 CCT CTC TAT GGG CAG TCG GTG ATCGAC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-3.6 CCT CTC TAT GGG CAG TCG GTG ATCGCC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-3.7 CCT CTC TAT GGG CAG TCG GTG ATCGGC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-3.8 CCT CTC TAT GGG CAG TCG GTG ATCGTC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-3.9 CCT CTC TAT GGG CAG TCG GTG ATCTAC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F1 P-3.10 CCT CTC TAT GGG CAG TCG GTG ATCTCC ACT TGT GCC CTG ACT TTC A  200N 
Exon 5 F2 A-3.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCAAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-3.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCCAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-3.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCGAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-3.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCTAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-3.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGAAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-3.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGCAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-3.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGGAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-3.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGTAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-3.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTAAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 A-3.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTCAGT ACT CCC CTG CCC TCA AC  200N 
Exon 5 F2 P-3.1 CCT CTC TAT GGG CAG TCG GTG ATCCAA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-3.2 CCT CTC TAT GGG CAG TCG GTG ATCCCA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-3.3 CCT CTC TAT GGG CAG TCG GTG ATCCGA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-3.4 CCT CTC TAT GGG CAG TCG GTG ATCCTA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-3.5 CCT CTC TAT GGG CAG TCG GTG ATCGAA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-3.6 CCT CTC TAT GGG CAG TCG GTG ATCGCA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-3.7 CCT CTC TAT GGG CAG TCG GTG ATCGGA GTA CTC CCC TGC CCT CAA C  200N 
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Exon 5 F2 P-3.8 CCT CTC TAT GGG CAG TCG GTG ATCGTA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-3.9 CCT CTC TAT GGG CAG TCG GTG ATCTAA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F2 P-3.10 CCT CTC TAT GGG CAG TCG GTG ATCTCA GTA CTC CCC TGC CCT CAA C  200N 
Exon 5 F3 A-3.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCATGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-3.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCCTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-3.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCGTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-3.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCTTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-3.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGATGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-3.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGCTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-3.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGGTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-3.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGTTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-3.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTATGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 A-3.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTCTGG CCA TCT ACA AGC AGT CA  200N 
Exon 5 F3 P-3.1 CCT CTC TAT GGG CAG TCG GTG ATCCAT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-3.2 CCT CTC TAT GGG CAG TCG GTG ATCCCT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-3.3 CCT CTC TAT GGG CAG TCG GTG ATCCGT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-3.4 CCT CTC TAT GGG CAG TCG GTG ATCCTT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-3.5 CCT CTC TAT GGG CAG TCG GTG ATCGAT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-3.6 CCT CTC TAT GGG CAG TCG GTG ATCGCT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-3.7 CCT CTC TAT GGG CAG TCG GTG ATCGGT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-3.8 CCT CTC TAT GGG CAG TCG GTG ATCGTT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-3.9 CCT CTC TAT GGG CAG TCG GTG ATCTAT GGC CAT CTA CAA GCA GTC A  200N 
Exon 5 F3 P-3.10 CCT CTC TAT GGG CAG TCG GTG ATCTCT GGC CAT CTA CAA GCA GTC A  200N 
Exon 6 F A-3.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCACAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-3.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCCCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-3.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCGCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-3.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCTCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-3.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGACAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-3.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGCCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-3.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGGCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-3.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGTCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-3.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTACAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F A-3.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTCCAG GCC TCT GAT TCC TCA CT  200N 
Exon 6 F P-3.1 CCT CTC TAT GGG CAG TCG GTG ATCCAC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-3.2 CCT CTC TAT GGG CAG TCG GTG ATCCCC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-3.3 CCT CTC TAT GGG CAG TCG GTG ATCCGC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-3.4 CCT CTC TAT GGG CAG TCG GTG ATCCTC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-3.5 CCT CTC TAT GGG CAG TCG GTG ATCGAC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-3.6 CCT CTC TAT GGG CAG TCG GTG ATCGCC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-3.7 CCT CTC TAT GGG CAG TCG GTG ATCGGC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-3.8 CCT CTC TAT GGG CAG TCG GTG ATCGTC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-3.9 CCT CTC TAT GGG CAG TCG GTG ATCTAC AGG CCT CTG ATT CCT CAC T 200N 
Exon 6 F P-3.10 CCT CTC TAT GGG CAG TCG GTG ATCTCC AGG CCT CTG ATT CCT CAC T 200N 
Exon 7 F1 A-3.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCACCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-3.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCCCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-3.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCGCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-3.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCTCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-3.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGACCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-3.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGCCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-3.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGGCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-3.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGTCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 A-3.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTACCT GCT TGC CAC AGG TCT  200N 
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Exon 7 F1 A-3.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTCCCT GCT TGC CAC AGG TCT  200N 
Exon 7 F1 P-3.1 CCT CTC TAT GGG CAG TCG GTG ATCCAC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-3.2 CCT CTC TAT GGG CAG TCG GTG ATCCCC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-3.3 CCT CTC TAT GGG CAG TCG GTG ATCCGC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-3.4 CCT CTC TAT GGG CAG TCG GTG ATCCTC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-3.5 CCT CTC TAT GGG CAG TCG GTG ATCGAC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-3.6 CCT CTC TAT GGG CAG TCG GTG ATCGCC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-3.7 CCT CTC TAT GGG CAG TCG GTG ATCGGC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-3.8 CCT CTC TAT GGG CAG TCG GTG ATCGTC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-3.9 CCT CTC TAT GGG CAG TCG GTG ATCTAC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F1 P-3.10 CCT CTC TAT GGG CAG TCG GTG ATCTCC CTG CTT GCC ACA GGT CT  200N 
Exon 7 F2 A-3.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCACCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-3.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCCCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-3.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCGCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-3.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCTCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-3.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGACCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-3.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGCCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-3.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGGCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-3.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGTCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-3.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTACCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 A-3.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTCCCT CAC CAT CAT CAC ACT GG  200N 
Exon 7 F2 P-3.1 CCT CTC TAT GGG CAG TCG GTG ATCCAC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-3.2 CCT CTC TAT GGG CAG TCG GTG ATCCCC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-3.3 CCT CTC TAT GGG CAG TCG GTG ATCCGC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-3.4 CCT CTC TAT GGG CAG TCG GTG ATCCTC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-3.5 CCT CTC TAT GGG CAG TCG GTG ATCGAC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-3.6 CCT CTC TAT GGG CAG TCG GTG ATCGCC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-3.7 CCT CTC TAT GGG CAG TCG GTG ATCGGC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-3.8 CCT CTC TAT GGG CAG TCG GTG ATCGTC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-3.9 CCT CTC TAT GGG CAG TCG GTG ATCTAC CTC ACC ATC ATC ACA CTG G  200N 
Exon 7 F2 P-3.10 CCT CTC TAT GGG CAG TCG GTG ATCTCC CTC ACC ATC ATC ACA CTG G  200N 
Exon 8 F1 A-3.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCATGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-3.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCCTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-3.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCGTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-3.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCTTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-3.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGATGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-3.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGCTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-3.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGGTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-3.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGTTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-3.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTATGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 A-3.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTCTGA TTT CCT TAC TGC CTC TTG C  200N 
Exon 8 F1 P-3.1 CCT CTC TAT GGG CAG TCG GTG ATCCAT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-3.2 CCT CTC TAT GGG CAG TCG GTG ATCCCT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-3.3 CCT CTC TAT GGG CAG TCG GTG ATCCGT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-3.4 CCT CTC TAT GGG CAG TCG GTG ATCCTT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-3.5 CCT CTC TAT GGG CAG TCG GTG ATCGAT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-3.6 CCT CTC TAT GGG CAG TCG GTG ATCGCT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-3.7 CCT CTC TAT GGG CAG TCG GTG ATCGGT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-3.8 CCT CTC TAT GGG CAG TCG GTG ATCGTT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-3.9 CCT CTC TAT GGG CAG TCG GTG ATCTAT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F1 P-3.10 CCT CTC TAT GGG CAG TCG GTG ATCTCT GAT TTC CTT ACT GCC TCT TGC  200N 
Exon 8 F2 A-3.1 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCAACT GGG ACG GAA CAG CTT TG  200N 
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Exon 8 F2 A-3.2 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCCACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-3.3 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCGACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-3.4 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCCTACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-3.5 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGAACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-3.6 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGCACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-3.7 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGGACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-3.8 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCGTACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-3.9 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTAACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 A-3.10 CCA TCT CAT CCC TGC GTG TCT CCG ACT CAGCTCACT GGG ACG GAA CAG CTT TG  200N 
Exon 8 F2 P-3.1 CCT CTC TAT GGG CAG TCG GTG ATCCAA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-3.2 CCT CTC TAT GGG CAG TCG GTG ATCCCA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-3.3 CCT CTC TAT GGG CAG TCG GTG ATCCGA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-3.4 CCT CTC TAT GGG CAG TCG GTG ATCCTA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-3.5 CCT CTC TAT GGG CAG TCG GTG ATCGAA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-3.6 CCT CTC TAT GGG CAG TCG GTG ATCGCA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-3.7 CCT CTC TAT GGG CAG TCG GTG ATCGGA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-3.8 CCT CTC TAT GGG CAG TCG GTG ATCGTA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-3.9 CCT CTC TAT GGG CAG TCG GTG ATCTAA CTG GGA CGG AAC AGC TTT G  200N 
Exon 8 F2 P-3.10 CCT CTC TAT GGG CAG TCG GTG ATCTCA CTG GGA CGG AAC AGC TTT G  200N 
Exon5 R1A CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG 200N 
Exon5 R1P CCT CTC TAT GGG CAG TCG GTG AT 200N 
Exon5R2A CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG 200N 
Exon5 R2P CCT CTC TAT GGG CAG TCG GTG AT 200N 
ExoN5 R3A CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG 200N 
Exon5 R3P CCT CTC TAT GGG CAG TCG GTG AT 200N 
Exon6 RA CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG 200N 
Exon6 RP CCT CTC TAT GGG CAG TCG GTG AT 200N 
Exon7 R1A CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG 200N 
Exon7 R1P CCT CTC TAT GGG CAG TCG GTG AT 200N 
Exon7 R2A CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG 200N 
Exon7 R2P CCT CTC TAT GGG CAG TCG GTG AT 200N 
Exon8 R1A CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG 200N 
Exon8 R1P CCT CTC TAT GGG CAG TCG GTG AT 200N 
Exon8 R2A CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG 200N 
Exon8 R2P CCT CTC TAT GGG CAG TCG GTG AT 200N 
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Appendix D: World Health Organisation TNM staging for pancreatic 
cancer. 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour limited to the pancreas, ≤ 2 cm in greatest dimension 
T2 Tumour limited to the pancreas, > 2 cm in greatest dimension 
T3 
Tumour extends beyond the pancreas but without involvement of the celiac axis or the superior 
mesenteric artery 
T4 Tumour involves the celiac axis or the superior mesenteric artery (unresectable primary tumour) 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
  
[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: 
Pancreatic Adenocarcinoma. V 2.2015. Available at 
http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed: December 30, 
2015. 
 
American Joint Committee on Cancer (AJCC) TNM staging system, September 6, 2013. American 
Cancer Society. Available at 
http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-staging. 
Accessed: December 30, 2015.   
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Appendix E: List of read depths for all chips used on the Ion Torrent. 
CHIP CYST 
- 
Read Average 
Fragment 
Length 
Average Depth of Reads for Each Fragment (Exon, Fragment) 
E5F1 E5F2 E5F3 E6 E7F1 E72 E81 E82 
1 1 1 78 bp 2120 1399 10801 82 7913 8306 4795 653 
2 71 bp 3249 6836 12146 198 347 7638 2863 619 
3 68 bp 5827 2859 5038 82 4129 8559 4822 75 
4 72 bp 7259 6520 4008 404 7919 9110 2831 239 
5 48 bp 2243 1643 7548 388 5851 491 5270 693 
6 51 bp 4594 584 11392 441 5777 5497 361 569 
7 70 bp 556 7593 7194 165 4344 8814 4000 768 
8 51 bp 2913 544 8673 241 1287 3423 1615 511 
9 52 bp 9559 3795 3481 310 749 1987 2433 570 
10 54 bp 10370 9434 7243 379 5697 8816 3806 140 
2 1 83 bp 2421 9284 10365 31 2029 4640 4754 230 
2 48 bp 3364 2094 1136 462 3760 697 5535 319 
3 63 bp 187 126 4638 22 3183 7131 4210 378 
4 47 bp 6353 824 539 458 7882 7679 4451 511 
5 57 bp 7089 3827 4762 123 2331 4630 2673 551 
6 54 bp 5544 2588 3640 123 7264 4653 5221 556 
7 63 bp 4997 8026 7511 373 1695 4336 3574 696 
8 42 bp 8268 9581 4417 283 5131 866 3630 953 
9 44 bp 5289 9711 5950 287 6237 7504 204 827 
10 43 bp 5711 6693 1275 331 3254 1137 2037 273 
3 1 86 bp 5579 3192 9003 165 5473 1272 731 686 
2 49 bp 2984 2873 4959 245 7794 165 2873 206 
3 66 bp 9045 4262 2146 56 22 8100 3155 314 
4 47 bp 8704 4371 6863 120 1852 5621 2873 119 
5 61 bp 1603 3125 10301 40 7042 5572 3390 884 
6 62 bp 7722 1064 12160 388 7191 4622 2643 897 
7 84 bp 6947 7778 840 406 2826 4634 872 436 
8 68 bp 6798 1956 8796 169 6523 4803 333 276 
9 50 bp 1132 9836 8217 160 4670 2151 3346 672 
10 62 bp 2239 6276 6669 382 4731 6775 5120 764 
2 4 1 63 bp 11469 6756 3938 301 1208 9044 3140 525 
2 51 bp 2284 1107 7634 188 4909 5607 3482 758 
3 53 bp 7203 1722 621 88 3687 7808 3250 77 
4 48 bp 2591 6201 921 45 6711 4706 2007 614 
5 49 bp 10240 8030 2119 440 772 3818 1321 654 
6 42 bp 10453 693 7905 179 4222 3710 3970 850 
7 51 bp 4855 929 7558 307 6411 3905 2177 75 
8 43 bp 9097 4202 3929 459 2170 7847 5949 140 
9 44 bp 8280 9630 4987 386 1275 5913 3358 409 
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10 55 bp 2973 2948 10063 438 4772 8156 4829 418 
5 1 0 bp 0 0 0 0 0 0 0 0 
2 0 bp 0 0 0 0 0 0 0 0 
3 0 bp 0 0 0 0 0 0 0 0 
4 0 bp 0 0 0 0 0 0 0 0 
5 0 bp 0 0 0 0 0 0 0 0 
6 0 bp 0 0 0 0 0 0 0 0 
7 0 bp 0 0 0 0 0 0 0 0 
8 0 bp 0 0 0 0 0 0 0 0 
9 0 bp 0 0 0 0 0 0 0 0 
10 0 bp 0 0 0 0 0 0 0 0 
6 1 56 bp 2217 5758 2088 456 4557 7990 1812 740 
2 57 bp 174 8321 9231 223 2001 7978 435 949 
3 58 bp 8921 3516 8417 268 7399 1242 762 349 
4 50 bp 10850 8472 8551 345 6576 3216 2881 360 
5 78 bp 9130 2321 3502 162 7425 4410 211 146 
6 58 bp 9027 1841 2009 397 6391 7461 3579 247 
7 77 bp 2916 1625 1785 3 7840 9556 3246 862 
8 44 bp 11080 2163 10361 487 7362 1534 551 318 
9 33 bp 3089 1740 8227 456 7465 6430 4634 203 
10 58 bp 10961 3593 6059 286 1248 5466 1876 743 
3 7 1 75 bp 2948 3200 7842 440 6529 9459 4554 495 
2 56 bp 9632 3742 7640 294 7162 9036 4106 950 
3 68 bp 10630 9662 2195 484 6658 4500 2264 292 
4 65 bp 10367 1346 10791 241 7328 3647 2599 50 
5 55 bp 7356 7735 1804 290 1055 4128 2173 781 
6 60 bp 4911 947 7623 480 3065 6118 1463 322 
7 73 bp 453 3661 9825 434 7128 8887 5903 411 
8 43 bp 10591 8414 7310 310 7738 512 1678 66 
9 72 bp 8988 9244 2012 425 7619 8127 4703 486 
10 74 bp 2198 7899 7387 334 7967 8203 5668 892 
8 1 86 bp 6105 8369 2899 320 1895 327 62 613 
2 52 bp 11360 3225 10569 299 3647 8178 5171 365 
3 73 bp 9299 8765 11479 365 1822 5329 4029 781 
4 77 bp 4297 9726 902 97 4415 2639 2072 328 
5 65 bp 9278 1061 2799 149 5405 6901 4467 90 
6 69 bp 8546 1013 4910 356 6987 2614 1068 979 
7 63 bp 7757 6338 8963 81 6897 1459 5427 351 
8 67 bp 10804 76 2802 136 3968 7454 1097 830 
9 70 bp 10366 9461 8726 421 6516 6733 3550 457 
10 88 bp 11680 4375 9502 25 7171 6603 1315 177 
9 1 68 bp 6170 4821 10781 168 6373 8224 5365 725 
2 62 bp 9012 377 11372 389 3701 7920 153 870 
3 66 bp 8339 3692 7116 209 6228 8444 2367 218 
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4 72 bp 3688 12 5452 124 6983 9326 4569 286 
5 80 bp 7813 921 3013 17 621 2285 328 187 
6 60 bp 5566 3712 8252 395 2611 934 2256 243 
7 81 bp 2340 1545 4279 408 6891 6239 4563 319 
8 55 bp 5135 3632 7626 72 7464 6284 4107 813 
9 55 bp 4673 4510 9946 289 7235 8076 3879 560 
10 68 bp 807 9627 8260 211 6911 1214 659 755 
4 10 1 86 bp 2393 6584 11706 202 1315 2898 4213 56 
2 96 bp 11605 9014 1992 211 2795 8484 3923 139 
3 95 bp 4747 1385 12161 441 7016 1119 5731 492 
4 80 bp 5944 6704 4062 371 1947 1738 5235 979 
5 79 bp 11693 7023 5906 230 2607 3305 5759 567 
6 69 bp 8913 6681 1846 294 3673 544 1081 951 
7 84 bp 4166 6301 9578 375 4503 6194 568 265 
8 106 bp 5903 7518 9079 391 2021 3998 1630 82 
9 84 bp 9747 8402 6659 285 6008 5308 5114 448 
10 100 bp 10002 5188 8543 425 1377 1108 473 228 
11 1 106 bp 217 7590 7907 452 6247 1575 4357 901 
2 78 bp 4823 8710 10161 330 2413 9027 3443 292 
3 93 bp 8062 8426 256 189 1579 2481 4929 725 
4 91 bp 10172 2955 12164 162 4721 9166 3091 434 
5 85 bp 4991 1231 10615 153 4005 7268 5137 741 
6 91 bp 4278 9234 10548 355 4861 2499 204 321 
7 82 bp 4720 6916 1727 315 3211 5821 2819 695 
8 74 bp 3958 1636 5528 463 134 868 4376 187 
9 44 bp 4261 6415 10127 21 2632 7664 5595 790 
10 45 bp 120 2624 4552 415 7292 8319 2020 585 
12 1 94 bp 3858 2484 3889 402 6279 8122 58 581 
2 87 bp 656 2627 9730 286 2995 7227 339 355 
3 90 bp 2382 2132 1478 121 2118 3980 5700 676 
4 88 bp 287 7791 12282 208 3957 6055 1138 502 
5 75 bp 3357 2836 10903 145 6807 1839 4486 645 
6 86 bp 1337 8766 2100 231 1184 6697 2749 219 
7 88 bp 9885 8865 1935 362 2256 3857 5314 412 
8 71 bp 3062 9344 1081 348 2848 5842 3128 247 
9 77 bp 11544 5008 1885 30 7502 3720 959 952 
10 81 bp 9398 1390 3222 449 2087 9166 4191 904 
5 13 1 89 bp 6116 4227 1867 17 2838 435 1286 773 
2 86 bp 1708 4257 4607 285 3252 9234 2441 822 
3 117 bp 2844 1763 9201 64 1776 5995 2892 613 
4 80 bp 11191 6022 10412 434 5330 9235 3642 665 
5 66 bp 5404 8176 5579 453 283 8445 1771 467 
6 109 bp 9484 6141 8900 70 213 4947 2739 176 
7 96 bp 6538 3621 12033 409 3756 7651 2697 920 
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8 87 bp 4113 7514 8547 131 7132 1802 5229 528 
9 99 bp 8887 2010 12547 52 4233 7643 3615 211 
10 104 bp 11382 3473 9796 341 5513 7356 555 278 
14 1 93 bp 6556 4835 973 175 5572 1857 1287 115 
2 47 bp 11263 1503 4747 37 7813 6710 3193 245 
3 61 bp 3897 409 8997 266 2018 2999 1961 339 
4 68 bp 6697 5818 11923 164 5959 3142 2647 457 
5 63 bp 5224 9541 10108 426 1631 1500 1012 333 
6 62 bp 2894 6349 4945 308 6888 1664 1177 802 
7 104 bp 4617 1285 12314 21 3292 259 5895 193 
8 106 bp 7900 5720 8042 66 7565 6810 1940 527 
9 51 bp 1342 753 7795 338 2223 8051 845 955 
10 50 bp 7519 979 11537 151 2016 5338 4818 242 
15 1 73 bp 5118 8612 10694 424 1116 3113 4707 399 
2 41 bp 4487 8165 5335 205 6753 6787 2705 498 
3 111 bp 1978 6979 1510 107 3421 9199 921 868 
4 80 bp 9825 5839 6094 474 456 8911 1593 279 
5 137 bp 5168 7147 11197 37 4216 1017 3863 765 
6 98 bp 1809 6672 10811 121 498 7337 2019 680 
7 100 bp 69 4901 356 172 7140 8852 3204 57 
8 86 bp 4143 5838 1016 282 2891 9020 648 612 
9 76 bp 11451 4531 11629 266 3445 3374 1487 172 
10 86 bp 6106 4888 11196 16 2919 2849 11 433 
6 16 1 47 bp 9704 5087 8808 445 775 7440 4684 308 
2 46 bp 11143 7799 8172 467 712 2185 4240 460 
3 41 bp 10275 1750 3174 71 5161 7650 2023 641 
4 42 bp 10288 2183 5678 68 367 9356 4319 156 
5 39 bp 10922 9584 578 294 7153 763 267 262 
6 39 bp 2418 8032 9188 224 2910 6564 2272 506 
7 44 bp 2099 9711 1559 378 3578 8630 1133 125 
8 33 bp 9142 6652 8303 105 3375 8536 4300 935 
9 36 bp 1834 8025 10708 152 710 80 82 758 
10 46 bp 2449 8189 7630 257 4067 3588 4681 246 
17 1 50 bp 9665 8262 2388 360 4583 3964 2346 363 
2 43 bp 5844 9250 6808 254 1579 3623 5529 467 
3 42 bp 8475 2553 10391 157 7392 9484 2982 249 
4 46 bp 5368 5523 10145 39 952 1398 1611 344 
5 49 bp 5076 5876 9213 66 6356 4024 105 303 
6 47 bp 7997 6176 10528 2 7950 4699 1545 115 
7 47 bp 8905 4445 4733 372 4623 7236 5201 825 
8 45 bp 8034 7013 12333 288 3741 2784 1560 123 
9 43 bp 10339 9958 11542 317 6639 144 1090 313 
10 42 bp 3795 8743 325 231 4180 9663 2555 613 
18 1 49 bp 11170 738 2220 302 4425 1877 2856 438 
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2 42 bp 6158 8193 5063 482 4685 9077 383 218 
3 44 bp 834 7893 7977 36 4537 8933 1533 553 
4 42 bp 7818 9977 9208 194 7179 7885 1539 924 
5 43 bp 222 174 5245 116 7804 590 5165 261 
6 47 bp 6805 471 10202 423 6960 687 1219 246 
7 46 bp 2635 8931 5842 148 797 4436 3624 901 
8 44 bp 7292 5386 5877 162 5938 739 4825 129 
9 39 bp 6625 8779 3025 263 3379 2138 5074 221 
10 53 bp 5392 3523 12133 262 7126 1556 1181 672 
7 19 1 53 bp 6877 5698 12542 307 6441 6764 4726 695 
2 57 bp 8955 7444 8873 349 4087 7929 4863 83 
3 57 bp 2552 7025 6844 304 2025 516 1840 404 
4 65 bp 8365 7393 11074 473 1925 6736 3451 812 
5 54 bp 4960 9860 5642 180 265 4358 5300 515 
6 63 bp 10486 6958 2825 444 1368 456 576 842 
7 50 bp 9420 6508 1240 70 2790 345 3691 112 
8 61 bp 3475 2325 5473 31 3012 878 2228 488 
9 46 bp 1261 1119 49 430 7588 8795 3954 709 
10 45 bp 2799 6316 1289 154 1957 120 1837 548 
20 1 47 bp 8721 477 10361 246 4760 1593 1068 429 
2 46 bp 9752 3392 8791 38 7352 110 4251 299 
3 53 bp 8610 2781 12125 125 1337 8843 1069 598 
4 57 bp 6037 2227 9959 264 1027 370 2441 333 
5 59 bp 8354 3352 7365 444 6751 3408 1547 62 
6 67 bp 7953 5705 9924 450 3504 4976 3424 513 
7 48 bp 1132 1680 5685 449 6702 6918 2332 221 
8 61 bp 1885 8029 10444 142 2692 1843 1402 561 
9 58 bp 6895 5781 10460 299 3060 9159 3726 498 
10 58 bp 7447 3280 424 402 6863 8890 4104 112 
21 1 50 bp 4037 5964 4468 285 6734 4947 3687 79 
2 44 bp 4042 5553 6899 394 3389 8248 2249 740 
3 53 bp 11826 4335 5257 216 5088 5061 4053 580 
4 63 bp 2676 5673 4951 60 2974 4199 4434 215 
5 47 bp 1332 7646 108 15 531 8612 1378 146 
6 44 bp 4668 7811 10643 156 4776 7300 2560 396 
7 55 bp 11017 4947 5794 393 349 8245 1345 74 
8 60 bp 5844 3874 2322 95 4248 2137 4013 822 
9 60 bp 9570 5753 6027 347 4617 6025 3947 775 
10 60 bp 11875 613 10240 353 3950 1061 2319 183 
8 22 1 67 bp 924 2760 12475 286 7506 1327 2512 641 
2 56 bp 9716 5090 2537 163 554 9354 5242 331 
3 71 bp 4725 4526 4008 148 6287 201 1437 510 
4 76 bp 2471 1170 3233 354 2733 8194 562 275 
5 89 bp 11146 4130 7043 42 6696 3260 3084 465 
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6 80 bp 5436 3314 6520 123 3491 1466 2052 586 
7 65 bp 10633 4582 6597 458 5154 9073 3357 893 
8 45 bp 4652 185 1923 146 611 1296 5298 367 
9 52 bp 5637 6612 6516 46 7471 3191 5659 769 
10 93 bp 3978 8361 1583 436 3972 2035 5375 866 
23 1 53 bp 1914 9032 8176 113 5431 8737 3185 620 
2 66 bp 235 3650 5379 393 7078 2440 5428 167 
3 66 bp 5696 9488 9506 126 2247 1295 4697 753 
4 50 bp 9786 362 3026 429 1576 4594 2480 706 
5 67 bp 3269 756 5395 360 7985 7554 4589 595 
6 72 bp 11546 4413 7085 204 132 599 474 970 
7 59 bp 8152 8801 8151 329 771 9245 1386 642 
8 48 bp 1523 5579 10276 370 3313 7421 4288 473 
9 75 bp 10583 9191 8579 365 3055 6210 4995 65 
10 71 bp 4613 7274 4678 43 2149 3555 2367 803 
24 1 58 bp 4781 3799 3958 15 7928 3503 334 524 
2 84 bp 695 3213 4264 141 1434 7008 5745 665 
3 78 bp 2020 2307 9222 123 5037 2832 1290 716 
4 79 bp 10257 6674 11820 248 2144 3253 1595 701 
5 142 bp 5127 7118 4224 171 1006 6816 1841 968 
6 56 bp 10394 2973 3013 225 5932 4102 5707 874 
7 110 bp 11577 9843 11074 451 2558 2795 3640 161 
8 94 bp 2931 2899 7981 469 4105 8061 434 685 
9 121 bp 11025 2308 7844 62 1302 1278 1979 717 
10 61 bp 11665 4645 1167 299 2913 6378 58 330 
9 25 1 50 bp 2611 5360 798 190 1955 2954 5256 611 
2 52 bp 8145 653 10612 22 6466 5404 3650 713 
3 52 bp 2999 8423 2184 294 919 9514 1180 319 
4 77 bp 6869 8643 3957 139 1580 5591 5615 585 
5 52 bp 11278 8513 3673 470 1145 1834 3945 579 
6 70 bp 2683 1970 4057 396 6714 7209 1735 513 
7 52 bp 7437 6122 2444 389 7403 1471 3289 567 
8 53 bp 10485 2095 4755 356 4851 7901 1945 486 
9 53 bp 2575 1993 1246 473 7199 7178 4764 882 
10 79 bp 10874 435 6861 201 4697 7724 5315 258 
26 1 82 bp 11466 1960 3421 326 4727 2162 3707 87 
2 100 bp 10596 1283 4427 386 2700 7150 1343 306 
3 104 bp 11004 3047 5748 286 3046 6976 4678 741 
4 88 bp 3198 6660 10094 292 6306 9337 2673 948 
5 100 bp 10564 2106 8314 398 4880 6696 2435 319 
6 104 bp 2795 5604 1644 218 6354 1013 3326 916 
7 52 bp 11773 5721 3328 415 6462 8335 4387 460 
8 76 bp 8680 5447 6190 354 6508 7590 2342 421 
9 105 bp 1412 3596 3068 348 101 2792 5118 907 
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10 93 bp 11651 5854 7934 139 1282 5891 517 962 
27 1 47 bp 11087 4995 10216 456 2188 8467 1902 418 
2 43 bp 2588 8753 7594 85 2007 5547 39 502 
3 47 bp 6523 6766 11023 315 2857 1221 3164 220 
4 48 bp 1094 7729 885 346 3096 2343 830 801 
5 40 bp 2644 2182 9666 209 3962 4671 1776 111 
6 56 bp 11192 3638 2307 306 1348 8218 3063 530 
7 45 bp 6452 3060 1896 193 1661 8793 4210 103 
8 53 bp 5096 2552 9588 479 7627 8118 4133 780 
9 45 bp 9494 2672 312 142 5067 8595 1588 426 
10 66 bp 11091 9746 7869 458 2276 4046 4328 912 
10 28 1 49 bp 1840 7774 10705 258 3914 3016 356 824 
2 51 bp 10835 6907 884 174 194 5082 661 698 
3 53 bp 7198 4249 1557 390 6152 372 4928 120 
4 55 bp 1054 629 6865 214 3639 5897 122 338 
5 53 bp 396 825 7036 400 493 3366 3836 448 
6 51 bp 4132 7159 9631 81 3230 6580 5736 598 
7 51 bp 7312 5735 2069 58 1752 8243 4139 552 
8 52 bp 4465 3615 1045 267 5566 8146 4501 157 
9 52 bp 164 2562 7552 93 1703 3100 3105 281 
10 49 bp 1775 6061 10902 289 4659 7989 1247 123 
29 1 55 bp 7102 6214 2120 45 2992 4912 781 304 
2 58 bp 825 2600 1512 410 7652 4140 4884 438 
3 62 bp 10585 7545 1135 225 5227 2779 5802 312 
4 57 bp 11757 719 5967 18 7802 3222 4456 527 
5 60 bp 1195 6933 1969 104 4158 8647 1793 511 
6 67 bp 9939 98 224 304 2082 822 3649 597 
7 37 bp 9569 7841 3553 190 1029 6781 5722 398 
8 60 bp 2386 5685 7445 408 4024 6185 5439 661 
9 75 bp 9274 210 8945 138 6684 3951 1837 388 
10 78 bp 2367 1189 5731 105 5353 886 2928 94 
30 1 49 bp 10181 7306 3829 404 4755 7106 4627 404 
2 19 bp 10104 7614 862 51 2765 1888 1782 674 
3 48 bp 9978 2471 8487 294 4610 2700 2070 816 
4 43 bp 5157 1240 9678 148 2199 4433 5343 130 
5 43 bp 9588 1577 2247 361 5890 6558 3062 976 
6 46 bp 8545 3354 8587 479 7782 2957 5461 702 
7 51 bp 10077 4858 6410 99 155 3111 2175 537 
8 60 bp 6102 2352 3845 427 5131 4443 708 146 
9 37 bp 2196 9092 2453 419 2568 6560 3907 255 
10 44 bp 2088 7337 5626 235 7879 8182 2862 810 
11 31 1 77 bp 8214 5348 12480 136 1177 6291 1149 362 
2 87 bp 9461 7028 6868 472 3892 4026 3663 497 
3 64 bp 7906 3025 11008 129 5890 2162 1089 944 
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4 62 bp 7171 7886 9440 120 1673 4568 3281 749 
5 77 bp 9247 2226 12220 314 1050 3010 4043 176 
6 69 bp 3183 6305 11670 214 6574 3121 1394 781 
7 104 bp 4352 8119 3586 233 6977 6475 364 185 
8 61 bp 2235 3737 12538 75 4313 421 5142 524 
9 71 bp 3913 9538 3282 105 6398 8782 4797 176 
10 66 bp 9576 9141 7104 200 3579 7255 3009 474 
32 1 84 bp 4536 5638 1648 227 2578 1469 715 136 
2 57 bp 3752 8193 1093 161 5847 5584 2888 735 
3 71 bp 7188 4476 8013 164 5986 5668 3299 721 
4 52 bp 2061 1621 7022 22 6920 7216 3967 200 
5 72 bp 5585 2989 2350 141 5014 1304 5650 365 
6 61 bp 10256 2127 7645 384 415 1461 238 909 
7 43 bp 8657 8597 9681 131 2488 4430 1255 707 
8 59 bp 3123 7704 2035 279 1672 5651 486 395 
9 55 bp 11593 6355 4124 39 5220 8999 2367 403 
10 53 bp 1024 9970 12295 397 7547 3340 1059 104 
33 1 56 bp 11537 5356 11784 206 2223 4226 4718 864 
2 67 bp 8727 5156 7151 211 5746 7431 5311 866 
3 59 bp 948 6058 9846 476 5925 5413 3593 899 
4 56 bp 8979 6454 2126 356 3590 8291 2968 309 
5 75 bp 7098 7970 3043 204 4916 592 4943 832 
6 94 bp 5044 8260 8530 297 7344 5544 3684 95 
7 79 bp 8872 3517 11105 314 7575 7392 499 548 
8 68 bp 8999 6112 1540 180 219 4896 3273 560 
9 64 bp 6035 2471 2343 105 1950 9459 2933 352 
10 74 bp 6972 9396 1128 104 4385 8927 253 63 
12 34 1 83 bp 10819 5506 6852 56 2733 330 1746 314 
2 98 bp 11181 1471 2792 191 7723 1316 2342 146 
3 92 bp 5278 5408 5243 71 5818 208 1516 936 
4 62 bp 54 7236 1321 481 1366 5839 1109 777 
5 65 bp 10845 8977 973 331 4485 1214 831 466 
6 102 bp 3675 1338 1439 163 1739 324 4910 413 
7 97 bp 8679 7807 6824 227 1595 9243 5672 879 
8 103 bp 76 1767 7540 439 7546 7225 1094 451 
9 96 bp 11627 1895 3239 54 6641 4557 3261 966 
10 109 bp 9452 4018 2309 350 5791 6379 5757 82 
35 1 86 bp 6478 6000 2890 431 4239 6428 4487 556 
2 84 bp 2874 4652 7567 460 2632 7633 3131 519 
3 100 bp 6798 4486 12122 268 5331 3136 3544 910 
4 112 bp 2751 5119 11393 50 2101 4921 5052 249 
5 97 bp 905 9279 282 268 5867 2201 4218 815 
6 97 bp 8154 2317 9014 200 5109 7057 4339 528 
7 115 bp 5364 2861 11219 160 2461 5422 1625 176 
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8 98 bp 2225 1842 4914 55 7682 4319 1738 652 
9 109 bp 2268 912 7210 34 6807 2701 618 619 
10 81 bp 7651 4034 7701 133 5059 3214 5286 749 
36 1 56 bp 3161 4660 2516 474 3849 2812 4094 821 
2 112 bp 10547 6902 6145 290 7065 7269 4116 744 
3 99 bp 7026 6036 9176 228 4929 9378 585 800 
4 101 bp 2810 3815 8837 362 5160 2666 1932 137 
5 80 bp 6365 7484 4784 279 7465 8373 5493 806 
6 100 bp 3828 9188 100 347 6240 4595 44 944 
7 112 bp 711 367 7267 273 908 246 3766 905 
8 115 bp 9472 7433 7752 369 68 8828 5619 312 
9 80 bp 4094 8443 6876 170 7184 4930 1584 89 
10 121 bp 10446 2003 11057 27 2842 1352 5022 508 
13 37 1 99 bp 9311 8451 2268 278 497 8085 4149 378 
2 83 bp 2148 7165 3808 262 1885 1801 4693 903 
3 108 bp 519 6892 10050 274 6121 6247 3914 57 
4 60 bp 4408 1699 11827 204 3141 9422 5112 804 
5 95 bp 9007 8552 8822 375 7575 2019 1530 311 
6 111 bp 7802 9079 1016 381 816 3008 3417 663 
7 94 bp 810 9057 3958 64 3901 8782 3850 602 
8 100 bp 10313 8761 4915 65 578 9237 561 488 
9 133 bp 8935 4015 4120 229 400 5066 529 916 
10 103 bp 10190 8085 6413 377 26 5097 2557 251 
38 1 118 bp 3062 1128 2236 358 3029 1344 876 262 
2 110 bp 1377 3449 199 264 5078 6783 4169 549 
3 91 bp 958 5493 10933 273 863 1465 3623 804 
4 74 bp 11080 7266 11238 248 3273 6319 1592 90 
5 64 bp 2594 2647 3116 342 1546 7480 5819 815 
6 69 bp 223 7605 7016 252 2347 9607 578 682 
7 80 bp 3195 9551 6642 254 5851 1687 3872 960 
8 88 bp 5493 5790 7359 437 7570 9197 231 764 
9 70 bp 5759 6469 10525 471 5207 8954 5157 305 
10 75 bp 5414 3426 6174 134 5463 7681 3462 437 
39 1 42 bp 4397 1195 7034 485 2369 1126 416 148 
2 110 bp 8399 2126 3038 364 6194 8101 2447 228 
3 116 bp 4262 8125 6911 314 838 3052 2632 125 
4 127 bp 4388 3660 7919 86 63 8682 2797 193 
5 116 bp 7236 9679 3956 398 6372 3417 5217 550 
6 106 bp 2858 5763 6463 172 3886 9085 4272 815 
7 116 bp 8678 16 1516 43 4730 8232 5085 636 
8 89 bp 10768 9517 1941 312 1999 8558 3044 504 
9 114 bp 9920 4230 4886 403 3193 3104 5215 701 
10 95 bp 8196 2025 6771 209 7566 4144 5048 607 
14 40 1 50 bp 11685 7661 6425 394 5412 2295 2803 912 
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2 62 bp 2964 3307 3020 435 2284 2124 2553 446 
3 63 bp 9847 2436 5288 147 4138 9145 3433 880 
4 51 bp 6215 3743 7004 175 7840 3651 5635 632 
5 53 bp 3737 3857 3565 361 3246 1336 5558 684 
6 48 bp 9099 4607 7507 29 4547 4847 2014 296 
7 49 bp 3171 8171 5255 112 2819 6234 4918 412 
8 42 bp 8561 3762 3088 467 736 7625 3107 604 
9 51 bp 9273 6958 11664 347 7578 5406 3782 211 
10 43 bp 155 3645 7694 183 2415 2960 4736 866 
41 1 44 bp 1719 5462 3942 169 425 8335 5040 70 
2 55 bp 2653 2143 9116 58 4325 2635 3050 955 
3 86 bp 4416 5475 3057 447 3611 8019 1628 206 
4 39 bp 6895 387 6829 158 5769 7594 4915 50 
5 44 bp 11514 4971 5786 93 728 9399 5446 992 
6 55 bp 3957 9861 12084 298 1634 3061 961 354 
7 50 bp 7753 5636 8811 146 5640 1826 259 118 
8 50 bp 5289 3549 4200 350 7333 9071 996 524 
9 48 bp 2034 3030 6720 304 3927 3954 3131 427 
10 46 bp 4427 5199 4396 197 2711 4599 621 569 
42 1 56 bp 6304 4840 10657 390 3450 429 312 258 
2 43 bp 8689 6460 11733 53 2480 6645 138 542 
3 56 bp 7840 8809 7723 139 5094 1824 676 838 
4 57 bp 11086 366 4722 265 3748 9242 5629 141 
5 58 bp 782 9726 10933 428 7965 7343 4175 313 
6 50 bp 7795 975 7491 401 1030 253 455 453 
7 78 bp 9065 7398 8603 349 4543 666 2838 926 
8 58 bp 4503 9482 2784 152 2908 6261 3763 862 
9 77 bp 2156 1811 6499 114 840 1883 1407 240 
10 44 bp 6079 1363 7366 371 1886 6935 2456 111 
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Appendix F: Primers used for p.L264R validation PCR. 
Nested PCR Round 1: 
p.L264R FwN:  5’ – CCTTACTGCCTCCTCTTGCTTCT – 3’ 
p.L264R Rv2:  5’ – CAGGCTAGGCTAAGCTATGA – 3’ 
Nested PCR Round 2: 
p.L264R Fw:  5’ – ATCCTGAGTAGTGGCAGTTG – 3’ 
p.L264R Rv:  5’ – GTTGGTGTTCTGAAGTTAGT – 3’  
 
 
 
 
 
